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Tailoring the extent of colorectal cancer surgical resection on an individual basis would 
improve patient outcomes, but to achieve this goal, staging of the disease, particularly lymph 
node status, must be improved. Sentinel lymph node mapping has been effective in other 
tumours types but is ineffective in colorectal cancer. Near infra-red fluorophores are of 
interest in fluorescent guided surgery, but lack the ability to target the specific tissue of 
interest. The aim of this research is to develop a targeted near infra-red based probe to 
identify tumour and lymph node metastases.  
 
Methods 
Immunofluorescence was used to determine appropriate target and control recognition 
molecules in addition to appropriate target and control cell lines. Semiconducting organic 
polymer CN-PPV nanoparticles were produced utilising a self-assembly method and 
characterised over time. The selected target and control recognition molecules were 
conjugated to non-functionalised (NPs) and maleimide functionalised (MNPs) 
semiconducting organic polymer CN-PPV nanoparticles and cell binding, as well as cell 
toxicity, were evaluated in vitro. 
 
Results 
Both the target anti-CEA recognition molecules bound specifically to the target cell lines and 
not to controls. Characterisation of the NPs and MNPs displayed physical stability over time 
as well as demonstrating negligible adverse cytotoxic effects. Conjugation of both target and 
control antibody recognition molecules to the MNP led to non-specific binding of the 
conjugate to control cell lines. The target affimer recognition molecule NP conjugates 
v 
demonstrated increased binding to target cell lines (42%, p<0.0001) and little non-specific 
binding to control cell lines (14%, p=0.3348).  
 
Conclusions 
Fluorescent guided surgery is a promising route for intraoperative stratification of colorectal 
cancer resections if an accurate probe were to be developed. I have shown that the 
semiconducting organic polymer nanoparticle used in this research possesses the attributes 
required of a clinical probe for fluorescent guided surgery. However, it requires modification 
with an appropriate recognition molecule to accurately target colorectal cancer tissue. The 
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1.1 Colorectal cancer 
1.1.1 Background information 
Colorectal cancer is the fourth most common cancer in the UK accounting for 12% of all 
new cancer diagnoses with 41,800 new patients presenting in 2015(1). It is the second 
most common cause of cancer deaths and in 2016 accounted for approximately 10% of 
all cancer-related mortalities. However, over the last 40 years, long-term survival rates 
have improved(1). Recently, the Office for National Statistics published data regarding 
cancer survival which highlighted that the age-standardised 5-year net survival for colon 
cancer is 59% and around 62% for cancers of the rectum(2). Survival is stage-
dependent with higher rates of being observed in earlier stages of disease(1–3). 
However, more than 50% of patients are diagnosed at a late stage, with a quarter of 
patients presenting with metastatic disease. 
 
Typically, patients are diagnosed either through referrals from general practitioners with 
concerning symptoms, such as a change in bowel habit or rectal bleeding (less than 
10% of 2 week wait referrals are positively diagnosed(4)). Alternatively, patients can also 
be diagnosed through the National Bowel Cancer Screening Programme. Identified 
patients will undergo diagnostic tests, such as colonoscopy or Computed tomography 
(CT)-based examinations, with biopsies taken of suspicious lesions(5). Following 
histological confirmation of malignancy, patients undergo staging investigations to 
establish whether the tumour is resectable and to determine the presence of any 
metastases. Magnetic Resonance Imaging (MRI) imaging of the pelvis is performed in 
patients with rectal tumours in addition to CT imaging of the thorax, chest and abdomen 
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for all colorectal tumours(6). In addition to determining which patients can be put forward 
for surgery, staging also allows for the identification of those patients who may benefit 
from neo-adjuvant therapies, such as chemoradiotherapy(3,6). Surgery with curative 
intent, plus or minus other therapies, is the only management option whereby a cure is 
possible(7). All decisions regarding a patient’s care in the UK originate from discussions 
at the local multi-disciplinary meeting(6,8). Input is received from different specialties to 
ensure that the patient receives the best individualised care. 
 
Surgery for colorectal cancer entails segmental resection of the bowel with en-bloc 
resection of the regional lymph nodes. Unless indicated by preoperative imaging or by 
intraoperative findings, the highest level of lymph nodes, the D3 nodes in the para-aortic 
area, are not routinely removed for surgeries performed in the UK (Figure 1.1). Rather, it 
is more common for only the D1 and D2 lymph nodes to be removed during routine 
segmental colectomy(9).  
 
The resected specimen is examined by histopathologists to accurately stage the depth of 
penetration of the tumour through the bowel wall (T-stage) and the presence of lymph 
node metastases (N-stage), which is important for predicting the patient’s prognosis. 
Involvement of the lymph nodes is an important prognostic factor, with lymph node 
positive disease correlating with poor prognosis(10–13). If the cancer has progressed 
beyond the bowel wall, infiltrated the lymph nodes, or spread to distant organs, then the 
chances of cure with surgery alone are greatly diminished.  
 
The lymphatic system is one route by which malignant tumour cells can spread 
throughout the human body(14). The lymphatic vessels follow the vascular supply to the 
different segments of the colon. The lymphatic drainage of the colon is believed to follow 
an orderly procession from the tumour into the epicolic lymph nodes, D1, then 
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sequentially up the lymphatic chain to the level of the para-aortic nodes, D3 (Figure 1.1). 
However, there are instances where lymph node metastasis can “skip” levels or drain to 
lymph nodes outside the conventional resection area, known as aberrant drainage, and 
these phenomena are noted in other solid tumours(15). Another definition of lymph node 
skip metastasis is metastases found within non-sentinel lymph nodes despite the 
sentinel lymph node being negative for disease. It is of vital importance to examine the 
lymph nodes within the resected specimen as the presence of nodal disease 
substantially alters the patient’s prognosis and therapeutic options(9). Around 25-40% of 




Figure 1.1. Diagram depicting different levels of lymph node stations within 
colonic mesentery. Taken from Andrew et al.(9).  D1 lymph nodes = red, D2 
nodes = blue, and D3 nodes = yellow. Coding for the lymph node stations; the first 
number of the code indicates the position of the lymph node and correlates with its 
colour (epicolic and paracolic D1 lymph nodes are denoted as 1X, intermediate D2 
lymph nodes are denoted as 2X and the D3 lymph nodes are denoted as 3X) and 
the second number indicates the position of the lymph node along the main arterial 
trunk (X1 nodes follow the ileo-colic artery, X2 follow the right colic artery, X3 
follow the middle colic artery, X4 follow the left colic artery, X5 follow the sigmoid 
artery and X6 follow the superior rectal artery). For example, lymph node station 
21 represents intermediate D2 nodes located along the ileo-colic artery. 
 
Currently, there is no reliable method to confirm the presence of lymph node metastases 
prior to histopathological examination of the resected colorectal specimen. This presents 
a clinical dilemma; if the patient has undergone a D2 lymphadenectomy and positive 
lymph nodes are found upon histological examination, then there is potential for residual 
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disease to persist within the higher level (D3) nodes. Conversely, if there is no disease 
present in the lymph nodes then the patient has had a more extensive resection than 
required. 
 
1.1.2 Complete mesocolic resection and D3 evidence 
The basis of CMR is the resection of the tumour and its draining lymphatics and vascular 
supply within a complete mesocolic envelope of mesenteric fascia and visceral 
peritoneum, similar to the now familiar total mesorectal excision (TME) dissection for 
rectal tumours(17,18). There is evidence suggesting lower rates of local recurrence and 
improved 5-year disease-free survival with complete mesocolic resection (CMR) of the 
tumour with central vascular ligation or extended D3 lymphadenectomy(19–23). 
Hohenberger et al.(19) introduced the technique of CMR and central vascular ligation 
into their surgical unit and were able to demonstrate with prospective data a 7% increase 
in 5-year survival and a 2.9% reduction in local recurrence rates compared with 
conventional resection. Bertelson et al.(24) performed a retrospective study comparing 
the disease-free survival in 1031 patients with conventional resections for their colonic 
tumours versus 364 patients who underwent CMR. They showed an increase in 4-year 
disease-free survival of 10.2%, 14% and 6% in stage I, II and III disease respectively. 
CMR was shown to be a significant independent predicative factor for improved disease-
free survival on multivariable Cox regression.  
 
Advocates for CMR or extended D3 lymphadenectomies highlight the oncological 
advantages in the technique in addition to a higher yield of excised LNs which studies 
have shown correlate to an increased survival rate(17,19). Chang et al.(25) performed a 
systematic review to determine whether the number of LNs examined following 
resections of colon cancer impact the patients oncological outcomes. Of the 17 studies 
included in the review, 16 demonstrated improved survival outcomes in patients with 
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stage II colon cancer with an increased number of evaluated LNs although they 
acknowledge that a minimum or threshold number of LNs could not be determined. Their 
review also showed that of six studies that looked specifically at stage III disease four 
studies were able to demonstrate improved survival outcomes with increased examined 
LNs. Studies have also suggested an additional survival benefit with increasing numbers 
of negative LNs within the resected specimen(17). West et al.(23) demonstrated a 15% 
increase in 5-year survival in patients with stage III disease who had a complete 
mesocolic resection of their tumour with no disruption of the mesocolic envelope. 
 
Saha et al.(26) conducted an investigation into the lymphatic mapping of 500 
consecutive patients with colorectal cancer and found the incidence of skip metastases 
to be 11% for colon cancer and 7% for rectal tumours. This means that even if all the 
examined lymph nodes within the resected specimen are negative for metastatic disease 
there may be D3 nodes or nodes outside of the traditional resection territories which are 
node positive. Supporters of CMR or extended D3 lymphadenectomy propose that skip 
metastases should be included in within the specimen addressing this issue(17,18). 
 
Criticisms of CMR and extended D3 lymphadenectomy include the lack of robust 
evidence of benefit as there have been no randomised controlled trials comparing the 
technique to standard conventional resection, doubts about the validity of the survival 
advantages and concerns regarding the exposure of patients to additional risks and 
functional problems(17,20). The study by Hohenberger et al.(19) showed increased 
disease-survival rate with reduced local recurrence when comparing CMR with extended 
D3 lymphadenectomy to conventional surgical resection in a large series of patients 
within a single unit. However, this study fails to take into account the introduction of 
adjuvant chemotherapy, which occurred around the same time as the change in surgical 
technique, and represents a significant confounding factor in these reported results(17). 
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It has also been suggested that the survival benefits seen in CMR and extended D3 
lymphadenectomy actually represents upstaging of tumours from stages I-II to III-IV with 
the increased likelihood of discovering occult LN metastases. 
 
There are concerns that an extended D3 lymphadenectomy might expose patients to 
increased intraoperative risks(27,28). CMR guidelines advise en-bloc resection of the 
LNs at the origin of the supplying vessel to the tumour but this exposes patients to the 
risk of nerve damage as well as vascular injury(18). Nerve injuries can lead to severe 
diarrhoea, sexual dysfunction and urological disorders. Killeen et al.(29) conducted a 
systematic review evaluating CMR with an extended D3 lymphadenectomy against 
patient survival statistics, local recurrence rates, and morbidity and mortality. Most of the 
studies were retrospective in nature, and there were no randomised control trials to 
provide more robust data. The review concluded that there were limitations within the 
included studies, such that CMR with extended D3 lymphadenectomy could not be 
recommended as standard practice, although the report did acknowledge that 
complications, morbidity and mortality rates of CMR with extended D3 lymphadenectomy 
were comparable to standard resections.  
 
It should also be noted that, as the vast majority of patients undergoing colorectal cancer 
surgery do not have lymph node disease, performing an extended lymphadenectomy in 
every individual would be over-treating ~70% of patients with node negative disease and 
potentially expose them to unnecessary risk with an unclear evidence base of survival 
benefit for doing so. In addition, LN metastases outside the conventional field of 
resection can be missed even with extended lymphadenectomy(18), under-treating a 
small proportion of patients. The parallel progression model of LN metastases theorizes 
that nodal involvement reflects the underlying biological behaviour of the tumour(30), 
indicating that these tumours are more aggressive and have disseminated cancer cells 
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early in their life span. If this model is correct it would suggest that the poor survival 
outcomes of patients with nodal disease is related to the tumour biology and therefore 
the extent of lymphadenectomy would not greatly impact the patient outcomes. 
 
Improvement in the ability to accurately stage the disease and locate metastatic disease 
prior to resection of the specimen would enable clinicians the opportunity to determine 
whether more extensive dissection of the LNs does in fact confer a survival advantage to 
patients and to strategize and counsel patients appropriately. 
 
1.2 Staging of colorectal cancer 
1.2.1 Current practice and importance of lymph node staging 
The staging system most commonly used is the TNM system classified by the American 
Joint Committee on Cancer (AJCC) and is based on the extent of the tumour growth (T), 
presence of disease within the regional lymph nodes (N), and spread to distant sites (M) 
(Table 1.1). Standard practice in the UK, as recommended by The National Institute for 
Health and Care Excellence (NICE), is for patients with colorectal cancer to have a 
contrast-enhanced CT scan of the chest, abdomen and pelvis to provisionally stage the 
disease(5). CT scanning indicates how far the tumour has penetrated through the bowel 
wall, potential involvement of regional lymph nodes, and the presence of distant 
metastatic disease(31), which are all prognostic factors. Patients with rectal cancer also 
undergo MRI to assess the resection margin, which determines whether surgery can 




Table 1.1.TNM Classification of Malignant Tumours staging system (8th edition)(32)  
Tumour 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour confined to submucosa 
T2 Tumour grown into (but not through) muscularis propria 
T3 Tumour grown into (but not through) serosa 
T4 
a Tumour penetrated through serosa and peritoneal surface 
b Perforation of bowel 
Tx Main tumour cannot be assessed due to lack of information 
Nodes 
N0 No regional lymph nodes contain tumour cells 
N1 
a Tumour cells present in 1 regional lymph nodes 
b Tumour cells present in 2-3 regional lymph nodes 
c Tumour deposits present locally but regional lymph nodes do not contain 
tumour cells 
N2 
a Tumour cells present in 4-6 regional lymph nodes 
b Tumour cells present in ≥7 regional lymph nodes 
Nx Regional lymph nodes cannot be assessed due to lack of information 
Metastases 
M0 No metastasis to distant organs 
M1 a Metastasis confined to one organ 
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b Metastasis in ≥1 organ 
c Metastasis to the peritoneum +/- other organ involvement 
Mx Metastasis cannot be assessed due to lack of information 
 
Staging of colorectal cancer is important because it determines whether the cancer is 
curable with surgery alone, or whether adjuvant chemo/radiotherapy is required. Staging 
also enables identification of patients with resectable distant metastatic disease, for 
instance within the liver. Patients who undergo resection of liver metastases have a 40% 
5-year survival rate compared with 0% survival at 5 years in untreated patients or 
patients with unresectable liver metastases(31). 
 
1.2.2 Limitations of current staging strategies  
CT and MRI are both limited in the accuracy of predicting nodal status in patients with 
colorectal cancer. Radiological criteria for possible lymph node metastases include 
irregular lymph node walls, calcification and nodes over 1cm in size. However, these 
criteria can be misleading, for example normal sized lymph nodes can contain 
metastases whereas enlarged lymph nodes can simply be reactive(31). For staging 
purposes, therefore, the value of radiological imaging is mainly to predict the depth of 
penetration of the tumour through the bowel wall and the presence of distant metastatic 
disease. 
 
A prospective study investigating CT scanning to identify lymph node metastases 
showed a diagnostic accuracy of 58% (95%CI: 48, 68), sensitivity of 64% (95%CI: 48, 
77) and specificity of 53% (95%CI: 39, 67)(33). A meta-analysis of 19 studies with a total 
of 907 patients indicated sensitivity and specificity for CT-detected malignant lymph 
nodes of 70% (95%CI: 59, 80) and 78% (95%CI: 66, 86)(34) respectively.  
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Positive emission tomography (PET) also has a role in assessing patients with primary 
and recurrent colorectal cancers. It has long been demonstrated that malignant tissues 
have an increased rate of glycolysis due to the increased presence of glucose 
transporters on the plasma membranes of cancer cells, such as GLUT-1, in addition to 
the increased expression of glycolysis rate-limiting enzymes, such as hexokinase(35). 
This phenomenon is exploited during FDG-PET imaging where the majority of malignant 
cells show an increased uptake of the glucose analogue, fluoro-2-deoxyglucose 
(FDG)(35). A prospective study of 104 patients comparing the pre-operative staging of 
colorectal cancer between conventional CT imaging and fluorine-18 fluorodeoxyglucose 
PET (FDG-PET) showed that the results for determining the nodal status between the 
two imaging modalities were similar(31). The accuracy for CT and FDG-PET were found 
to be 60% and 56% respectively. The sensitivity for detecting nodal disease was 25% 
and 21% respectively for CT and FDG-PET. The authors concluded that although 2-
3mm sized lymph nodes could be seen on these imaging techniques the reliable 
detection of metastatic nodes remains impossible using radiological imaging alone. 
 
1.2.3 Area of clinical need 
In order for the radicality of surgery to be tailored to the fitness of the patient and the 
biology of the primary cancer it is necessary to accurately identify, either preoperatively 
or during intraoperative assessment, the nodal status of the patient prior to surgical 
resection. Without an accurate knowledge of lymph node status, introducing a routine 
policy of radical resection with extended lymphadenectomy could have a detrimental 
effect on the outcome for elderly patients(9). The incidence of lymph node metastases in 
early cancer is low and therefore radical resection with extended lymphadenopathy 
would again be exposing patients to increased surgical risks with no survival 
benefit(9,27). Current radiological staging is not sensitive enough to accurately detect 
lymph node metastases pre-operatively(33,34,36). Therefore, there is a need for a 
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clinical modality to accurately predict nodal status in patients, prior to a decision 
regarding the extent of lymphatic resection. 
 
1.3 Strategies to improve staging of lymph node involvement 
1.3.1 Sentinel lymph node biopsy and mapping 
Sentinel lymph node biopsy (SLNB) and mapping was first described in 1992 by Morton 
et al. investigating patients with melanoma(37) and is a technique that has been 
developed to aid lymph node identification during surgery. The sentinel lymph node 
(SLN) is defined as the first regional lymph node that receives lymphatic drainage from 
the primary tumour and is considered to be the first potential site for lymphatic 
metastasis. Sentinel node mapping is based on the concept that the status of the 
sentinel lymph node reflects the status of the remaining regional lymph nodes(38). 
Therefore, if the sentinel lymph node does not contain any metastases it is assumed that 
the remaining lymph nodes are also free of metastatic activity(39). 
 
Sentinel lymph node mapping (SLNM) involves a peritumoural injection (Figure 1.2) of a 
colorimetric dye, such as methylene blue. It is given prior to resection and ligation of the 
supplying vasculature and it spreads through the draining lymphatic system, allowing the 
draining nodes (Figure 1.3) to be identified (13,37). A radioisotope tracer is frequently 





Figure 1.2. Illustration depicting sentinel lymph node mapping technique in 
breast cancer surgery. Taken from www.medicalook.com(41). The labelling 
agent is injected into the breast tumour where it disperses into the lymphatic 
system enabling the surgeon to identify the initial lymph nodes within the 




Figure 1.3. Axillary sentinel lymph node identified during lymphatic mapping in a 
breast cancer patient. Taken from ClinicalGate(42). Intraoperative photograph 
demonstrating lymphatic vessels draining into an axillary sentinel lymph node 
during a sentinel lymph node biopsy for breast cancer staging. The lymphatic 
vessels and lymph nodes are easily identifiable due to the presence of the 
colorimetric dye, methylene blue.  
 
SLNB has become routine practice for certain cancers, such as breast cancer (43,44). It 
has reduced the morbidity associated with axillary lymph node clearance to determine 
lymph node status. SLNB has been shown to be accurate at predicting the nodal status 
in breast cancer and melanoma patients (45). This has stimulated a number of studies 
investigating whether SLNB can be used in other cancers . Some early studies of SLNB 
in colorectal cancer have suggested improved staging, increased lymph node 
yield(26,46) and evidence of aberrant lymphatic drainage outside the planned resection 
area(45). Saha et al.(47) used blue dye sentinel lymph node mapping in 192 patients 
with colon cancer and found that aberrant lymphatic drainage was present in 22%. 
These patients subsequently underwent extended mesenteric dissection and 
interestingly there was a higher incidence of nodal disease within this sub-cohort 
compared to those patients without aberrant drainage (62% vs 43%).  
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Sentinel lymph node mapping techniques have also been attempted with oesophago-
gastric tumours, with the intention of avoiding unnecessary lymphadenectomy and 
permitting the use of minimally invasive techniques whilst maintaining adequate 
oncological resection. Matsuda et al.(39) used a dual tracer technique in 15 patients with 
junctional oesophago-gastric tumours and managed to detect a mean of 5.5 SLNs per 
patient with a 100% identification rate. 56% of SLNs were detected with radioactivity 
alone, 20% with only methylene blue dye and the remaining 24% were both blue and 
radioactive. Sensitivity was 100%, however, only two patients in the cohort of 15 had 
nodal disease and therefore these results may not be truly representative due to the low 
numbers. An additional limitation to this study is that only patients with cT1 N0 M0 
tumours of a diameter < 4cm were included, which have a low incidence of nodal 
disease (2-18%)(48). Ishizaki et al.(49) investigated 101 patients with T1/2 gastric 
cancer to determine if SLNM with blue dye alone could accurately stage the nodal status 
and consequently be used to prevent unnecessary gastrectomy with D2 
lymphadenectomy in node-negative patients. They found an identification rate of 100%, 
with a sensitivity of 85.7% and 3 false-negatives (3%). The main concern regarding this 
study is that although it has a large number of patients, changes were made to 
histopathological examination of the LNs, with extensive examination of all SLNs and 
non-SLNs in the last 32 patients, accounting for a third of the cohort. This increased the 
sensitivity and reduced the false-negative rate, but it is unfeasible to implement such 
extensive examination of all lymph nodes in standard practice. A similar, smaller study of 
29 patients was conducted by Cozzaglio et al.(48) in T1/2 gastric cancer patients, using 
blue dye SLNM performed by a single operator. The detection rate was 96.6% although 
the authors excluded the single patient where a SLN was not identified from further 
analysis. The sensitivity was 75% with a false-negative rate of 18%. Collectively, the 
main conclusions from these studies is that conventional SLNM is technically feasible in 
oesophago-gastric cancer patients but is lacking in the ability to accurately stage the 
nodal status of the patient and therefore cannot be recommended. 
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1.3.1.1 Sentinel lymph node mapping in colorectal cancers 
Difficulties in utilising SLNM techniques in colorectal cancer could be attributable in part 
to the higher complexity and non-linear distribution of the lymphatic pathways in the 
colon, as compared to the breast(50). In addition to the anatomical challenge in 
colorectal cancer, the current gold standard is a full lymphadenectomy as described 
earlier and sentinel node studies have not yet demonstrated sufficient accuracy at 
identifying nodal status to influence surgical strategy. Neoadjuvant chemotherapy(26) or 
radiotherapy(13) can cause sclerosis of the lymphatic pathways, resulting in a distorted 
lymphatic anatomy. Other technical errors include incorrect injection of dye, insufficient 
experience with the technique, resecting the specimen before or immediately after dye 
injection thereby disrupting the lymphatic basin, and the administration of an insufficient 
volume of dye(13,51). There is also the potential issue of tumour deposits within the 
lymphatic channels causing obstruction and thereby affecting the results of SLNM(52). It 
has been suggested that the lower identification rates in obese patients is attributable to 
the lipophilic nature of the colorimetric dye(13,45,51). Sentinel lymph node mapping has 
disadvantages including the limited tissue penetration of the colorimetric dyes, making 
identification of deeper lymph nodes difficult. The use of dyes for SLNM has also been 
associated with causing potential allergic reactions(53). Laparoscopic lymphatic mapping 
has posed problems with the correct identification of the peritumour injection site, 
particularly when the tumours are small(50), as well as intra-abdominal spillage of the 
dye(52). Radioisotopes carry the disadvantage of potential harm from ionising radiation, 
as well as posing difficulties in handling radioactive substances in the operating theatre 
(40). Colorimetric dyes carry the potential risk of adverse reactions, which include a mild 




Bembenek et al.(45) performed a controlled multi-centre prospective trial, enrolling 315 
patients with colon carcinoma. The primary aim of the study was to establish whether 
SLNB using colorimetric dye alone in these patients could accurately predict the nodal 
status of the specimen. Nineteen university hospital centres were recruited for the study. 
The study design was strong with a sizable cohort of patients, however, peritumoural 
injection of the dye was performed following mobilisation of the colon which may have 
influenced the results. If the SLN was clear of disease on routine sectioning more 
invasive histopathological techniques (Haematoxylin & Eosin staining and 
immunohistochemistry) were performed. 85% of patients in the study had at least one 
sentinel lymph node detected although this was significantly affected by the experience 
of the centre. A ROC-curve analysis demonstrated a learning curve with a cut-off of 22 
patients. The SLN detection rate in centres with less than 22 patients was 76.4% 
compared to 91% in centres with more than 22 patients.  
 
Within the Bembenek et al.(45) study, 31% of the cohort had positive nodal disease. The 
sensitivity of SLNB in this cohort was 54%, with a false-negative rate of 46%, which the 
authors acknowledged clearly does not support using SLNB in colon cancer to stage 
nodal disease. Further subset analysis indicated that there was an effect on the 
sensitivity of SLNB related to the patient’s body mass index (BMI). A ROC-curve 
analysis showed that the sensitivity of SLNB increased to 80% where the BMI was less 
than or equal to 24. The sensitivity was 42% in patients with a BMI greater than 24. 
Sixteen patients out of 315 met the criteria of having a BMI  24 and had their SLNB and 
resection performed in a centre with more than 22 patients enrolled in the study. 
Analysis of these 16 patients results showed a sensitivity of 88%, which is still too low to 
recommend implementing this strategy into current practice. Although numbers are low, 
it would be interesting if the study was repeated to see what the detection rates, 
sensitivity and false-negative rates would be if these parameters were part of the trial 
inclusion criteria.  
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Another area of interest in SLNM in colon cancer is whether it could identify aberrant 
lymphatic drainage thereby altering the resection margins. Bembenek et al.(45) found 
aberrant drainage in only five patients (1.6% of the cohort), with no evidence of 
metastatic disease in the aberrant nodes and concluded that blue dye SLNB could not 
be relied upon to identify the resection margins of the tumour specimen. The study also 
assessed whether SLNB could be used to upstage patients by identifying 
micrometastases and isolated tumour cells within the SLN. There was an overall 
upstaging rate of 21.3% in node negative patients which increased to 24.2% in the 
clinically important Stage II patients. However, the prognostic significance of 
micrometastases and isolated tumour cells is unclear, and there is no current evidence 
to alter patient’s post-operative management on the basis of these histopathological 
findings.  
 
Bianchi et al.(50) agree that in today’s climate with changing demographics and 
minimally invasive techniques, such as natural orifice transluminal endoscopic surgery 
(NOTES), there should be an emphasis on avoiding unnecessary extended 
lymphadenectomy. The authors propose that sentinel lymph node mapping could be an 
effective solution. They published results from a cohort of 75 patients over five years with 
early disease colon cancer and demonstrated a false-negative rate of 22.2%. 
Furthermore, in ~10% of patients, ex vivo lymphatic mapping was necessary to identify 
at least a single sentinel lymph node. A smaller cohort of eight patients who received a 
radiocolloid tracer, instead of the colorimetric dye, showed an impressive negative 
predictive value of 100% with no false-negatives or side-effects from the tracer. This 
shows promise, but it is difficult to judge these results with such a small cohort of 
patients and there is a lack of data investigating the combination of colorimetric dye and 
radiocolloid tracer in colon cancer.  
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Park et al.(52) compared in vivo versus ex vivo SLNM techniques to determine whether 
either techniques could improve nodal staging by focused intensive histopathological 
examination of the SLN. The study was conducted in a cohort of 69 consecutive patients 
with colorectal cancer. The authors described that ex vivo SLNM could be as accurate 
as in vivo SLNM but without the disadvantages inherent in performing blue dye mapping 
intraoperatively. In both techniques, the specimen was mobilised prior to blue dye 
injection. This raises the concern that the results could have been affected by disruption 
of the lymphatic pathways. Overall, with the combination of the two techniques, the  
overall SLN detection rate was 85.5% with 89.8% accuracy, 81.2% sensitivity, and 
18.8% false-negative rate. 
 
The detection rates of SLN were 81.1% and 90.6% for the in vivo and ex vivo 
techniques, respectively. With regard to accuracy (93.1% vs. 86.6%), sensitivity (86.7% 
vs. 76.5%) and false-negative rates (13.3% vs. 23.5%), the ex vivo technique 
outperformed the in vivo technique, although no significant difference was found 
between the results. Neither technique has performed adequately to recommend a 
change to clinical practice. Although ex vivo SLNM had similar results to in vivo SLNM, 
the authors have not addressed the issue of missing any aberrant lymphatic drainage 
with the ex vivo technique. They also fail to justify ex vivo SLNM with respect to 
disrupting the lymphatic pathways by resecting the specimen and ligating the supplying 
vasculature.  
 
The overall disease recurrence rate in patients with early stage node-negative disease is 
20-30% and this is thought to be due to inadequate lymphadenectomy, histopathological 
understaging of the specimen or a combination of the two. Chan et al.(44) hypothesised 
that SLNM could reduce the recurrence rate by accurately identifying patients with 
positive nodal disease and enabling focused histopathological examination of the SLN. 
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They conducted a prospective trial of blue dye SLNM in 31 patients undergoing surgery 
for colorectal cancer and demonstrated a detection rate of 80.7%. The detection rate for 
colonic tumours was 94.7% (19 patients) compared with 58.3% for rectal tumours. The 
false-negative rate was 21.4% with a sensitivity of 78.6% and an accuracy of 88%. The 
sensitivity of SLNM in colonic versus rectal tumours was 75% and 83.3% respectively. 
The discrepancy between the colonic and rectal tumour results was attributed by the 
authors to the time delay between peritumoural submucosal injection of the dye via a 
proctoscope and visual inspection of the specimen for SLNs, which is a plausible 
explanation. The results from this study (with the exception of the detection rate in the 
colonic tumours alone) are in concordance with other studies. However, there are 
several concerns regarding the methodology. In addition to the tumour being mobilised 
prior to blue dye injection, the median number of LNs harvested from the patients was 6 
with a mean of 7.48. This is below the recommended minimum of 12 harvested LNs(54) 
and therefore raises questions either about the surgical technique or the 
histopathological examination. 
 
Albayrak et al.(13) had a SLNM detection rate of 94.7% in a cohort of 38 colon cancer 
patients with a sensitivity of 100% and a false-negative rate of 0% using blue dye. The 
authors suggested that their high detection and accuracy rates could be related to the 
fact that the procedure was carried out by an experienced single operator in patients with 
Stage I-III disease. However, the numbers are low, especially compared with studies 
such as Bembenek et al.(42), and are not representative of other larger studies.  
 
In Japan, patients with T3/4 low rectal tumours undergo radical extended retroperitoneal 
and lateral pelvic lymphadenectomy (RLPL) as part of their standard surgical resection. 
However, this technique is not part of Western practice mainly due to the increased 
morbidity, the low incidence of nodal metastases within this distribution of lymph nodes, 
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and the belief that disease present in these nodes may represent incurable, systemic 
disease(55). Japanese surgeons, therefore, have a similar dilemma faced by breast 
surgeons prior to SLNB, where they were unnecessarily exposing node negative patients 
to the increased morbidity of axillary clearance. Quadros et al.(55) used a combination of 
blue dye and radiocolloid tracer to investigate SLNB in 97 patients undergoing resection 
of invasive rectal adenocarcinoma by a single surgeon. Although this is a worthwhile 
endeavour, which at first glance has favourable results with an accuracy of 100%, 
sensitivity of 100% and a 0% false-negative rate, there are a number of serious issues 
with the study. Firstly, the TME was performed prior to lymphatic mapping, which 
potentially disrupts the lymphatic pathways, and secondly the authors analysed the 
accuracy, sensitivity and false-negative rates in patients where identification of SLNs 
was achieved; this only occurred in 37.1% of the cohort which is a low identification rate. 
In addition, only blue radioactive SLNs underwent intensive histopathological analysis 
due to budget constraints and therefore the false-negative data could potentially be 
inaccurate. 
 
Van der Zaag et al. performed a meta-analysis(56) of 57 studies comprising a total of 
3934 patients investigating sentinel lymph node mapping in colorectal cancer. The 
majority of studies were conducted using an in vivo technique. However, there were a 
number of studies using the ex vivo technique and eight studies used a combination of 
the two. Identification of the SLNB was either by colorimetric dye alone or with a 
radiocolloid tracer; 11 studies used a dual approach. Although the meta-analysis showed 
an overall detection rate of 92%, there was an overall false-negative rate of 30% and a 
diagnostic accuracy of 69%. It should be noted that only 10 out of 57 studies had a 
cohort larger than 100 patients. Mulsow et al. (57) conducted an earlier similar 
systematic review of SLNM methods including both blue dye and radiocolloid tracer 
alone and with a combination of both as well as in vivo and ex vivo techniques. Their 
results demonstrated low and variable detection rates of 58-98%, with sensitivity rates 
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varying between 40% and 100%. They also reported a high false-negative rate of up to 
60%. Therefore, sentinel lymph node mapping as a staging procedure in colorectal 
cancer resections is not routinely practiced. 
 
Typically, histopathologists examine a single section level in each lymph node for 
metastases on standard analysis of a resected specimen. Metastatic foci of tumour cells 
can be unevenly distributed throughout the node and therefore missed using this 
technique, ultimately understaging the patient(13). This is termed tissue allocation bias 
and can be reduced by intensive histopathological analysis, in combination with 
immunohistochemistry (IHC). However, this is time consuming and expensive, rendering 
it impossible to employ for every node harvested from each patient. Retter et al.(51) 
suggested that sentinel lymph node mapping could be employed to better identify 
patients who should have more intensive examination of their lymph nodes. A 
prospective study in 31 patients undergoing laparoscopic resection of colon cancer using 
blue dye only was undertaken and showed a sentinel lymph node detection rate of 90%. 
It was noted that sentinel lymph node mapping was not achievable in the patients with 
morbid obesity (two patients), and it was felt this could be related to the lipophilic nature 
of the patent blue dye. Twelve patients had stage III disease and it was found on a 
subset analysis of these patients that there was a high false-negative SLNB rate of 66%. 
This suggests that perhaps SLNB should only be considered in patients with early stage 
disease, especially given that SLNB is recommended only for small to medium sized 
tumours in patients with melanoma or breast cancer(58). The published data from this 
study has not included the number of patients with positive nodal disease, which 
precludes confirmation of the statistical analysis. However, the rate of upstaging from 
stage II to stage III disease by employing intensive histopathological techniques in 
patients with sentinel lymph nodes containing metastatic disease was 5%. Although 
there were low numbers in the study, the authors felt that given the poor results and an 
accuracy of 14%, SLNB could not be supported in predicting the nodal status of patients 
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with colon cancer. One factor not considered within this study is that sentinel node 
mapping was performed post mobilisation of the colon which may have disrupted the 
lymphatic pathways producing poor results. 
 
The above studies have also shown that blue dye sentinel lymph node mapping is safe 
and does not caused additional harm to patients(51).  
 
In summary, SLNM in colorectal cancer patients has not been able to achieve the high 
SLN identification and sensitivity rates, as well as the low false-negative rates, achieved 
with SLNM in melanoma and breast cancer patients. This means that with the current 
techniques available, SLNM with blue dye +/- radiocolloid tracer, cannot be 
recommended for intraoperative lymph node staging for colorectal adenocarcinoma.  
 
1.3.2 One Step Nucleic Acid Amplification 
NICE has recently recommended the use of One Step Nucleic Acid Amplification 
(OSNA) in vitro diagnostic molecular assay system in the post-operative staging of 
colorectal cancer(59). This system detects the level of a biomarker, cytokeratin-19 
(CK19), which correlates with the number of metastatic cells present in the examined 
tissue and was originally developed as a tool to reduce the burden of pathologists 
examining SLNs for breast cancer patients(60). Although this technique was developed 
for use in breast cancer, several other studies have explored using OSNA in other 
tumours such as gastric, lung, thyroid and colorectal cancer. Three studies(61–63) 
investigating the use of OSNA in patients with colorectal cancer, with a combined total of 
253 patients and 2,232 lymph nodes, showed a sensitivity of 92.5-94.5%, a specificity of 
96.5-97.6% and an upstaging of node negative to node positive disease in up to 25% of 
patients. A more recent study conducted in Japan included 284 patients and examined 
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1925 lymph nodes using the OSNA system. Yamamoto et al.(64) showed a concordance 
rate of 95.7% between one slice of H&E staining and OSNA with a sensitivity of 86.2% 
and specificity of 96.5% for the latter technique.  
 
OSNA allows the entire lymph node to be assessed thereby reducing the effect of tissue 
allocation bias and has been shown to be more accurate than standard histopathological 
assessment. However, it is unclear whether the increased detection of malignant lymph 
nodes is due to OSNA detecting micrometastases, which are of uncertain clinical 
significance(65), and one study suggested that intensive histopathological assessment 
with IHC had comparable results. Currently, OSNA is only recommended for assessment 
of lymph nodes obtained from the pathology specimen. However, there is scope to 
investigate its ability to assess sentinel lymph nodes taken at the time of surgery in order 
to facilitate intraoperative decision-making.  
 
1.3.3 Fluorescence-guided surgery in colorectal resections 
1.3.3.1 Fluorescence 
A potential solution to intra-operative lymph node staging involves fluorescence-guided 
surgery with the intention of allowing identification of the tumour and the presence of 
lymph node metastases. Several photoactive drugs have been investigated for this 
purpose, including indocyanine green (ICG) and 5-aminolevulinic acid (5-ALA). 
Fluorescence refers to the emission of light from a photoactive molecule (fluorophore) 
after it has absorbed electromagnetic radiation from an external source and ceases as 
soon as the exciting radiation is withdrawn. This phenomenon can be exploited clinically 
with fluorescence imaging, whereby a fluorophore is exposed to the excitation radiation 
and a light detecting instrument is used to detect and image the emitted light.  
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The emission of light from a molecule is termed luminescence; luminescence is further 
characterised into fluorescence and phosphorescence depending on whether the 
luminescence is due to excitation of an electron in the singlet or triplet state 
respectively. Fluorescence occurs when a fluorophore (a fluorescent chemical 
compound that can re-emit light upon excitation) is exposed to a wavelength that 
causes an electron to transition from the ground state to a maximal energy level, termed 
the excited electronic singlet state(68–70). The fluorophore will undergo atomic 
structural changes releasing some energy, for example as heat, and the electron falls to 
a lower and more stable energy level, the singlet state. Return of the electron to ground 
state from singlet state involves the emission of residual energy (Figure 1.4). The 
surplus energy is then released as fluorescence(68,70). The emitted light is usually of 
lower energy than the absorbed light and is therefore of a longer wavelength (as the 
wavelength is inversely proportional to the energy of light)(68). Fluorescence will cease 
once the stimulating excitation source is removed, whereas phosphorescence will 
persist as an afterglow. The lifetime of a fluorophore is the average of the length of time 
between the excitation of the electron and its return to ground state(70). As long as the 
fluorophore is not damaged irreversibly in its excited state the process can be repeated. 
Photobleaching occurs when high intensity illumination degrades the fluorophore during 
its excited state where the molecular structure is unstable, irreversibly changing the 








If the emitted photon has less energy than the absorbed photon (as highlighted in 
Figure 1.4) the energy difference is termed the Stokes shift, after the Irish physicist 
George Gabriel Stokes. This can be represented as the difference between the peaks 
(band maxima) of the excitation and emission spectra of the fluorophore(73). An 
example of an approved fluorescent probe called Indocyanine Green is shown in Figure 
1.5. The band maxima of the excitation and emission spectra are 788nm and 813nm 




Figure 1.4. Energy level diagram for fluorescence (Jablonski Diagram). Taken from 
https://gauravtiwari.org/jablonski-diagram/(292). S0 = resting ground state, S1 = 
excited electronic singlet state, S2 =  second excited electronic singlet state. A 
Jablonski diagram illustrates the transition of a molecule through its electronic 
states following exposure to an excitation wavelength. When a fluorophore is 
exposed to light energy, it’s excited to a higher vibrational energy level in the first 
excited state (S1) before relaxing to the lowest S1 energy level. Fluorescence 
represents the release of the surplus energy as the electron returns from the 













The brightness or intensity of a fluorophore is determined by the quantum yield and the 
extinction coefficient. Quantum yield in terms of fluorescence refers to the ratio of the 
number of photons emitted to the numbers of photons absorbed through fluorescence. 
Increasing the intensity of the exciting irradiation may increase the brightness of the 
emitted fluorescence, however this may impact on the photostability of the probe(74). 
The extinction coefficient is dependent on the fluorophores chemical and structural 
composition and is a value depicting how strongly the fluorophore absorbs light radiation 
at a particular wavelength. Therefore, increased intensity in the emission of photons from 
a fluorophore results in increased overall brightness. Anything that decreases the 
intensity of the fluorescence of a given fluorophore is a reversible process known as 
quenching. Photostability of a fluorophore refers to its resistance to reactions or 
processes that induce quenching(71) and can be measured as the time taken for 50% of 
the fluorescent brightness to dissipate.  
 
Stokes shift 
Figure 1.5. Excitation and emission spectra of Indocyanine Green in water. Taken 
from www.iss.com(293). Blue = fluorescence excitation spectra, purple = 
fluorescence emission spectra. This excitation and emission spectra depict the 
change in the intensity of fluorescence of indocyanine green as a function of 
wavelength measured by a spectrofluorometer scanning across the desired 
wavelength range.  
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Photodynamic diagnosis (PDD) utilises these properties of fluorophores to help identify 
and visually localise tumour tissue for diagnostic purposes. Photodynamic therapy (PDT) 
involves the administration of photosensitising agents which are taken up and retained 
within cells. Under non-light conditions these compounds possess negligible toxicity. 
However, upon exposure to light of a specific wavelength these compounds will generate 
reactive oxygen species, resulting in oxidative stress and cellular destruction(75). There 
are several clinical advantages that near infra-red (NIR) fluorescent probes hold over 
other fluorophores. This includes minimal tissue autofluorescence and light absorption; 
tissue autofluorescence is due to the presence of different fluorescent biological 
structures such as flavins, collagen and mitochondria, which absorb in the range of 355-
488nm and emit in the range of 350-550nm(76). NIR wavelengths are also invisible to 
the human eye, with no visual impact on the surgical field and have deep tissue 
penetration (up to 1cm)(16,77,78).  
 
Examples of photosensitising agents that are currently being utilised for PDT in clinics 
today include Photofrin and 5-ALA. Photofrin has been approved to treat many cancers 
including bladder, oesophageal and endobronchial cancers(79) and 5-ALA is in routine 
use for the treatment of dermatological malignancies(9,80). A drawback to many 
photosensitisers is their hydrophobicity which significantly reduces their clinical 
potential(69,81). This is in addition to being limited by their lack of tumour specificity, 
tendency to form aggregates, poor circulation pharmacokinetics, short half-lives and 
adverse cutaneous photosensitive reactions(9,82). These disadvantages have prompted 
the incorporation of photosensitisers within a nanomedicine system in order to overcome 
limitations and actively target the photosensitiser against the desired tumour tissue. A 
study by Patel et al.(83) encapsulated a fluorescent dye, indocyanine green, into 
poly(lactic-co-glycolic acid) nanoparticles (NPs) which were then conjugated to different 
targeting ligands (RGD-4C peptides, folic acid and R11 peptides). There was significant 
increase in uptake of the targeted dye-loaded NPs in the prostate cancer cell line, PC3, 
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as compared to the bare non-targeted NP, suggesting their potential for photodynamic 
therapy.  
 
1.3.3.2 Indocyanine Green 
Indocyanine green (ICG) is a Food and Drug Administration (FDA) approved fluorescent 
probe which has previously been used for fluorescence-guided surgery. In comparison to 
the colorimetric dyes used for SLNM, ICG possess a safe toxicity profile. ICG 
accumulates within malignant tissue and is retained for a prolonged time as compared to 
benign and normal tissues(84). Activation of ICG with NIR light results in fluorescence in 




Figure 1.6. ICG fluorescence during laparoscopic right hemicolectomy showing 
the position of regional lymph nodes within the mesentery. Taken from 
Barocchi et al.(85). A – Laparoscopic visualisation of the ileocolic pedicle under 
white non-fluorescent light (top image), under fluorescence (middle image) and the 
composite overlay view of both white and fluorescent light (bottom image). B – 
Laparoscopic composite overlay view during dissection of the ileocolic pedicle 
demonstrating the presence of a fluorescent lymph node. C – Laparoscopic 
composite overlay view of the fully dissected ileocolic pedicle with lymph nodes 
visible within the mesocolic tissue due to ICG fluorescence.  
 
Sentinel lymph node mapping using ICG has previously shown high identification rates 
of 83-100% with a low number of false-negatives (<6%) in patients with breast, gastric, 
anal and skin cancers(86–89). It has also been reported that the sensitivity of blue dye 
SLNM is affected by the patient’s body mass index (BMI)(45), but this does not appear to 
be the case for ICG SLNM(90–92). Emile et al.(93) showed that the results of ICG SLNM 
were optimal when the ICG dose was calculated based on the patients weight as 
opposed to a standard dose. Limitations of ICG fluorescence includes the rapid 
clearance of the dye, meaning that training in the technique is essential to achieve high 
identification and accuracy rates(94).  
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Hirche et al.(12) presented data where ICG dye was used to identify and map the 
sentinel lymph nodes in 26 patients with colon cancer. Fifteen patients underwent open 
surgery whereas the remaining 11 patients had laparoscopic resections. The sentinel 
lymph node identification rate was 96%, with a sensitivity of 82% and a false-negative 
rate of 18%. The study was conducted by two surgeons experienced in fluorescence-
guided surgery although exact details regarding their experience was not documented. 
The results appear promising and show that ICG fluorescence-guided surgery is 
technically feasible in colon cancer, however, the study population was small with only 
26 patients. A further limitation is that the description of the method of peritumoural 
injection is unclear. It appears that two different methods were employed, which were not 
related to whether the patient had open or laparoscopic surgery. From the authors’ 
discussion it may be that an in vivo and ex vivo technique was used for ICG SLNM as 
they have claimed that the two techniques were comparable in their study but have not 
given any subset data analysis to support this claim. 
 
Cahill et al.(94) also investigated the use of ICG in the intraoperative identification of 
sentinel lymph nodes in laparoscopic colorectal cancer resections. In this study, 18 
consecutive patients were included. Thirteen patients had localised colorectal cancer, 
four had endoscopically unresectable dysplasia, and the remaining patient had a polyp 
cancer. All patients demonstrated lymph node fluorescence, including four patients 
where fluorescent lymph nodes were identified outside the conventional field of resection 
indicating aberrant lymphatic drainage. None of the aberrant lymph nodes contained 
metastatic disease which is in keeping in with the fact that ICG fluorescence is not 
tumour specific.   
 
Liberale et al.(84) have published initial data from a prospective trial investigating 
whether intravenously administration of ICG intraoperatively could detect LN metastases 
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in patients with colorectal cancer. They have reported the outcomes on their first two 
patients demonstrating that the technique is feasible and should be investigated further 
as the results are promising. With their first patient, in vivo fluorescence did not detect 
any SLNs. However, with an ex vivo technique three SLNs were detected, all of which 
contained metastatic disease. All remaining LNs were non-fluorescent. The second 
patient presented with recurrent disease following a previous right hemicolectomy and 
no evidence of LN involvement on CT or PET-CT imaging. In vivo and ex vivo 
fluorescent ICG imaging detected a single LN outside the planned resection margin 
which was found to be the only metastatic deposit in the specimen.  
 
Intraoperative sentinel node mapping using ICG has also been evaluated in open, early 
stage gastric cancer surgery. It has been suggested that ICG fluorescent guided surgery 
might address the high rate of extended lymphadenectomy. Miyashiro et al.(38) 
conducted a study which comprised 241 patients with T1/2 N0 gastric cancer and found 
the technique accurately identified SLNs in 99.6% patients, with a false-negative rate of 
10.3% and false-positive rate of 1.4%. Positives from this study are the high identification 
rates in a large patient cohort with no adverse reactions to ICG reported. Tajima et 
al.(89) had previously investigated ICG fluorescence-guided surgery in 77 patients 
undergoing surgery for early gastric cancer and evaluated the technique between open 
(39 patients) and laparoscopic (38 patients) groups. Similar detection rates were found 
between the laparoscopic (94.7%) and open (94.9%) groups. The accuracy and false-
negative rates were 97.2% and 25% respectively in the laparoscopic group and 91.9% 
and 23.1% respectively in the open group. The higher false-negative rates in this study 
may be explained by the smaller patient sample.  This study demonstrates the feasibility 
of ICG fluorescence-guided surgery in both the laparoscopic and open setting.  
 
34 
Yuasa et al.(95) described a novel approach for sentinel lymph node navigation in 
patients with superficial oesophageal cancer by combining ICG fluorescence with 
preoperative CT lymphography. This study consisted of a group of 20 patients who 
underwent endoscopic submucosal injection of a water-soluble iodine contrast medium 
surrounding the tumour 5 minutes prior to their routine staging CT, which enabled 
visualisation of the lymphatic drainage from the primary tumour. ICG was injected 
around the tumour during surgery and the lymphatic drainage was visualised 
intraoperatively. The detection rate of sentinel lymph nodes was 100% with CT 
lymphography and 95% with ICG fluorescence. In this study three out of the 20 patients 
had lymph node metastasis within sentinel lymph nodes that had been detected on both 
techniques with an accuracy of 95%. However, histopathology showed an additional 
malignant sentinel lymph node that both techniques missed.  
 
None of the studies described above reported any adverse side-effects related to ICG 
occurring in any participating patient. 
 
Accurate probes that can be used intraoperatively to predict nodal status would go a 
long way towards preventing unnecessary lymphadenectomy and reducing operative 
morbidity. However, ICG cannot currently be recommended for intraoperative nodal 
staging as part of standard practice due to the sub-optimal sensitivity and high false-
negative rates. 
 
1.3.3.3 5-aminolevulinic acid 
5-aminolevulinic acid (5-ALA), an endogenous compound within the human body, is 
metabolised within the cell mitochondria as part of the heme biosynthesis pathway to 
generate Protoporphyrin IX (PPIX), a precursor to heme. PPIX is a fluorescent molecule 
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which emits between 630 to 700nm when excited by blue-violet light (405nm) and is a 
potent photosensitiser. 5-ALA is taken up preferentially into malignant cells which have a 
higher metabolic rate than normal cells, altered levels of transporter molecules 
compared to normal cells and differences between the concentrations of the opposing 
catalytic enzymes porphobilinogen deaminase and ferrochelatase to normal cells. This 
typically allows generation of large amounts of PPIX within the cell. Under normal 
physiological conditions a negative feedback mechanism is triggered by the production 
of heme to prevent an excess production of endogenous 5-ALA and subsequent 
PPIX(80). This phenomenon is exploited in fluorescent-guided surgery, whereby 
exogenous 5-ALA is administered which can override the negative feedback mechanism 
and increase the production of intracellular PPIX. The excess PPIX cannot be quickly 
converted to heme and therefore this photosensitiser remains within the cell for a 
prolonged period of time, up to 48 hours(9). Upon irradiation with blue-violet light, cells 
with excessively accumulated intracellular PPIX levels will fluoresce allowing detection of 
malignant cells enabling photodynamic diagnosis(80) (Figure 1.7). When administered in 
high doses and exposed to the appropriate wavelength 5-ALA is cytotoxic to cells 
exhibiting a photodynamic therapeutic effect. However, in lower doses it can be used for 




Figure 1.7. 5-ALA fluorescence of colonic tumour and lymph node metastases 
within mesentery. Taken from Andrew et al.(9). A + B – Laparoscopic 
visualisation of a caecal tumour during a right hemicolectomy under white light (left 
hand images) and under fluorescence (right hand images). C – Laparoscopic 
intraoperative visualisation of a pericolic D1 lymph node during the resection under 
white light (left hand image) and under fluorescence (right hand image). 
 
Side-effects reported with the use of 5-ALA include photosensitivity, nausea, vomiting, 
tachycardia, hypotension and elevated liver function tests. However, no safety concerns 
or serious adverse effects have been documented in any published clinical studies(80).  
 
There have been several clinical studies investigating the use of 5-ALA as a 
photodynamic diagnostic agent in fluorescence-guided surgery for bladder transitional 
cell carcinoma(96–98), detection of endometriosis(99) and peritoneal metastases in 
ovarian cancer(100). Neurosurgeons have also used exogenous 5-ALA to improve 
37 
tumour detection and clearance of resection margins in glioma tumours(101–103). In 
addition, there have been several studies advocating the use of 5-ALA for the detection 
of colorectal tumours and metastases(11,104–108). Interest in the use of 5-ALA as a 
photodiagnostic agent also extends to the detection of colon cancer and its ability to 
accurately detect lymph node metastases, which was investigated in the GLiSten clinical 
trial(9). This study included 41 patients, 19 of whom had nodal disease and compared 
two cohorts to assess the optimum dosage of administered 5-ALA (cohort 1 patients 
received a dose of 20mg/kg and cohort 2 patients received 30mg/kg). 5-ALA showed low 
sensitivity (11.1% and 0% for cohorts 1 and 2 respectively) and specificity (75% for both 
cohorts 1 and 2) for colonic tumours and their lymph node metastases. The trial report 
concluded that 5-ALA was not accurate enough to detect lymph node metastases and 
therefore could not be used for intraoperative staging of colon cancer.  
 
1.4 Nanomedicine 
The increased understanding of the mechanisms and pathophysiology of diseases has 
resulted in progress in the development of novel treatments. In anti-cancer research 
there have been significant advancements in the production of new chemotherapy 
agents. Despite having improved mechanisms of action and being more efficacious than 
classical anti-cancer drugs, newer classes of drugs still possess many limitations(109). 
These include problems with drug-dose toxicities (narrow therapeutic index), lack of 
specificity and poor pharmacokinetics i.e. rapid clearance from systemic circulation 
mainly due to their low molecular weights. Traditionally chemotherapy agents are given 
systemically into the circulation and will affect rapidly proliferating cells and tissues, 
giving rise to potent adverse toxicities which can limit the dose administered and, in 
some cases, can result in the premature termination of treatment. Common unwanted 
side-effects of chemotherapy include hair loss, nausea and vomiting, anaemia, fatigue, 
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neurosensory toxicity, insomnia, immunosuppression, anorexia, mucositis and weight 
loss among others. Another disadvantage of chemotherapy is the development of 
acquired and multi-drug resistance to treatment in cancers, particularly within recurrent 
tumours(110).  
 
The advantage of directly targeting treatment towards cancers would mean a reduction 
in the amount of anti-cancer drug given and reduction in adverse toxicities in healthy 
normal tissue. Ultimately this would reduce the side-effects experienced by the patient 
and increase the efficacy of the treatment(110).  
 
The first example of a targeted drug therapy to be used clinically is Tamoxifen, however, 
it was not initially developed or intended as a treatment for breast cancer. Tamoxifen 
was created as part of an antifertility project to discover a new non-steroidal anti-
oestrogen oral contraceptive in the 1960s by a pharmaceutical company now known as 
AstraZeneca(111). Tamoxifen showed promising results in murine studies, but had the 
opposite effect in humans and improved fertility. The development of Tamoxifen 
transitioned into breast cancer treatment with potential for its application in antagonising 
the hormone oestrogen, which is involved in the growth of breast cancers. Tamoxifen 
inhibits the binding of oestradiol to oestrogen receptors which appears to block the 
transcription of growth factor genes (for example HER-2) within breast tumour cells(112), 
thereby reducing the rate of cell proliferation. Clinical trials(113–116), the first beginning 
in the 1970s, have supported its use in the treatment of advanced breast cancer 
patients.  
 
Nanomedicine refers to the use of nanotechnology in clinical applications for diagnosing 
or treating diseases such as cancer(117). Nanomedicine formulations are 
submicrometer-sized carriers(118) that are being investigated to overcome the 
39 
pharmacokinetic limitations of these novel chemotherapy agents by prolonging their 
retention within systemic circulation and improving delivery of the drug to the specific 
target site. 
 
Nanoparticles are of interest in nanomedicine formulations due their inherent advantages 
of size and physical-chemical properties. NPs currently being investigated for clinical use 
include quantum dots, polymeric NPs or micelles, gold NPs, liposomes, dendrimers as 
well as carbon nanotubes and nanofibers(119). NPs can range from 20nm to 200nm in 
size which is large enough to avoid clearance through the renal excretion system, 
enabling prolonged circulating time while being small enough to travel across cell 
membranes(119). NPs can be designed to incorporate hydrophilic, hydrophobic, 
amphiphilic compounds as well as those that are negatively or positively charged 
enabling them to be present in environments where they would normally be rendered 
inactive. For instance, many chemotherapy agents are hydrophobic and are difficult to 
dissolve in solution however encapsulating these hydrophobic or positively charged 
compounds within NPs can improve their solubility and increase drug dose delivery(120). 
NPs can also be created to be structurally large and flexible enough so that different 
compounds can be encapsulated within the NP resulting in high drug loading, as well as 
allowing the development of combination therapy(121,122). NPs can be internalised into 
cells by endocytosis effectively bypassing mechanisms of resistance to drug 
delivery(123). 
 
The surface of NPs can also be modified to allow conjugation of chemotherapy agents or 
targeting molecules. Functionalising the surface of NPs with targeting or recognition 
molecules such as antibodies, peptides, DNA or RNA affimers is of great interest as this 
would allow specific delivery of the NP, with either its diagnostic or therapeutic abilities, 
to the target tissue thereby increasing the efficacy of the nanomedicine formulation. NPs 
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can also be designed to aid in diagnosis of disease as well as improving the efficacy of 
imaging modalities(110). 
 
1.4.1 Targeting of tumour 
1.4.1.1 Passive targeting 
Passive targeting of tumours exploits the pathophysiological mechanism termed the 
enhanced permeability and retention (EPR) effect, which was originally described by 
Matsumura and Maeda in 1986(124). Malignant tumours develop more aggressively 
than normal tissues and many advanced tumours can induce angiogenesis. However, 
this often results in a poorly structured vascular network which is hyperpermeable and 
allows the leakage of fluid and macromolecules from systemic circulation(125–127). NPs 
can extravasate from the micro vessels and into the interstitial spaces within the tumour 
microenvironment. Under normal physiological conditions the lymphatic system drains 
interstitial fluid back into the systemic circulation and eliminates any macromolecules 
that may have leaked out. However, within the tumour microenvironment improper 
lymphatic drainage coupled with the leakiness of tumour vasculature means that 
macromolecules (such as NPs) can accumulate and are retained, resulting in an 
elevated interstitial fluid pressure(128). This elevated pressure reduces the transport of 
macromolecules(129) and diffusion is hindered by the dense extracellular matrix(130). 
Passive targeting of tumours uses the EPR effect to increase the concentration of the 




Figure 1.8. Diagram illustrating Passive drug targeting. Taken from Lammers et 
al.(118). The leaky vessels in the tumour microenvironment can allow 
macromolecules such as NPs to passively extravasate and accumulate within the 
interstitial spaces and increase the concentration of NPs in the tumour vicinity. 
Grey spheres represent the NP drug delivery system with the therapeutic drug 
depicted as red stars. 
 
Kim et al.(131) utilised the EPR effect to treat SCC7 (murine head and neck carcinoma 
cell line) xenografts in vivo, using cisplatin-loaded glycol chitosan NPs. Using a NIR non-
invasive imaging technique they were able to demonstrate improved localisation of 
fluorescence within the tumour xenografts as compared to free cisplatin control. As a 
result, cisplatin-loaded glycol chitosan NPs showed better anti-tumour efficacy and lower 
adverse toxicity than free cisplatin. Another study by Cho et al.(132) developed sodium 
deoxycholate-heparin NPs to target tumours in vivo using the EPR effect. Athymic 
BALB/c-nu/nu female nude mice were used with a KB (human epidermoid carcinoma cell 
line) xenograft. The study showed that overall tumour volume was reduced in the group 
treated with the NPs as compared to the control group that received saline only. Chytil et 
al.(133) used a murine lymphoma model to determine the effect of doxorubicin-HPMA 
co-polymer micelle conjugate which targets the tumour via passive targeting and the 
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EPR effect. Their study demonstrated increased antitumour activity, slower blood 
clearance and enhanced tumour accumulation of the drug-copolymer conjugate 
compared to free doxorubicin.  
 
Despite a large number of studies advocating the use of the EPR effect for passive 
targeting of tumours, clinical studies have shown no advantage or increased 
efficacy(130,134). Maeda et al. suggest that inadequately vascularised tumours, such as 
prostatic or pancreatic tumours, will naturally display a lower tendency for the EPR 
effect. They also argued that the EPR effect may be affected by obstruction within the 
vascular supply due to thrombus formation which could potentially account for the lack of 
increased efficacy within clinical studies(135). The EPR effect was discovered using 
murine models and has been well documented in other small animal studies. However, 
murine models may not translate well into humans(124). Human clinical cancers have 
significant differences, particularly in the tumour microenvironment, as compared to 
murine models (Figure 1.9). This is in part due to the accelerated tumour development in 
murine models. Tumours are induced in immunocompromised mice allowing them to 
develop large tumours in as little as 2 weeks, in addition to causing a change in tumour-
to-body weight ratio(110). These features are not representative of clinical tumour 
growth thereby resulting in disparities in the ability of macromolecules to utilise the EPR 
effect between murine and human cancers. The rapid growth of the murine tumour 
compared to human cancers could potentially result in poorer development of the 
tumoural vasculature with increased hyperpermeability due to increased fenestrations 
with the endothelium and poorer pericyte coverage(118). In human tumours, varying 
fenestrations in the vascular endothelium results in a heterogenous distribution of 
hyperpermeability or extravasation of the macromolecules(130). The EPR effect can also 
vary largely with intra- and inter-heterogeneity between different pre-clinical tumour 
models and also between clinical cancers(118). 
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Further heterogeneity within human tumours is also demonstrated by the presence of 
hypoxic areas (Figure 1.9) resulting from the proliferation of malignant cells at sites away 
from the nearest supplying blood vessel(130). The poor vascularity of the core compared 
to the periphery means that any nanomedicine is required to diffuse across large 
distances and pass through multiple layers of cells and extracellular matrix in order to 
access all areas of the tumour. Blood flow within the tumour vasculature is also noted to 
be transient due to their inherent abnormal and poor development, limiting the supply of 




Figure 1.9. Representative diagram of the tumour micro-environment and passive 
targeting of a nanomedicine system using the EPR effect. Taken from Danhier et 
al.(130). The tumour microenvironment consists of different stromal cells (fibroblasts, 
endothelial cells, pericytes), the extracellular matrix, tumour vasculature and the tumour, 
differing markedly from murine models: 1 – heterogenous distribution of fenestrations 
within human tumour vasculature, 2 – human solid tumours tend to contain hypoxic 
areas due to heterogenicity of blood flow through the tumour, 3 – the pericyte coverage 
and degree of attachment varies throughout a human tumour whereas all tumour 
vasculature has low and loose pericyte coverage in murine models, 4 – the morphology 
of the basement membrane varies within a single tumour, 5 – the extracellular matrix is 
more dense and thick in human tumours compared with murine models. 
 
The tumour micro-environment in human cancers differs from murine models (Figure 
1.9). Examples of such differences include the level of pericyte coverage on the 
endothelial cells, differences within the basement membrane (BM), and differences in 
the composition and density of the extracellular matrix (ECM). The BM is a specialised 
form of the ECM and is composed of layers of laminin and type IV collagen that anchors 
epithelial cells to the underlying connective tissue and separates it from the endothelium. 
The density of the BM and the number of layers within it vary and form a barrier to 
extravasation of nanomedicines(137–139). The endothelial cells composing tumour 
vasculature in clinical cancers are covered with a layer of smooth muscle cells and 
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pericytes to varying degrees of coverage(140). The neo-vasculature in colorectal 
cancers generally has a thinner layer of pericyte coverage, as compared to glioblastoma 
for example, and heterogeneity in pericyte coverage is also observed between different 
types of colorectal cancers(130). A higher level of pericyte coverage means that there is 
a thicker layer for macromolecules to permeate through before reaching the tumour 
tissue. The ECM represents the last barrier that nanomedicines have to cross before 
reaching their target tissue. 
 
Interstitial fluid allows the exchange of oxygen, nutrients and waste products between 
cells and systemic circulation. Interstitial fluid pressure refers to the hydrostatic and 
colloid osmotic pressures exerted by the interstitial fluid and is affected by the EPR 
effect, which increases the pressure due to the increased concentration of 
macromolecules present in the interstitial fluid(128). Diffusion and convection are the 
main molecular transport mechanisms across the ECM, and elevated interstitial fluid 
pressure will hinder larger sized nanomedicine compounds, reducing the effectiveness of 
the EPR effect(109,141). In human cancers the ECM is more abundant than tumours in 
murine models and this reduces the ability of large nanomedicines to penetrate through 
to the target tissue(140).  
 
In summary, the EPR effect has shown great promise in numerous studies and many 
nanomedicines that have been developed rely upon this mechanism. However, there are 
several factors that affect the efficacy of EPR in clinical cancers hindering the translation 
of pre-clinical results into clinical practice. Indeed, despite the complexity of 
nanomedicine preparations within the literature, very few have been approved by the 
FDA and those that have been are relatively simple in design(142). 
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1.4.1.2 Active targeting 
Active targeting of nanomedicines refers to the concept whereby functionalising the 
nanomedicine with a recognition agent, such as an antibody, will enable the 
nanomedicine to selectively bind to the desired target site (antigen) thereby improving 
the efficacy of treatment(118). Passive targeting increases the accumulation of the 
nanomedicine within the peritumoural area and active targeting aims to improve uptake 
of the nanomedicine within the target cancer cell (Figure 1.10). Active targeting of 
tumours uses one of two approaches; the first being to exploit the specific biochemical 
interactions between a ligand and its corresponding target molecule and the second 
approach taking advantage of either internal or external signals(126) such as pH or 
enzymatic reactions. Tumours are known to induce the upregulation of specific cell 
surface markers, for example the carcinoembryonic antigen (CEA) is upregulated in 
colorectal tumours(143). Therefore, functionalising a nanomedicine with a CEA-targeting 
ligand will actively target cells overexpressing CEA thereby increasing the intracellular 
uptake of the nanomedicine with little to no effect on non-CEA expressing cells. The 
development of molecular probes that actively target tumours for diagnostic and 




Figure 1.10. Diagram illustrating Active drug targeting. Taken from Lammers et 
al.(118). The leaky vessels in the tumour micro-environment can allow 
macromolecules such as functionalised NPs to passively extravasate and 
accumulate within the interstitial spaces. The targeting ligands conjugated to the 
NPs can recognise and bind to tumour cell specific antigens, thereby increasing 
the uptake of NP into cells. Grey spheres represent the NP drug delivery system, 
the therapeutic drug depicted as red stars with the yellow arrows representing the 
targeting ligand. 
 
The aim of modifying the surface of nanomedicines with recognition molecules is to 
promote accumulation, internalisation and retention of the macromolecule within the 
tumour. However, active targeting also relies upon the EPR effect in order for the 
targeted nanomedicine to accumulate within the region of the tumour, and therefore 
suffers from similar limitations as passive targeting(118,134). In order to target cancers 
actively, the recognition molecule must be conjugated to the nanomedicine. Most of the 
biochemical conjugation systems used are based upon covalent bonds. Commonly used 
conjugation reactions use carbonyl reactive groups, amine reactive groups or Click 
Chemistry(144,145). Another commonly used high affinity conjugation reaction is the 
non-covalent interaction between (strept)avidin and biotin(144).  
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1.4.2 Recognition molecules 
Recognition molecules or targeting agents include but are not limited to small molecules, 
peptides, proteins, whole antibodies, antibody fragments, and NPs(121,129). The 
recognition molecule on its own or conjugated to a nanomedicine can be considered as 
a form of a molecular probe. The ideal characteristics of an effective molecular probe are 
summarised in Table 1.2. 
 
Table 1.2. Ideal characteristics of a molecular probe 
High binding affinity to target 
High specificity to target 
High sensitivity to detect the biochemical process of disease 
High contrast ratio 
High stability in vivo 
Low immunogenicity and toxicity 
Feasible and economical production 
 
In the 1960s there was interest within the research community to explore unique cancer 
cell surface antigens that could identify malignant from benign tissue for the purposes of 
diagnosis and therapy(146,147). This followed the discovery that the cell surface 
membrane is highly differentiated with different types of cells exhibiting a profile of cell 
surface markers that enabled differentiation(148). Following extensive resections to 
surgically remove colorectal tumours, healthy colorectal tissue can be harvested from 
the same patient providing a control to the tumour tissue. The disparity in expression of 
cell surface markers between healthy and tumour tissue could potentially be exploited. 
Animal studies using rabbits compared benign and malignant colonic tissues from the 
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same animal using immunologic tolerance and absorption techniques(146) and found a 
single unique antigen present in higher concentrations in colonic malignant tissue than 
benign tissue; carcinoembryonic antigen (CEA). CEA has subsequently been shown to 
be upregulated in all tumours originating from the endoderm of the digestive system as 
compared to their corresponding normal healthy tissue(149). CEA is therefore one of 
several cell surface antigens being investigated as potential targeting agents for 
colorectal tumours.  
 
1.4.2.1 Antibodies 
Antibodies (also known as immunoglobulins) are the most common recognition 
molecules used for active targeting. Monoclonal antibodies have been used extensively 
to actively target tumours due to their high affinity and specificity(119). Initially, 
monoclonal antibodies were generated from mouse hybridoma technology(150). 
However, this produced an immunogenic reaction upon introduction into a human host. 
This reaction resulted in the rapid clearance of the murine monoclonal antibody from the 
circulation thereby greatly reducing its clinical efficacy. Chimeric (a combination of 
sequences from different species, most commonly human and murine) and fully 
humanised monoclonal antibodies have subsequently been developed that exhibit lower 
immunogenicity(150,151).  
 
Antibodies have a basic structure composed of two heavy and two light polypeptide 
chains held together by disulphide bonds(152) forming a Y-shape as shown in Figure 
1.11. Immunoglobulin G (IgG) antibodies are approximately 150KDa with each heavy 
chain approximately 50KDa and the light chains being 25KDa. The antigen recognition 
and binding fragment of the antibody (Fab) is formed by the interaction of the two 
identical domains, comprised of the whole of the light chain and half of the heavy chain. 
This interaction folds the Fab fragment into a complex globular structure and is highly 
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specific giving antibodies their high affinity and specificity properties(153). The Fab 
fragment contains the three hypervariable amino acid domains (variable domains) which 
give the antibody its specificity.  
 
 
Figure 1.11. A schematic representation of the structure of an IgG monoclonal 
antibody. Taken from what-when-how.com(154). The antibody is composed of 
four polypeptide chains, two heavy chains and two light chains attached together 
by disulphide bonds, creating a Y-shaped protein. Blue squares depict intrachain 
disulphide bonds, blue bars depict interchain disulphide bonds. Each polypeptide 
chain has constant regions (yellow) whose amino acid sequences are unvarying as 
well as variable regions (red). These variable regions on both the heavy and light 
chains fold to create a specific recognition site (antigen binding site).  
 
Antibodies can be reduced into different fragments which can be of clinical use(155). 
These fragments include monovalent IgG (“half-antibody”), single chain Fv antibody 
fragments (consisting of the variable regions of the heavy and light chains bound by a 
disulphide bond), diabodies, triabodies and minibodies (Figure 1.12). These smaller 
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antibody fragments can penetrate cells more quickly than the larger whole monoclonal 
antibodies and have been shown to be less immunogenic(152,156,157).  
 
 
Figure 1.12. Examples of different antibody fragments formed from an IgG 
monoclonal antibody. Taken from www.absoluteantibody.com(158). The 
polypeptide IgG monoclonal antibody is modular and can be reduced into its 
separate domains, or combination of domains, producing a variety of different 
antibody fragments. Antibody fragments possess altered physiochemical features 
of the original antibody that can be exploited for clinical purposes. For instance, the 
smaller size of the Fab fragment allows penetration into tissues not accessible to 
the full-sized IgG antibody molecule(159).   
 
Monoclonal antibodies can exert a therapeutic effect on tumour cells through 
mechanisms such as binding to and inhibiting receptors on cell membranes or by 
disrupting intracellular signalling pathways. This suppresses further cell growth, inhibits 
angiogenesis or induce apoptosis(156). The epidermal growth factor receptor (EGFR) 
and vascular endothelial growth factor (VEGF) signalling pathways have both been 
highlighted as important therapeutic targets for colorectal cancer(156). Cetuximab and 
panitumumab are examples of anti-EGFR monoclonal antibodies which are approved by 
the FDA for the treatment of colorectal cancer, as is Bevacizumab, an anti-VEGF 
monoclonal antibody to treat metastatic colorectal cancers(160). Use of monoclonal 
antibodies as stand-alone therapeutic agents have shown limited therapeutic effects, 
which could be attributed in part to the host immunogenic reaction(160).  
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Currently, monoclonal antibodies are used as targeting agents in haematological 
malignancies, such as Non-Hodgkin’s lymphoma (the first monoclonal antibody 
approved for clinical therapy was for NHL; Rituximab), Hodgkin’s lymphoma and chronic 
lymphocytic leukaemia, and solid tumours including those affecting the lung, renal tract, 
brain, breast and prostate in addition to colorectal cancer(150). 
 
The disadvantages of monoclonal antibodies include their high molecular weights, 
limited tissue penetration, instability, expense (high production costs), requirements for 
large doses to achieve clinical efficacy and potential immunogenicity(156,161–163). 
Monoclonal antibodies targeting immune checkpoint molecules have been reported to 
have adverse effects similar to those experienced with chemotherapy agents(164). A 
phase I clinical trial(165) investigating an anti-CD28 monoclonal antibody was found to 
affect T-cells with severe side-effects secondary to a cytokine storm. The trial was 
subsequently ended, and further development of the antibody was abandoned.  
 
A phenomenon known as the binding site barrier(162) can also reduce tissue 
penetration. Once bound, high affinity antibodies will not dissociate from their antigens. 
This means that all the antigens in the tumour periphery have to be saturated before 
unbound antibody will penetrate deeper into the tumour. In contrast, molecules with 
moderate binding affinity are released and are able to penetrate and bind to antigens 
deeper within the tumour, ultimately leading to higher tumoural uptake. Antibody 
engineering and antibody fragments are undergoing further research to overcome these 
limitations of monoclonal antibodies.  
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1.4.2.1.1 Studies using monoclonal antibodies as recognition molecules 
A particular antibody of interest in colorectal cancer nanomedicine research is the 
monoclonal anti-CEA antibody. Although there are numerous cell surface proteins, such 
as tumour-associated glycoprotein-72 (TAG-72), folate receptor– (FR) and EGFR, 
that are upregulated on the cell membrane of colorectal cancer cells, CEA has been 
shown to be the most reliable biomarker(143). Tiernan et al.(16) successfully conjugated 
a humanised anti-CEA monoclonal antibody to a glycolated iodoacetamide dye-doped 
(NIR-664) silica NP. This study showed strong CEA-specific targeting of colorectal 
tumour cells in vitro, as well as revealing positive tumour-specific fluorescence in vivo 
using a murine tumour xenograft model. Campos da Paz et al.(166) also showed the 
conjugation of an anti-CEA antibody to a meso-2,3-dimercaptosuccinic acid (DMSA) 
functionalised magnetic NP. The authors demonstrated an increased uptake into 
LS174T cells, a cell line expressing high levels of cell membrane CEA, as compared to  
HCT116 cells, a cell line with low levels of CEA expression.  
 
Cohen et al.(72) developed a cyanine dye-based NIR albumin NP system that was 
actively targeted to colon cancers using an anti-CEA antibody. Three human colorectal 
adenocarcinoma cells lines (LS174T, SW480 and HT29) were used in a chicken embryo 
model. LS174T and HT29 tumours were developed on the chorioallantoic membrane of 
the chicken embryos with differing cell membrane expression levels of CEA between the 
different cell lines (HT29 has lower CEA expression as compared to LS174T). The 
authors observed a 6-fold increase in NIR fluorescence in embryos with LS174T tumours 
as compared to embryos with HT29 tumours when treated with the anti-CEA antibody 
conjugated NIR albumin NP. No difference was seen between the two cell lines when 
tumours were exposed to bare non-functionalised NIR albumin NPs.   
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A humanised monoclonal anti-CEA antibody was conjugated to a fluorophore with similar 
excitation and emission profiles to ICG, and the ability of the antibody-targeted 
fluorophore to bind specifically to colorectal cancer cells was observed in a murine 
model(167). The study sample was small (n=3) however, the antibody targeted 
fluorophore showed good specificity for the tumour xenograft. It was noted that there 
was significant accumulation of the antibody-conjugated fluorophore in the liver and 
kidneys. This was presumed to be secondary to rapid clearance from the circulation due 
to the hydrophobic nature of the fluorophore used.  
 
Cho et al.(168) conjugated the chimeric monoclonal antibody Cetuximab (anti-EGFR), 
which is licensed for use in advanced colorectal cancers, to silica-coated iron-oxide NPs. 
This antibody-NP conjugate system was then tested in a murine HCT116 colon cancer 
xenograft model and accumulation of iron-oxide NPs was observed through MRI 
imaging. The authors demonstrated a decrease in MRI signalling in xenografts exposed 
to the Cetuximab-conjugated NP compared to non-functionalised NPs. The decrease in 
the MRI signal represents increased intracellular uptake of the NP and therefore 
successful targeting of the tumour xenografts.  
 
A single chain Fv (scFv) antibody fragment which targets CEA (sm3E) was used as the 
recognition molecule to actively target superparamagnetic iron oxide NPs (SPIONs) and 
improve MRI imaging of colorectal cancers(157). SPIONs with different coatings were 
conjugated to the anti-CEA scFv forming separate conjugate systems. These were 
tested against a CEA positive colorectal cancer cell line (LS174T) and a CEA negative 
melanoma cell line (A375M). The coatings were dextran only and a dextran-PEG 
coating. Bare unfunctionalised SPIONs of each specification were used as controls. An 
ELISA assay demonstrated that the functionalised NPs specifically bound to the CEA 
antigen, and binding of the bare non-functionalised NP was not detected. In vitro studies 
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confirmed that all 3 specifications (uncoated, dextran only and dextran-PEG) of scFv-
functionalised SPIONs showed specific binding to the CEA positive cell line compared to 
the control cell line and bare non-functionalised SPIONs. The dextran-coated 50nm 
SPIONs showed clear internalisation into the LS174T cell line with no apparent binding 
to the A375M cell line. However, there was evidence to suggest that PEGylation of 
SPIONs enhanced non-specific binding of the NPs to the A375M cell line, in addition to 
the increased cellular uptake mediated by the recognition molecule. This may have been 
due to a negative surface charge created by the carboxylated PEG chain terminals. 
Similarly, other studies have explored the use of different cell surface receptors for the 
targeting of colorectal cancer cells. Fay et al.(169) investigated the use of 
Conatumumab, a human antibody that binds to the cell surface receptor DR5 (part of the 
TNF receptor superfamily), and can initiate apoptosis through the activation of Caspase 
8(170). The study found that Conatumumab-conjugated camptothecin (a chemotherapy 
agent) loaded NPs were able to incite cell death via apoptosis in addition to delivering a 
payload of camptothecin. Hsieh et al.(171) created an anti-VEGF antibody-conjugated 
dextran-coated iron oxide NP that actively targets the vascular endothelial growth factor 
(VEGF), which is an important signalling protein involved in angiogenesis. The 
conjugated magnetic NPs were specifically taken up into murine colorectal cancer 
models in vivo and increased MRI contrast intensity as compared to unconjugated (bare) 
magnetic NPs.  
 
1.4.2.2 Affimers 
Affimers (also known as aptamers) are short single-stranded RNA or DNA 
oligonucleotides that bind with high affinity and specificity to target molecules and are of 
interest as an alternative to antibodies for the active targeting of tumours(144,172). They 
are a type of non-immunoglobulin protein scaffold(161) which are chemically 
synthesised. Their primary sequences are usually 20-80 nucleotides in length and this 
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determines the 3-dimensional tertiary shape of the affimer (173), similar to the structural 
conformation of an enzyme. The binding clefts formed through their 3-D conformation 
enables affimers to bind to their specific targets with a specificity rivalling monoclonal 
antibodies(174). This is achieved through a combination of van der Waals, hydrogen 
bonding, hydrophobic and electrostatic interactions(175).  
 
Ellington and Tuerk(176,177) were the first to develop affimers through a complex but 
powerful purification method termed Systematic Evolution of Ligands by Exponential 
Enrichment (SELEX). A library consisting of a large pool of short oligonucleotides of 
random sequences is initially incubated with the target molecule. This incubation process 
is used to isolate the nucleic acid sequences which bind to the target molecule. Once 
isolated the nucleic acid sequences are eluted and then amplified, by either reverse 
transcription polymerase chain reaction (RT-PCR) for RNA or simply just PCR for DNA. 
This process of incubation, elution and amplification is repeated until the pool has 
reduced to a small but enriched size of nucleic acid sequences with a high affinity to bind 
to the target molecule. These high affinity sequences (affimers) are then tested against 
the target molecule and their binding affinities are compared to determine potential 




Figure 1.13. Diagram depicting the process of Systematic Evolution of Ligands by 
Exponential Enrichment (SELEX). Taken from Ellington et al.(178). Initially 
different oligonucleotides (affimer or aptamer library) are incubated with target 
protein (represented by the blue stars with orange centre); affimers bound to the 
target protein are separated and the unbound affimers are discarded (positive 
selection). Bound affimers are released from the target protein and then incubated 
with the negative control protein. Affimers binding to the negative control protein 
are discarded and the unbound affimers are recovered (negative selection). These 
affimers are amplified and subjected to repeated positive and negative selection 
followed by amplification until the final selection cycle where the affimers are 
sequenced.  
 
The advantages affimers exhibit over antibodies are that they of a much smaller size, 
promoting higher levels of tissue penetration and are rapidly cleared by the renal system. 
Higher levels of tissue penetration with rapid clearance from the circulation is desirable 
for diagnostic applications, however, high tissue accumulation and prolonged circulating 
time is preferable for therapeutic purposes(156,161). Affimers lack 
immunogenicity(173,179) and can be used to recognise both intracellular and 
extracellular targets whereas antibodies are designed for extracellular targets(173). They 
can also easily be modified, produced at low cost with little variability between batches 
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and are stable over prolonged periods of time(172,179). Monoclonal antibodies and 
whole humanized monoclonal antibodies can induce an immunogenic reaction with the 
generation of T-cell dependent neutralising antibodies. This could precipitate resistance 
against treatment with monoclonal antibodies in relapsed patients. Currently, there is no 
evidence suggesting that similar neutralising antibodies are induced against 
affimers(163). However, they can be unstable within serum environments(175) as they 
are susceptible to enzymatic degradation leading to a reduced circulation time. This 
coupled with the fact that they are rapidly cleared by the renal system means their 
clinical efficacy could be limited(141). 
 
Affimers can be modified following post-sequencing to promote bioavailability, improve 
their biocompatibility profile or for conjugation to other molecules such as fluorescent 
NPs. Affimer-conjugated NPs have been shown to enhance the uptake and retention of 
therapeutic agents in tumours(179), although modifying the affimer may also alter the 
conformational structure potentially reducing the binding affinity and specificity(141).  
 
Ahmadzadeh-Raji et al.(180) attached an anti-CEA affimer on to gold NPs, which were 
electrodeposited on to indium tin oxide, to create a biosensing device capable of 
detecting colorectal cancer cells. In vitro studies were performed, and the anti-CEA 
functionalised gold NPs were tested against HCT116 (colorectal cancer, CEA positive) 
and HEp-2 (laryngeal cancer, CEA negative) cell lines. The study demonstrated that the 
affimer-NP system was more sensitive in detecting HCT116 cells compared to HEp-2 
cells.  
 
Li et al.(181) conjugated an EpCAM affimer on to mesoporous silica NPs loaded with the 
chemotherapy agent DM1 or Mertansine (anti-mitotic tubulin inhibitor). EpCAM is a 
transmembrane glycoprotein overexpressed in epithelial cancers such as colorectal 
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tumours(182). The authors demonstrated increased uptake of the NPs in the human 
colorectal adenocarcinoma cell line, SW480, expressing high cell surface levels of 
EpCAM, as compared to low and negligible EpCAM expressing cell lines. The affimer-
NP system effectively delivered its chemotherapy payload. Similar findings have been 
shown with curcumin-loaded lipid-polymer hybrid NPs conjugated to an EpCAM 
affimer(183).  
 
MRI is a common used imaging modality in colorectal cancers, however, the 
conventional MRI contrast agent gadolinium diethylenetriaminepentaacetic acid has a 
short circulation time in addition to high toxicity(171). Supermagnetic NPs are of interest 
in MRI imaging as they can be used as contrast enhancement and signal amplification 
agents without the disadvantages of gadolinium(166). Iron-based magnetic NPs are 
particularly useful as their surface can be chemically modified to bind recognition 
molecules and promote active targeting to the desired tissue(166). A 5TR1 affimer, 
which targets the MUC-1 cell surface marker on epithelial tumours such as colorectal 
cancer, has previously been conjugated to a superparamagnetic iron oxide NP(184) 
containing the chemotherapy agent epirubicin to act as a nanomedicine with theranostic 
applications. This study demonstrated that the 5TR1 affimer-conjugated 
superparamagnetic iron oxide nanomedicine improves MRI imaging in addition to 
inducing targeted toxicity within colorectal tumours.  
 
Affimers can also be used as stand-alone therapeutic agents as they typically become 
internalised via endocytosis after binding to their target molecule. The commercially 
available RNA affimer, Pegaptanib (Macugen), has been shown to have a high affinity 
for the vascular endothelial growth factor isoform (VEGF-165). VEGF-165 is responsible 
for pathological ocular neovascularisation and vascular permeability seen in conditions 
such as age-related macular degeneration and diabetic macular oedema, in addition to 
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tumours(185). Ng et al.(185,186) showed that Pegaptanib binds and inactivates VEGF-
165 demonstrating significant clinical benefit following intravitreal injection in several 
clinical trials. Due to the inhibitory effects on endothelial cells Pegaptanib was 
investigated as an anti-angiogenesis agent for cancer therapy in malignant brain 
tumours. However, the impressive results seen with ocular conditions were not 
replicated (179). Direct conjugation of affimers to chemotherapy agents has been shown 
to facilitate the internalisation and increase the efficacy of the drug. Taghdisi et al.(187) 
demonstrated targeted delivery of epirubicin to prostate cancer cells in vitro using a 
PEGylated prostate-specific membrane antigen affimer. Affimers are also being 
investigated as photodynamic therapy agents after conjugation to photosensitisers. 
Mallikaratchy et al.(188) successfully conjugated an affimer that specifically targets a 
Burkitt lymphoma cell line to a photosensitiser and induced selective cell death in this 
cell line when treated with light radiation. Similar results have been demonstrated using 
affimer conjugated photosensitiser systems in breast(189,190) and lung cancer(172). 
 
1.4.3 Nanoparticles 
As described in 1.4.1.1, NPs are designed to accumulate in tumour tissue due to the 
EPR effect(191,192). EPR (193) refers to the combination of rapid tumour growth, 
hyperpermeable tumour neovasculature and ineffectual development of lymphatics, 
enabling the passive extravasation and retention of NPs within the tumour. Yuan et 
al.(194) demonstrated that particles up to 400nm can pass into solid tumours due to the 
enhanced permeability of tumours. Other studies(195,196) have equally demonstrated 
that particles ≤200nm accumulate within tumours more effectively. In cancer-related 
nanomedicine, NPs are usually designed to be given intravenously. The macromolecule 
travels through the systemic circulation prior to arriving at the site of tumour growth. 
Therefore, there are many steps and obstacles involved before a nanomedicine is able 
to achieve its effect(110). These involve travelling extensively through systemic 
61 
circulation, extravasation within the tumour micro-environment, accumulation into the 
interstitial fluid and uptake into cancer cells.  
 
1.4.3.1 Opsonization and the Mononuclear phagocyte system 
Some of the challenges faced by nanomedicine whilst in human systemic circulation are 
opsonization, the mononuclear phagocyte system (MPS) and clearance by either the 
liver or kidney. Even NPs that have been functionalised to actively target tissues will be 
present in non-targeted organs, particularly the liver and spleen. 
 
NPs can have very high surface areas due to their surface-to-volume ratio which can 
lead to their aggregation. Aggregation will significantly increase the size of the NP and 
potentially have adverse effects on its biodistribution(197,198). Upon introduction into 
systemic circulation, serum proteins can adhere to the NP creating a corona (known as 
non-specific adsorption) which not only promotes aggregation but also promotes uptake 
within macrophages and will affect extravasation of the NP, thereby reducing cell 
uptake(110). Adsorption of proteins on to the surface of the nanomedicine may also 
interfere with its function(199). Blood serum proteins have an enhanced affinity for 
adsorption on to hydrophobic particles and opsonization of these particles has been 
shown to occur more quickly compared to hydrophilic particles(200,201). Opsonization is 
the term referring to the binding of certain proteins to the surface of a foreign body, such 
as a NP, rendering it more visible to phagocytic cells(202). The phagocyte then proceeds 
to engulf the bound NP complex leading to the destruction and removal of the NP from 
the circulation. The proteins which mediate opsonization are known as opsonins, the 
most common of which are complement proteins C3-5 and immunoglobulins(202).  
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The MPS, also termed the reticulo-endothelial system (RES), refers to a system of 
specialised macrophages (phagocytes), usually Kupffer cells, most prominently located 
in the liver and spleen(110). These macrophages do not directly detect foreign NPs, 
however they recognise specific opsonin proteins which become bound to the surface of 
the NP as described above. This is the main mechanism by which foreign particles 
present within the circulation that are too large to be excreted via the kidney are 
removed. Following opsonization the foreign particle is phagocytosed into the 
specialised macrophages. Firstly, the macrophage must attach to the opsonin protein via 
one of three different mechanisms and then engulf the particle into itself(202). The first 
and simplest mechanism is non-specific adherence of the bound opsonin protein to the 
phagocyte. This typically occurs due to the association of opsonins with more 
hydrophobic particle surfaces. The second mechanism involves the foreign particle-
bound opsonin protein to undergo conformational changes. This activates the protein 
and allows it to interact with specialised receptors found on the cell membranes of 
macrophages. The final mechanism is through complement activation either through the 
classical, alternative or lectin pathways. Once the foreign particle has been attached to 
the phagocyte, via the bound opsonin protein, the phagocyte ingests the particle via 
endocytosis. The particle is then broken down by various enzymes and oxidative-
reactive chemicals such as nitric oxide and hydrogen peroxide. If the NP cannot be 
degraded by these processes then they become sequestered within one of the MPS 
organs such as the liver or spleen, unless they are of a small enough size to be excreted 
via the kidney(202). Particles with a molecular weight of less than 5000g/mol can be 
excreted via renal clearance(202). 
 
1.4.3.2 PEGylation 
The ability to modify the surface of NPs has an inherent advantage in trying to reduce 
aggregation and opsonization. The surface of the NP can be altered to contain long 
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hydrophilic polymer chains which extend into the media, forming a barrier that blocks the 
adhesion of opsonin proteins and can therefore shield hydrophobic or charged particles 
from the MPS(202). These polymer chains are also usually charge neutral lessening the 
effect of electrostatic interactions. This method of avoiding or reducing opsonization 
creates what is thought of as ‘stealth NPs’ due to their ability to evade the MPS-mediated 
elimination. The most commonly used polymer is an FDA-approved reagent(145) called 
poly(ethylene glycol) (PEG). NPs are readily excreted from the human body, via the 
MPS, and generally have a relatively short circulation time. However, incorporating PEG 
chains on to the surface of a NP can provide protection and reduce aggregation(53,199). 
This reduces the clearance of the NP from the blood by the MPS thereby prolonging the 
circulation time(170,191,202) and allowing increased accumulation of the NP in tumour 
tissue(126). Non-PEGylated NPs by contrast can be excreted within minutes. Choi et 
al.(203) compared outcomes including circulation time between non-PEGylated 
hyaluronic acid NPs and a PEGylated version. Their results suggested that PEGylation of 
the NPs reduced uptake within the liver and increased the circulation time compared to 
non-PEGylated NPs. It is also possible to PEGylate affimer molecules which increases 
their half-life within the circulation(172), but may alter their conformational structure 
reducing their binding affinity. 
 
A key factor in the application of nanomedicine is the biocompatibility profile. Concerns 
have been raised regarding the use of heavy metals such as gold or iron oxide NPs 
(inorganic NPs), as they have relatively prolonged circulation times and very few studies 
on the effects of exposure have been conducted(204–207). Sadauskas et al.(204) 
showed a reduction in the number of Kupffer cells after exposure to gold NPs potentially 
indicating damage to these cells taking up the inorganic NP and being removed by 
phagocytosis. Hanini et al.(206) investigated the effects of iron oxide NPs on endothelial 
cells and showed convincing evidence that exposure of endothelial cells to iron oxide 
NPs, even at low doses, caused a severe drop in cell viability after 24 hours. PEGylated 
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NPs show decreased immunogenicity in vivo compared to non-PEGylated NPs(53) as 
the PEG chains reduce the interaction between the highly charged NP surface and the 
cell membrane which potentially disturbs the cells lipid bilayer(208). There are less 
inherent concerns regarding the biocompatibility of organic NPs as the metabolites 
formed from the breakdown of these nanomedicines are readily excreted(110). 
 
PEG also has the advantage of being easily modifiable so that a wide range of different 
ligands can be attached at the terminal end of the PEG chain enabling conjugation to 
targeting agents(209). Attaching the ligand at the terminal end of the polymer chain 
reduces steric hindrance between the targeting moiety and the PEG chain. PEG is a 
hydrophilic compound meaning that it is water soluble; PEGylation of a NP can, in 
addition to conferring protection from the MPS, render an insoluble NP soluble within an 
aqueous environment such as the human circulatory system(126). It has to be noted that 
PEG can also potentially induce an immunogenic response and formation of antibodies, 
particularly after repeated administrations which can accelerate the clearance of the 
PEGylated nanomedicine from the circulation(210). A recent Phase III clinical trial, 
investigating an anti-IX coagulation factor PEGylated affimer, demonstrated significant 
toxic side-effects in a small number of patients (10 out of 1605) with one fatality which 
was initially thought to be due to the affimer(211). However, after analysis(212) it was 
found that the toxicity observed in these patients was secondary to a PEG allergy as 
evidenced by the presence of anti-PEG antibodies. 
 
1.4.3.3 Fluorescent nanoparticles 
NPs make effective imaging agents for clinical purposes due a number of inherent 
features such as their small size, enabling the NP to utilise the EPR effect for tumour 
targeting. The surfaces of these NPs are also amenable to modification allowing the 
conjugation of recognition molecules and enabling the NP to be used to actively target 
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tissue. They have a capacity to deliver a large payload of therapeutic agents in addition 
to tunable biodistribution properties and multi-modal signalling capacities(213). The field 
of fluorescent NPs is of particular interest as these can potentially overcome the 
limitations associated with traditional fluorescent dyes or proteins(74,214) used for 
imaging purposes, specifically photostability and brightness. Due to the aforementioned 
surface modification and drug internalisation properties they have therapeutic potential in 
addition to diagnostic applications. However, the use of fluorescent NPs as fluorescent 
probes does impose restrictions on their properties such as size, biocompatibility and 
surface chemistry(74).  
 
Fluorescent NPs can be designed to emit wavelengths in the NIR region (>780nm)(16) 
which makes them ideal for intraoperative imaging. This is due to the deeper penetration 
of light at long wavelengths (>600nm), through multiple layers of cells and tissue. 
Fluorescent probes which emit in the NIR region have good tissue penetration and also 
reduced autofluorescence(16,215). Other features of an ideal probe includes bright 
fluorescence with good tissue penetration, negligible photobleaching and quenching, 
stability(53,215,216), high degree of sensitivity and specificity for the target tissue and 
biocompatibility(217). 
 
Quantum dots (QDs) have been extensively investigated, in addition to other inorganic 
fluorescent NPs. Quantum dots are fluorescent nanocrystals whose emission spectrum 
can be altered by adjusting their size and composition. Other advantages of quantum 
dots over conventional dyes include high quantum fluorescent yield, superior brightness 
in addition to a broader spectrum of excitation, photostability and resistance to 
photobleaching(75). However, there are inherent limitations with these inorganic NPs as 
there is less flexibility with surface modification, their lack of biodegradability, inadequate 
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in vivo stability due to their hydrophobic nature and concerns regarding toxicity following 
their accumulation within organs of the MPS(74,75,172).  
 
One clinical use that QDs are being investigated for is in sentinel lymph node biopsies in 
breast cancer surgery and have shown early promise. However, this has been limited by 
the inherent toxicity of the heavy metal ions, particularly Cadmium, which has traditionally 
been used to produce QDs. Cadmium-free QDs have been developed for clinical 
translation which do not exhibit toxicity to tissues. Yaghini et al.(218) developed a water-
soluble heavy metal ion free QD with an emission range of 500-700nm for lymphatic 
mapping applications. Cell toxicity tests did not show any significant difference between 
cells exposed to various concentrations of the QD over 24 and 48 hours compared with 
controls, although the study acknowledges that further long-term toxicity studies need to 
be completed. Their animal model, however, showed promising results with the QDs 
accumulating in the regional lymph nodes from the injection site (subcutaneous injection 
of QDs into rat paws) and demonstrating stable fluorescence, with only trace amounts of 
the QD being detectable in other tissues.  
 
Fluorescent NPs composed of organic materials can offer more flexibility than inorganic 
NPs as their constituents can be altered and modified to control their properties such as 
brightness, size and surface chemistry. These include dye NPs (comprised of small 
organic dyes) and lipid or polymer NPs that have encapsulated fluorescent dyes within 
their cores. A balance for the latter type of organic NP needs to be achieved as the 
brightness of the fluorescent probe is dependent on the number of dye molecules 
(fluorophores) within the core. Increasing the number of fluorophore molecules present 
should theoretically increase the brightness of the probe. However, the structure of the 
fluorophore encourages aggregation of the dye molecules leading to quenching(74). The 
aggregation of fluorophores with subsequent quenching decreases the quantum yield 
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and brightness of the fluorescent dye-loaded NP. Permanent encapsulation of the dye 
must also be assured as leaching of the dye from the probe could affect its ability to 
complete accurately its intended diagnostic function.  
 
1.4.3.3.1 Semiconducting polymer nanoparticles 
Semiconducting polymer NPs (SCNPs) are composed of electronically and optically 
active polymers which render them of interest in applications such as sensors, electronic 
devices and as fluorescent probes for molecular imaging(213,219–222). Inherent 
properties within SCNPs include large absorption co-efficients, tunable optical 
properties, surface properties, excellent photostability and oxidative tolerance(223–225). 
SCNPs are usually found to exhibit higher levels of fluorescence compared with organic 
dyes(145). The optical properties of SCNPs are influenced by their component 
polymers(199) and, unlike quantum dots, the size of the NP does not affect the emitted 
fluorescence(213). SCNPs can be designed to have a small diameter making them 
effective for tumour penetration(223) as well as having a suitable Stokes shift(226). 
Furthermore, SCNPs are primarily composed of biologically inert organic materials unlike 
heavy metal dependant quantum dots, making them biocompatible(74,213).  
 
Pu et al.(213) performed in vivo SCNP biocompatibility studies on murine models with 
fully functioning immune systems. The control group were injected with saline whereas 
the study group were injected with a SCNP compromised of a copolymer of poly(styrene) 
and poly(ethylene glycol). No observable behavioural differences were observed 
between the control and study groups, nor was there evidence of acute or chronic 
toxicity. However, there was evidence of a transient inflammatory response (decrease in 
mean corpuscular volume, increase in neutrophils and elevated hepatic enzymes), that 
was attributed to the normal immune response of a host to foreign material. The study 
did acknowledge the small murine population (n=5 for both study and control groups) 
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used for the study but concluded that it was a pilot study demonstrating positive results 
that could warrant further investigation on a larger sample size.  
 
SCNPs are synthesised from hydrophobic conjugated polymers and therefore require 
either formulation with a hydrophilic polymer or chemical modification in order to be 
stable within an aqueous environment(198). Where the NP contains both hydrophobic 
and hydrophilic polymers, the core of the SCNP is comprised of the hydrophobic polymer 
which surrounds itself via hydrophobic interactions with the hydrophilic polymer. The 
sizes of these self-assembling polymer NPs can be controlled by altering the size of the 
hydrophobic and hydrophilic constituents of the NP(145).  
 
It is this outer layer of hydrophilic polymer that determines how the SCNP interacts with 
substances within a biological environment, such as aqueous media. Proteins have a 
tendency to adhere to the surface of these NPs by non-specific adsorption(199), 
although PEG has been shown to reduce protein attachment which is a further 
advantage of PEGylation. This is of particular importance for clinical translation as 
protein adsorption to the surface of the SCNP has been shown to cause quenching(227). 
 
One method of producing SCNPs is reprecipitation which is also known as 
nanoprecipitation or post-polymerization. The constituent amphiphilic polymers (a 
polymer with both hydrophobic and hydrophilic parts(145)) are dissolved in an organic 
solvent and are then mixed with a second solvent, for example water, in which they have 
poor solubility. Usually the SCNPs are dispersed via ultrasound waves and the initial 
solvent is then evaporated(145). This method has been used to create many fluorescent 
SCNPs as it is a relatively simple process, of low cost and has a high yield of SCNPs. A 
second strategy of SCNP is via mini-emulsion. This is essentially the same process as 
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nanoprecipitation; the difference between the two processes is that the solvent used in 
nanoprecipitation is miscible with water but immiscible for mini-emulsion(228).  
 
Surface modification of SCNPs to allow conjugation of recognition molecules and enable 
active targeting for clinical applications can be achieved by several methods. One 
strategy is to use amphiphilic polymers that already possess a functional group and 
coprecipitate with the semiconducting polymers to form a functionalised SCNP. Although 
these functional groups are non-covalently bound to the amphiphilic polymer and 
therefore may become dissociated once exposed to a complex biological 
environment(145).  
 
Ding et al.(223) fabricated a fluorescent folic acid conjugated SCNP to target cancer 
cells that overexpress folate receptors. The SCNPs were ~80nm in diameter as 
determined by dynamic light scattering (DLS) measurements. The SCNPs were 
incubated with MCF-7 breast cancer cells with a high expression of folate receptors on 
their cell surface membranes and NIH/3T3 fibroblasts cells which were used as a 
negative control. Fluorescent imaging confirmed that SCNPs specifically targeted the 
breast cancer cells in comparison to the control. In vivo experiments were performed in 
tumour-bearing murine models using hepatic H22 cancer cells. The control group were 
injected with bare non-functionalised SCNPs and the study group received functionalised 
folic acid conjugated SCNPs. Both groups showed tumour fluorescence indicting the 
presence of the SCNP within tumour tissue regardless of whether it possessed the 
functional recognition molecule folic acid. This was attributed to the EPR effect (passive 
targeting). However, the intensity of fluorescence was higher at the site of the tumour in 
the study group. This suggested that functionalisation of the SCNP allowed greater 
accumulation of the NP within tumour tissue due to the active targeting effects of the folic 
acid.  
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Combining the advantages of SCNPs with NIR fluorescence for the purposes of 
biomedical imaging would be ideal given their high brightness, excellent photostability 
and biocompatibility(229). Hydrophobic low molecular weight NIR dyes have been 
encapsulated within the core of a SCNP (“dye-doping”) enabling emission of NIR 
fluorescence. Unfortunately, the systems that have manufactured these fluorescent NIR 
SCNPs have produced low yields, leakage of the dye from the SCNP core, a broad 
spectrum of emission and poor stability(229). Another limitation of using a fluorescent 
dye with a SCNP is that excessive aggregation of dye molecules within the core can lead 
to quenching(145).  
 
The NP I propose to use in this research project is a fluorescent organic SCNP PEG-
shell dye-doped NP manufactured via a nanoprecipitation method. The fluorescent core 
is comprised of poly(2,5-di(hexyloxy)cyanoterephthalylidene) (CNPPV), a red-emitting 
conjugated polymer which is hydrophobic but exhibits bright fluorescence and 




Figure 1.14. Proposed structure of self-assembled fluorescent CN-PPV dye-doped 
PLGA-PEG semiconducting polymer NP. Taken from Kemal et al.(229). The 
image on the left shows the chemical structure of CN-PPV, a hydrophobic red-
emitting conjugated polymer, which is represented as red lines in the bottom left 
hand image. The image on the right shows the chemical structure of PLGA-PEG, 
an amphiphilic biodegradable diblock polymer. The bottom right hand image shows 
the hydrophobic CN-PPV dye encapsulated within a PLGA-PEG shell, where the 
hydrophobic PLGA is represented by yellow lines and the hydrophilic PEG is 
represented as blue lines. 
 
For the NP to have a role as a fluorescent probe for colorectal cancers it must be soluble 
in water. To achieve this, the fluorescent core is surrounded by a shell of poly(ethylene 
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glycol) methyl ether-block-poly(lactide-co-glycolide)(PLGA-PEG). This is a biodegradable 
diblock co-polymer composed of units of PEG and PLGA. The PLGA end of the co-
polymer is hydrophobic whereas the PEG end is highly hydrophilic. When these 
components are placed within an aqueous environment the polymer chains associate 
with the hydrophobic segment facing inward and the hydrophilic segment projects 
outwards. This minimises the contact between the hydrophobic PLGA and the aqueous 
media. As CNPPV is also hydrophobic it becomes incorporated within the centre of the 
NP. This means the NP can self-assemble with the CNPPV and PLGA in a hydrophobic 
core surrounded by a hydrophilic shell of PEG in an aqueous environment. This 
manufacturing process yields an increased amount of PEGylated NIR fluorescent 
SCNP(229).  
 
Kemal et al.(229) showed that the hydrodynamic diameter of this specific CN-PPV dye-
doped SCNP ranged from 110-140nm, and an increase in size correlated to an increase 
in the proportion of PLGA-PEG used in the SCNP. However, increasing PLGA-PEG 
content was also associated with increased emission intensity and reduced quenching. 
Quenching has been shown to be reduced with the use of PEGylated polymers(145). 
Normalised absorption and emission spectra comparing CN-PPV SCNPs versus CN-
PPV dye-doped PLGA-PEG SCNPs showed no differences in the emission profiles, 




Colorectal cancer presents a huge clinical burden to healthcare with over 40,000 new 
patients diagnosed per year and representing 10% of all cancer deaths annually in the 
UK. Surgical resection of the tumour is the basis for curative treatment however, there 
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are limitations in the ability to accurately stage the involvement of the regional lymph 
nodes. This creates differences in the treatment of patients whereby node-negative 
patients are unnecessarily exposed to the risks of an extensive resection and node-
positive patients may potentially have residual disease left behind in unresected D3 
lymph nodes. This latter group of patients receive adjuvant chemotherapy which poses 
its own profile of toxicities and adverse effects. There is a clear need to improve the 
staging of patients prior to removal of the tumour enabling the extent of surgical 
resection to be tailored to the patient. Sentinel lymph node mapping and biopsy is a 
potential solution which has been used successfully in the treatment of other types of 
tumours, particularly in breast cancer. However, the excellent results seen in breast 
cancer surgery have not translated to colorectal cancer surgery. These poor results have 
shown that traditional SLNM cannot be recommended in colorectal cancers and there is 
a need for a more appropriate and specific probe.  
 
Near infra-red fluorophores are of interest as they exhibit good tissue penetration and 
reduced rates of autofluorescence. Several studies investigating NIR fluorophores as 
SLN probes in colonic cancer have been conducted. However, findings from these 
studies have shown below acceptable levels of sensitivity and accuracy in addition to 
high false-negative rates. The main limitation for these fluorophores is that they do not 
specifically target colorectal cancer cells.  
 
NPs have many advantages for clinical applications such as prolonged circulating time, 
their ability to cross through the cell surface membrane and the potential for modification 
allowing active targeting of a tissue or encapsulation of hydrophobic drugs. Therefore, it 
is unsurprising that NIR fluorescent NPs conjugated to a ligand capable of accurately 
targeting colorectal cancer cells represents a large area of current clinical research. 
Monoclonal antibodies are an effective ligand for targeting specific receptors on cell 
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surface membranes in addition to exhibiting a therapeutic effect on the tumour cells. 
Semi-conducting organic fluorescent NPs are also of particular interest in clinical 
imaging applications due to their biocompatibility, ability for surface modification with 
recognition molecules, tunable optical properties as well as their brightness and 
photostability.  
 
1.6 Aims and Objectives 
The aim of my research is to create and evaluate a fluorescent probe which can be used 
intra-operatively to target colorectal cancers. This will help identify the position of the 
tumour as well as any potential lymph node metastases. 
 
The objectives of my research are as follows: 
• Evaluate 5-ALA, as an example of a small drug fluorophore, for use in 
colorectal cancer fluorescent guided surgery 
• Fabrication and characterisation of a semiconducting polymer NP 
• In vitro evaluation of anti-CEA antibody as a targeting molecule for 
colorectal cancer  
• Optimise methods for conjugating anti-CEA antibody to NP 













Materials and Methods 
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2 Materials and Methods 
2.1 Next Generation intraoperative Lymph node staging for 
Stratified colon cancer surgery 
2.1.1 Trial protocol 
The Next Generation intraoperative Lymph node staging for Stratified colon cancer 
surgery (GLiSten) trial was a bi-centre, multi-national feasibility study. The primary aim of 
this study was to determine the optimum dose of the fluorescent photosensitiser, 5-
aminolevulinic acid (5-ALA) (Photonamic GmbH & Co. KG, Pinneberg, Germany), to 
detect lymph node (LN) metastases during laparoscopic surgery. Pre-operative CT 
reporting of LN status, intra-operative fluorescence and quality of surgical resection with 
D3 lymphadenectomy were secondary aims. Safety data was also collated. This study 
was conducted with approval from the Medicines and Healthcare Products Regulatory 
Agency and IRAS ethics committees (reference number: ISRCTN79949827) from both 
hospital sites involved in the trial (St James’s University Hospital, Leeds, UK and The 
Mater Misericordiae University Hospital, Dublin, ROI). Funding for the trial was obtained 
from the Efficacy and Mechanism Evaluation programme; a Medical Research Council 
and National Institute for Health Research partnership. The trial registration number is 
ISRCTN79949827 and the EudraCT number is 2012-002623-15.  
 
Adult patients with locally advanced right-sided and sigmoid colon tumours, as identified 
using the Fluoropyrimidine, Oxaliplatin and Targeted-Receptor pre-Operative Therapy 
(FOxTROT) trial criteria(230), undergoing elective laparoscopic resection of colon 
tumours with extended D3 lymphadenectomy and meeting the inclusion criteria (Table 
2.1) were recruited across the two sites. The FOxTROT trial criteria defined locally 
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advanced colonic adenocarcinomas as T3/4 disease with extramural depth ≥5mm on 
preoperative CT imaging. 
 
Table 2.1. Inclusion and exclusion criteria 
Inclusion Criteria Exclusion Criteria 
• Able to give informed consent 
and willing to follow trial protocol 
• Aged over 18 years 
• Patients with cancers of the right 
and sigmoid colon amenable to 
laparoscopic resection 
incorporating D3 
lymphadenectomy, as agreed by 
MDT discussion following 
histopathological confirmation of 
cancer diagnosis and 
radiological staging.   
• Patients with distant metastatic 
disease will be eligible, provided 
laparoscopic resection of the 
cancer is part of routine clinical 
care. 
• Fit for standard laparoscopic 
resection 
• American Society of 
Anaesthesiologists (ASA) 
classification ≤ 3 
• Normal hepatic and renal 
function on most recent blood 
tests (to be within 30 days prior 
to surgery). For the purposes of 
the trial, normal hepatic and 
renal function were defined as: 
 
• Patients with cancers of the 
transverse and left colon, due to 
difficulty in defining D3 
lymphadenectomy in these 
anatomical locations 
• Past history of hypersensitivity 
reactions to 5-ALA or colorimetric 
dye 
• Acute or chronic porphyria or a 
family history of the same 
• Patients with synchronous colonic or 
rectal cancer (but patients with 
synchronous benign polyps are 
eligible) 
• Patients with co-existent 
inflammatory bowel disease, such as 
Crohn’s disease, ulcerative colitis or 
active diverticulitis, which may 
influence the lymphatic uptake of 5-
ALA 
• Pregnant (positive pregnancy test) or 
breast feeding  
• Received an investigational medicinal 
product at any dose within 28 days 
before registration 
• Poorly controlled or serious medical 
or psychiatric illness that, in the 
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a. Total bilirubin within 
normal institutional limits 
b. AST/ALT < 2.5 X 
institutional upper limit of 
normal 
c. GFR ≥ 60 ml/min/1.73m2 
or Creatinine within 10% 
of upper value for normal 
institutional limits  
Investigator’s opinion, was likely to 
interfere with participation and/or 
compliance in this clinical trial.  
 
Recruited patients were administered 5-ALA shortly before undergoing laparoscopic 
surgery and any intra-operative fluorescence of the primary tumour and/or any lymph 
nodes or aberrant tumour deposits was documented. In the subsequent 
histopathological examination of their specimen patients were identified as node positive 
if metastatic disease was detected in at least one lymph node and node negative if no 
metastatic disease was detected in the lymph nodes. Assessment of the accuracy of 5-
ALA to detect metastases was based on whether fluorescence correctly distinguished 
between node positive and node negative patients. The sensitivity and specificity of 5-
ALA was based on whether 5-ALA fluorescence detected an involved lymph node. A 
positive diagnosis was categorised by the identification of metastatic disease in a lymph 
node as characterised by PPIX fluorescence. 
 
The primary aim of this trial was to determine the optimal dosage of 5-ALA therefore the 
trial was designed to assess an initial cohort of patients receiving a single dose of 
20mg/kg of oral 5-ALA, which is the most commonly administered dose of 5-ALA taken 
from previous studies(9). Reaching 10 patients with post-operative histopathological 
confirmation of positive lymph node disease at a dose of 20mg/kg marked the end of 
recruitment to Cohort 1. The dose of 5-ALA administered to a second cohort was 
dependent on the results from Cohort 1 and would either increase to 30mg/kg or 
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decrease to 10mg/kg (Figure 2.1). As pre-operative CT staging cannot accurately predict 
the lymph node status of colorectal tumours it was anticipated that more than 10 patients 
would be recruited per cohort to achieve the required number of patients with post-
operative histopathological confirmation of positive lymph node disease. 
 
The dose of 5-ALA that correctly identified the most number of patients with lymph node 
positive disease via fluorescence would be further evaluated in a developmental phase 
of the trial, with a set minimum of 2 correctly identified patients from a single cohort. The 
developmental phase would treat a third cohort of 10 patients with the optimal dose to 
confirm the validity of the technique. The trial ended if an optimal dose was not correctly 
identified by a minimum of two patients from either cohort.   
 
All patients underwent standard pre-operative assessments, including a pre-operative 
staging CT of the thorax, abdomen and pelvis. Oral doses of 5-ALA were calculated 
based on the weight of the patient. 5-ALA was reconstituted in water to a stock 




Figure 2.1. GLiSten trial flow diagram. Taken from Andrew et al.(9). Eligible patients 
meeting the inclusion and exclusion criteria were identified at the local colorectal 
MDT meeting at trial sites and approached by trial research personnel. Patients 
consenting to participation in the GLiSten trial were prescribed the appropriate 
dose of 5-ALA according to their weight and trial cohort on the morning of their 
surgery. Patients underwent fluorescence guided laparoscopic segmental 
colectomy with D3 lymphadenectomy with the specimen examined within the local 
histopathology department. All patients were followed up in clinic 30 days following 
their surgery.   
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The intraoperative fluorescence detecting system used to assess the tumour and 
draining lymphatic field was the Storz D-Light Laparoscopic System (KARL STORZ 
GmbH & Co. KG; Tuttlingen, Germany). This infrared laparoscopic camera has a blue-
light setting emitting light from 380-440nm. The location of fluorescent lymph nodes was 
documented and marked with surgical clips to allow identification during 
histopathological examination. 
 
 Patients underwent segmental colectomy with D3 lymphadenectomy and tissue 
specimens were subjected to standard histopathological examination(231). In addition, 
identified fluorescent lymph nodes underwent step-sectioning to identify micrometastatic 
disease.  
 
To determine the sensitivity and specificity of pre-operative CT reporting in this study CT 
reports were compared to histopathological examinations.  
 
Resection specimens were examined for oncological quality, including the plane and 
completeness of mesocolic resection and the extent of lymphadenectomy.  
 
Following surgery patients received standard post-operative care with additional 
monitoring for any adverse effects due to 5-ALA, such as cutaneous photosensitivity. To 
reduce the risk of photosensitivity reactions all patients skin and eyes were protected 
from the theatre operating lights and were kept out of direct sunlight on the ward for at 
least the first 48 hours following surgery. Patients were monitored for any 5-ALA related 
adverse effects in addition to the normal complications of major colorectal cancer 
surgery and general anaesthesia such as anastomotic leak, conversion to open surgery 
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and venous thromboembolism. Any adverse side effects or complications in the first 30 
postoperative days were recorded. All patients were followed up at 30 days post-surgery. 
 
2.1.2 Patient samples 
Paired normal and colonic tumour tissues were taken from each patient to allow further 
investigation of factors that could influence 5-ALA mediated fluorescence. Details 
regarding the use and storage of tissue samples were discussed with patients during the 
trial recruitment and consenting process.  
 
2.1.2.1 Snap freezing specimens 
Following surgical resection, tissue samples were rapidly cooled to preserve tissue 
integrity and prevent the degradation of biological molecules such as proteins and RNA. 
Biopsy samples were fixed on to cork discs using Optimal Cutting Temperature (OCT) 
compound (VWR International Ltd, Lutterworth, UK) ensuring the tissue samples were 
completely embedded into the OCT compound. The cork board were then submerged 
into liquid nitrogen cooled iso-pentane. For long-term storage, samples were stored at -
80C . 
 
2.1.2.2 Cryoscrolling and cryosectioning snap frozen specimens 
Snap frozen tissue samples were cryoscrolled (RNA extraction) and cryosectioned 
(histopathological examination) by mounting the cork board containing the snap frozen 
specimens onto a chuck using OCT. Sections were cut using a Leica CM3050 S 
Research Cryostat (Leica Microsystems (UK) Ltd, Milton Keynes, UK) that was set 
to -20C. For RNA extraction, specimens were sectioned at 10m and 30m and the 
cryoscrolled samples were collected. For histopathological examination, 10m sections 
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were cut and fixed onto SuperFrost™ Microscope Glass Slides (Thermo Fisher Scientific 
Inc., Waltham, Massachusetts, USA).  
 
2.1.2.3 H&E staining of sectioned tissue specimens 
Cryosectioned samples on glass slides were initially stained with Mayer’s Haematoxylin 
solution then rinsed in running water for 1 minute. The slides were washed in Scott’s Tap 
Water for 1 minute before being rinsed in running water for a 1 minute. Slides were 
counterstained with Eosin for 1 minute before being rinsed in running water for 1 minute. 
Slides were then dehydrated in ethanol, rehydrated in xylene and mounted on to 
coverslips using DePeX Mounting Medium (Sigma Aldrich, Gillingham, UK).  
 
Slides were assessed by an experienced gastrointestinal histopathologist to identify 
samples with the highest percentage of malignancy to allow a reasonable comparison 
between fluorescent and non-fluorescent tumours. Six specimens from the fluorescent 
tumours and six non-fluorescent tumour specimens were selected for RNA analysis. 
 
2.1.2.4 Extraction of RNA from snap frozen specimens 
Three different RNA extraction methods were compared to identify the most effective 
protocol. The first and second protocols utilised the PureLinkTM RNA Mini Kit (Thermo 
Fisher) and the third protocol utilised the RNeasy Mini Kit (Qiagen, Manchester, UK) for 
RNA extraction. A single cryoscrolled sample (as described in 2.1.2.2) of normal colonic 
tissue was randomly selected and used for each protocol. 
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2.1.2.4.1 RNA separation using PureLinkTM RNA Mini Kit – Protocol 1 
In the first protocol, 20x cryoscrolls of 30m thick tissue were transferred into a 
PureLinkTM RNA Mini Kit 1.5ml RNA/DNA free cartridge. 500l of TRIzol reagent 
(Thermo Fisher) was then added into the cartridge. Repetitive pipetting using RNA/DNA 
free pipette tips was performed to lyse the cells and the solution transferred into a 
PureLinkTM RNA Mini Kit 2ml RNase-free cartridge. After 5 minutes at room temperature, 
100l of chloroform was added and the cartridge was agitated for 15 seconds. The 
solution was left for a further 3 minutes at room temperature before being centrifuged for 
15 minutes at 12,000g at 4C. This separates the solution into a lower red phenol-
chloroform phase, an interphase, and a colourless upper aqueous phase. The upper 
phase contains the RNA fragments and 400l of this phase was transferred into a fresh 
RNase-free cartridge and mixed with 400l 70% ethanol. 
 
2.1.2.4.2 RNA separation using PureLinkTM RNA Mini Kit – Protocol 2 
For the second protocol, 20x cryoscrolls of 30m thick tissue were transferred into a 
PureLinkTM RNA Mini Kit 1.5ml RNA/DNA free cartridge. 700l of TRIzol reagent was 
then added into the cartridge. Repetitive pipetting using RNA/DNA free pipette tips was 
performed to lyse the cells and 140l of chloroform was immediately added. The 
cartridge was then agitated for 15 seconds. The solution was left for a further 3 minutes 
at room temperature before being centrifuged for 15 minutes at 12,000g at 4C. The 
upper aqueous phase was transferred to a fresh RNase-free cartridge and an equal 
volume of 70% ethanol was added. 
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2.1.2.4.3 RNA extraction using PureLinkTM RNA Mini Kit 
Following RNA separation utilising the PureLinkTM RNA Mini Kit, the subsequent steps 
were identical for both protocol 1 and 2. The RNA-ethanol mixtures were transferred into 
a spin cartridge with a collection tube and centrifuged at 12,000g for 15 seconds at room 
temperature. The flow-through was discarded and the spin cartridge reinserted. 700l 
Wash Buffer I was added to the spin cartridge and centrifuged again at 12,000g for 15 
seconds at room temperature. Both the flow-through and collection tubes were discarded 
at this point and the spin cartridge placed into a new collection tube. 500l Wash Buffer 
II with ethanol was added to the spin cartridge and centrifuged at 12,000g for 15 
seconds at room temperature. The flow-through was discarded and this wash step with 
Wash Buffer II was repeated once more. The flow-through was again discarded and the 
spin cartridge was centrifuged at 12,000g for one minute at room temperature. The spin 
cartridge was then placed in the recovery tube and 30l RNAase-free water was added 
and left to incubate at room temperature for a further minute. RNA fragments were 
recovered by centrifuging the spin cartridge at room temperature for two minutes at 
12,000g. 
 
2.1.2.4.4 RNA extraction using RNeasy Mini Kit – Protocol 3 
For the third protocol, 30x cryoscrolls of 10m thick tissue were harvested and 
transferred into a RNeasy Mini Kit RNA/DNA free cartridge. 10μl of -mercaptoethanol 
(-ME) was added to 1ml RNeasy Mini Kit Buffer RLT and 350μl of this solution was 
added to the cryoscrolls prior to centrifuging at 15,000g for 3 minutes at room 
temperature. The supernatant was removed using an RNA/DNA free pipette tip into a 
sterile micro-centrifuge tube and an equal volume of 70% ethanol was added and 
thoroughly mixed. The lysate was then added to a RNeasy spin column within a 2ml 
collection tube and centrifuged at 8,000g for 15 seconds at room temperature. The flow-
through was discarded and 700μl  of Buffer RW1 was added to the same spin column. 
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This was then centrifuged at 8,000g for 15 seconds at room temperature and the flow-
through discarded. RNeasy Mini Kit Buffer RPE was diluted at 1 in 5 with 96-100% 
ethanol and 500μl added to the same spin column. This was then centrifuged at 8,000g 
for 15 seconds at room temperature and the flow-through discarded. A further 500μl of 
the diluted Buffer RPE was again added to the same spin column, which was centrifuged 
at 8,000g for two minutes at room temperature. The spin column was placed in a new 
collection tube and 50l RNAase-free water was added directly to the membrane. 
Elution of the RNA was achieved by centrifuging at 8,000g for one minute at room 
temperature. 
 
2.1.2.4.5 Analysing the quality of extracted RNA 
Following extraction of RNA from the samples using the three different protocols, the 
quality of RNA was assessed. Quality assessment was based on: 
1. The concentration of extracted RNA 
2. RNA integrity number (RIN) value 
 
2.1.2.4.5.1 – Determining RNA concentration 
The concentration of RNA was determined by calculating the ratio between the optical 
density absorbance values between 260nm and 280nm using a NanoDrop 1000 
Spectrophotometer (Thermo Fisher). The Nanodrop was initially calibrated using 
deionised water. The absorption spectrum of RNase-free water was measured as a 
blank control to normalise RNA absorption spectra. RNA absorption was mapped out 
between 200nm and 350nm. Absorption values at 260nm and 280nm were recorded and 




2.1.2.4.5.2 – Determining RIN value 
RIN values were determined using the RNA ScreenTape Assay (Agilent Technologies, 
Waldbronn, Germany). Firstly, a running ladder was prepared by mixing 5l RNA 
Sample Buffer with 1l RNA Ladder. All extracted RNA samples were prepared by 
mixing 5l RNA Sample Buffer with 1l extracted RNA sample. The ladder and all 
samples were then heated at 72°C for 3 minutes after which they were placed on ice for 
2 minutes. Samples were then loaded and analysed in an RNA ScreenTape 2200 
TapeStation (Agilent Technologies). 
 
2.1.2.5 Gene expression analysis 
RNA was extracted from selected fluorescent and non-fluorescent tumours using the 
optimal RNA extraction protocol. Gene expression analysis was carried out to identify 
any underlying factors that could be responsible for the differences in observed tumour 
fluorescence. The analysis was performed by Fios Genomics Ltd (Edinburgh, UK). 
 
2.2 Recognition molecules 
2.2.1 Immunofluorescence 
2.2.1.1 Cell lines 
LoVo (metastatic colorectal), HEK293 (renal epithelial) and EA.hy926 (endothelial) cell 
lines were obtained from the European Collection of Authenticated Cell Cultures 
(Salisbury, UK). LoVo cells were cultured in Ham's F-12 Nutrient Mixture Medium (Life 
TechnologiesTM, Paisley, UK) supplemented with 10% heat-treated foetal calf serum 
(FCS) (Sigma Aldrich). HEK293 and EA.hy926 cells were cultured in Dulbecco's 
Modified Eagle Medium (DMEM) + GlutaMAXTM (Life Technologies, Paisley, UK) 
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medium supplemented with 10% heat-treated FCS. All three cell lines were cultured in 
75cm2 tissue culture flasks (Corning Inc., New York, USA) and incubated at 37°C, 5% 
CO2 and 95% Relative Humidity (RH).  
 
2.2.1.2 Passaging cell lines 
Upon 70% confluency, cell cultures were washed with Dulbecco’s Phosphate-Buffered 
Saline (DPBS) (Life technologies, Paisley, UK) and incubated for 5 minutes with 0.05% 
(v/v) trypsin and 0.5% (v/v) ethylenediaminetetraacetic acid (Life technologies, Paisley, 
UK) in DPBS. FCS-supplemented cell media was then added to the flasks, cell 
suspension was collected and centrifuged for 5 minutes at 400g. The supernatant was 
discarded and the pelleted cells were resuspended in fresh medium and re-seeded into 
75cm2 tissue culture flasks at 1:10 to 1:3 dilutions. Excess cells were used for 
experiments or subsequently discarded. 
 
2.2.1.3 Fixing cells 
For immunofluorescence, 2ml of a 1:15 dilution of cells in appropriate cell media were 
seeded onto sterile glass cover slips in 6-well plates (Corning, New York, USA) and 
incubated for 48 hours at 37°C, 5% CO2 and 95% RH. Cell media was discarded and 
cells were washed with DPBS. Cells were then fixed with 4% paraformaldehyde (Sigma 
Aldrich) for 10 minutes at room temperature then washed twice with DPBS. For long-
term storage the plates were stored at 4°C.  
 
2.2.1.4 Immunofluorescence protocol 
Fixed cells were washed with PBS for 5 minutes and blocked using 0.5% skimmed milk 
solution (Marvel, Premier Foods Group, London, UK) in PBS for another 5 minutes. A 
1:10 dilution of primary anti-CEA antibody (A5B7, Biotherapeutics Development Unit, 
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Cancer Research UK, Clare Hall Laboratories, Potters Bar, UK) in the blocking solution 
was centrifuged for 5 minutes at 13,000g. 100μl of the diluted primary antibody was then 
added to the fixed cells and left to incubate at room temperature for 1 hour. Cells were 
then subjected to three wash cycles lasting 5 minutes each with PBS. A fluorescent 
secondary goat anti-mouse Alexa Fluor 488 antibody (Thermo Fisher) was diluted in 
the blocking solution to a concentration of 1 in 300 and similarly centrifuged. 100μl 
diluted secondary antibody was then added to the cells and incubated at room 
temperature for 30 minutes and protected from light. Another three wash cycles with 
PBS were performed before the cover slips were removed from the wells and mounted 
onto glass slides using Prolong Gold Antifade reagent with DAPI (Thermo Fisher). Slides 
were sealed with ethyl acetate and cured overnight at room temperature whilst protected 
from light and then imaged at x63 magnification using a Zeiss Axioimager fluorescent 
microscope (Carl Zeiss, Herts, UK).  
 
2.2.2 Antibodies 
Recombinant chimeric anti-CEA monoclonal IgG antibody A5B7 (supplied by Cancer 
Research UK Biotherapeutics Development Unit, UK) that was raised against purified 
human CEA from human metastatic colon tumour tissue was used as the primary 
targeting antibody. Monoclonal mouse anti-human anti-CD31 IgG antibody clone JC70A 
(Dako, Glostrup, Denmark) was selected as the control antibody. CD31 is a type 1 
transmembrane glycoprotein known as platelet endothelial cell adhesion molecule-
1(232). Both these antibodies were tested against all three cell lines. 
 
2.2.2.1 Reduction of antibody 
Reducing agents break the disulphide bonds holding the light and heavy chains of the 
antibody together, exposing a free cysteine (sulfhydryl) group for conjugation(233). A 
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half antibody fragment is created when the disulphide bond holding the two heavy chains 
together is broken, but the antigen recognition site created by the folding of the heavy 
and light chain remains intact. This means that there is a free cysteine group available 
on the heavy chain of the antibody with an intact antigen recognition site. A half antibody 
fragment should allow orientation of antibody when bound to the functionalised NP. 
 
Three reducing agents were tested on the target antibody in an attempt to identify the 
optimal agent to produce the largest proportion of half antibody fragments:- 
1. Tris(2-carboxyethyl)phosphine (TCEP) (Thermo Fisher) 
2. 2-mercaptoethanol (2-ME) (Sigma Aldrich) 
3. 2-mercaptoethylamine-HCl (2-MEA) (Sigma Aldrich) 
The target anti-CEA antibody described in 2.2.2 was added separately at a concentration 
of 0.44μg/μl to 10mM TCEP, 0.1M 2-ME  and 0.18M 2-MEA and incubated at 37°C for 
90 minutes. 
 
2.2.2.2 Gel electrophoresis 
5μl of non-reducing buffer dye was added to 10μl of each reduced target antibody. Each 
reduced antibody-dye complex was added separately to a column in a Mini-Protean TGX 
Precast gel cartridge (Bio-Rad, Watford, UK) with a Spectra Multicolour Broad Range 
Protein ladder dye (Thermo Fisher) to enable reading of the size of the bands. The 
cartridge was then placed into a gel electrophoresis tank (Bio-Rad) which ran for 1 hour 
at 120V and 20mA. The gel was then removed from the cartridge and incubated with 
Instant Blue Commassie stain (Generon, Maidenhead, UK) for 1 hour. The gel was 
rinsed with distilled water to remove excess dye before exposure and imaged using a 
G:Box (Syngene, Cambridge, UK). 
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2.2.2.3 Dot blotting 
Dot blotting was used to identify any potential glycoprotein side chains from the heavy 
chains of the anti-CEA antibody. 
 
4.2mg sodium meta-periodate (Sigma Aldrich) was added to 1ml Glycolink Coupling 
Buffer (Thermo Fisher). 1ml of 2mg/ml target antibody solution was added to the sodium 
meta-periodate solution and incubated at room temperature for 30 minutes whilst 
protected from light. Excess sodium meta-periodate was removed by gel filtration 
through a 50K Amicon Ultra centrifugal filter (Merck Millipore Ltd, Cork, Ireland) that had 
been equilibrated with the Glycolink Coupling Buffer. The filtrate was recovered and 
made up to a volume of 2ml using the buffer producing an oxidised antibody solution at a 
concentration of 1mg/ml.  
 
The presence of any oxidised glycoprotein was tested by labelling with a biotin group. 
This was done by adding 200μl 5mM hydrazine-biotin (Sigma Aldrich) to 1.8ml oxidised 
1mg/ml target antibody and incubating for 1 hour at room temperature. The resulting 
solution was filtered using the same centrifugal filter to remove any excess hydrazine-
biotin and the recovered filtrate was made up to a 1mg/ml concentration by dilution in 
PBS. This oxidised and biotinylated antibody solution was used in subsequent dot 
blotting and western blotting. Untreated target antibody was used as a control. 
 
2μl biotinylated target antibody and 2μl untreated target antibody were spotted onto two 
separate nitrocellulose membranes which were allowed to air dry for 15 minutes before 
blocking with a 5% non-fat milk solution for 1 hour at room temperature. The milk 
blocking solution was removed and 10μl streptavidin-HRP (Sigma Aldrich) was added to 
10ml 5% non-fat milk solution. 5ml streptavidin-HRP-milk solution was incubated with 
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each membrane for 1 hour at room temperature. Two wash steps were performed with 
PBS containing 0.1% tween-20 (PBST) (Acros Organics, Geel, Belgium) with another 
wash in PBS. The membrane was subsequently exposed using a PierceTM ECL Western 
Blotting Substrate Kit (Thermo Fisher) according to the manufacturer’s protocol and 
imaged using a G:Box (Syngene, Cambridge, UK).  
 
2.2.2.4 Western blotting 
Biotinylated and untreated target antibodies were mixed with a reducing dye buffer 
containing dithiothreitol (DTT) (Sigma Aldrich) and incubated at 90°C for 10 minutes. 
15μl of each antibody-dye mixtures were loaded into a nitrocellulose gel and resolved for 
60 minutes at 120V and 20mA. The gel was removed from the cartridge, assembled 
between felt pads and a nitrocellulose membrane in a transfer cassette and placed into a 
Western Blot gel tank (Bio-Rad) containing transfer buffer for 1 hour at 120V. Following 
the transfer of proteins, the membrane was blocked in 5% bovine serum albumin (BSA) 
(Thermo Fisher) for 30 minutes, then incubated with 10ml 5% BSA containing 10μl 
streptavidin-HRP for 1 hour at room temperature. The membrane was then washed with 
PBST twice followed by another wash in PBS. The membrane was subsequently 
exposed using a PierceTM ECL Western Blotting Substrate Kit (Thermo Fisher) according 
to the manufacturer’s protocol and imaged using a G:Box. 
 
2.2.2.5 Oxidation of antibody 
Both target and control antibodies underwent oxidation of the glycoprotein side chains to 
enable conjugation to the funtionalised NP. The control antibody was diluted in a solution 
containing BSA which needed to be extracted prior to oxidation. This was an additional 
step not required for the target antibody. This was achieved by filtering the control 
antibody through a 100K Amicon Ultra centrifugal filter (Merck Millipore Ltd, Cork, 
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Ireland) that had been equilibrated with Glycolink Coupling Buffer (Thermo Fisher). All 
subsequent steps were the same for both antibodies. 
 
4.2mg sodium meta-periodate (Sigma Aldrich) was added to 1ml Glycolink Coupling 
Buffer. Equal volumes of the sodium meta-periodate solution and 2mg/ml antibody were 
allowed to incubate for 30 minutes at room temperature whilst being protected from the 
light. Excess sodium meta-periodate was removed by gel filtration through a 50K Amicon 
Ultra centrifugal filter that had been equilibrated with the Glycolink Coupling Buffer. The 
filtrate was recovered and made up to the original volume of solution filtered using the 
buffer producing an oxidised antibody solution at a concentration of 1mg/ml. Both the 
oxidised target and oxidised control antibodies were then tested against fixed cell lines 
using the immunofluorescence technique described in 2.2.1.4.  
 
2.2.2.6 Biotinylation of antibody 
Oxidation of the target and control antibodies was performed as described in 2.2.2.5 and 
then labelled with biotin. This was achieved by adding 5mM hydrazine-biotin to the 
filtered antibody solution followed by the addition of aniline and mixed for 1 hour at room 
temperature. Using the same desalting column as the oxidation process the antibody-
biotin solution was centrifuged at 10,000g for 1 minute to remove any unreacted biotin. 
The filtrate was recovered and made up to the original volume of solution and filtered 
using PBS producing a biotinylated antibody solution at a concentration of 1mg/ml. 
 
The three cell lines were prepared and fixed in 6-well plates as described in 2.2.1.3. If 
cells on glass slides had been stored at 4°C prior to use cells were rehydrated in PBS for 
5 minutes. The PBS was then discarded and an avidin-containing reagent (Vector 
Laboratories Ltd, Peterborough, UK) was added to the wells and incubated at room 
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temperature for 15 minutes. Following a rinse with PBS a biotin solution (Vector 
Laboratories Ltd, Peterborough, UK) was added to the wells and incubated at room 
temperature for 15 minutes. A blocking solution containing 0.1% bovine serum albumin 
was then added to the cells for 30 minutes. This blocking solution, in addition to the 
original antibodies, were used as controls to be compared to the biotinylated antibodies. 
1 in 100 solutions of the controls and biotinylated antibodies were added to the wells and 
incubated at room temperature for 1 hour. The cells were subjected to three wash cycles 
lasting 5 minutes each with PBS (Sigma Aldrich). A fluorescent secondary goat anti-
mouse Alexa Fluor 488 antibody (Invitrogen, Oregon, USA) was diluted in the blocking 
solution to a concentration of 1 in 300 and similarly centrifuged. 100μl diluted secondary 
antibody was added to the cells and incubated at room temperature for 30 minutes 
protected from light. Another three wash cycles with PBS were performed before the 
cover slips were removed from the wells, mounted onto glass slides, cured and imaged 
as described in 2.2.1.4. 
 
2.2.3 Biotinylation of affimer 
The anti-CEA affimer used in this project was kindly supplied by the Department of 
Biotechnology (School of Molecular and Cellular Biology, Faculty of Biological Sciences, 
University of Leeds, UK). 
 
Reduction of 155μl anti-CEA affimer at a concentration of 0.82mg/ml was performed 
using a TCEP Disulfide Reducing Gel. 4μl of PBS with 50mM EDTA was added to the 
prepared gel prior to the affimer being added. This was incubated for one hour at room 
temperature on a rotator at 20rpm. The gel was then centrifuged at 1,000g for 1 minute 
and the clear supernatant containing the reduced affimer was recovered. This was 
immediately mixed with 44.28μl 2mM biotin-maleimide and incubated for 2 hours at room 
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temperature. The biotinylated affimer solution was then filtered through a prepared Zebra 
spin desalting column 7K MWC to remove any unbound biotin.  
 
The three cell lines were prepared and fixed in 6-well plates as described in 2.2.1.3. If 
cells on glass slides had been stored at 4°C prior to use cells were rehydrated in PBS for 
5 minutes. The PBS was removed, an avidin-containing reagent added to the wells and 
incubated at room temperature for 15 minutes. Following a rinse with PBS, Biotin was 
added to the wells and incubated at room temperature for 15 minutes. A blocking 
solution containing 0.1% bovine serum albumin was then added to the cells for 30 
minutes. A 1 in 100 dilution of the biotinylated affimer in the blocking solution was 
incubated with the cells in addition to a control of plain blocking solution. This was left to 
incubate overnight at 4°C. The cells were subjected to three wash cycles lasting 5 
minutes each with PBS. A fluorescent protein that binds to biotinylated proteins, 
Streptavidin Dylight 488, was diluted in the blocking solution to a concentration of 1 in 
300. 100μl diluted Streptavidin Dylight 488 was added to the cells and incubated at room 
temperature for 1 hour protected from light. Another three wash cycles with PBS were 
performed before the cover slips were removed from the wells, mounted onto glass 
slides, cured and imaged as described in 2.2.1.4. 
 
2.3 Nanoparticle 
2.3.1 Fabrication of nanoparticles 
The semiconducting organic polymer NP is comprised of a fluorescent core, poly(2,5-
di(hexyloxy)cyanoterephthalylidene) (CN-PPV) (Sigma-Aldrich, Dorset, UK), 
encapsulated in a shell of poly(ethylene glycol) methyl ether-block-poly(lactide-co-
glycolide) (PLGA-PEG) (Sigma-Aldrich, Dorset, UK). The average molecular weight (Mn) 
for PLGA was 55,000Da and 5,000Da for the PEG component of the polymer.  
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A 2.5mg/ml solution of CN-PPV and a 5.56mg/ml solution of non-functionalised PLGA-
PEG in tetrahydrofuran (THF) (Fisher Scientific, Loughborough, UK) were created. 900μl 
PLGA-PEG solution was added to 100μl CN-PPV solution. 5ml distilled water was then 
added slowly and sonicated for 15 minutes in an ice water bath using a Bandelin 
Sonorex (Bandelin Electronic, Berlin, Germany). This mixture was then continuously 
stirred for 24 hours in a fume cupboard to allow the THF to evaporate. These non-
functionalised NPs were then stored in the dark at 4C. 
 
PLGA-PEG with a functional terminal maleimide group (Akina Inc., Indiana, USA) with a 
Mn of 30,000Da and 5,000Da respectively was used to form a maleimide functionalised  
NP using a similar method. The maleimide functionalised PLGA-PEG was dissolved in 
THF at a concentration of 5.56mg/ml. Maleimide functionalised NPs were then created 
with different ratios of the functional group in increments of 25% as detailed below. This 
was done by combining different volumes of the PLGA-PEG-Maleimide and standard 
PLGA-PEG (total volume equal to 900μl).  
• 25% MNP: 675μl non-functionalised PLGA-PEG, 225μl maleimide functionalised 
PLGA-PEG and 100μl CNPPV solution 
• 50% MNP: 450μl non-functionalised PLGA-PEG, 450μl maleimide functionalised 
PLGA-PEG and 100μl CNPPV solution 
• 75% MNP: 225μl non-functionalised PLGA-PEG, 675μl maleimide functionalised 
PLGA-PEG and 100μl CNPPV solution 
• 100% MNP: 0μl non-functionalised PLGA-PEG, 900μl maleimide functionalised 
PLGA-PEG and 100μl CNPPV solution 
 
NPs with a shorter PEG component were also fabricated for conjugation applications. 
The Mn values for PLGA was 11,500Da and 2,000Da for the PEG component of the 
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polymer in these NPs. Both non-functionalised and maleimide functionalised NPs with 
this shorter PEG component were fabricated and stored as described above. 
 
For the purposes of this thesis, non-functionalised NPs are NPs that have been formed 
using PLGA-PEG that does not possess the maleimide functional group and 
functionalised NPs are NPs whose PLGA-PEG possess a functional terminal maleimide 
(MNP) or streptavidin (SNP) group. Bare NPs refer to non-functionalised and 
functionalised NPs that have not been conjugated to a recognition molecule. 
 
2.3.2 Characterisation of nanoparticles 
All non-functionalised and maleimide functionalised NPs were characterised by the 
following methods. Serial characterisation was also performed over the course of up to 
12 weeks to establish bench life of these NPs. 
 
2.3.2.1 Characterisation of nanoparticle sizes 
The hydrodynamic diameter of all NPs and MNPs was established using dynamic light 
scattering via a Malvern Zetasiser Nano ZSP (Malvern Instrument, Worchestershire, UK) 
at 25°C in micro UV-Cuvettes (Brand GmbH & Co., Wertheim, Germany). The z-average 
is the intensity weighted mean hydrodynamic diameter measured by dynamic light 
scattering and this measurement is what was used to characterise the size of the NPs 
over time. The polydispersity index was also measured; this represents the 
heterogenicity of the hydrodynamic diameters of the NPs in a single sample. The back 




2.3.2.2 Characterisation of the nanoparticle absorption and emission 
profiles 
The absorption spectrum was measured using a Perkin Elmer UV/Vis/NIR 
Spectrophotometer (Perkin Elmer GmbH, Uberlingen, Germany) using a slit width of 
2nm and an absorption range between 300nm and 800nm. The emission spectrum was 
tested using a Jobin Yvon Horiba FluoroMax-3 spectrofluorimeter (Jobin Yvon Ltd, 
Stanmore, UK) using a slit width of 2nm and an emission range between 300nm and 
800nm. Emission spectra were tested at 4 different excitation wavelengths; 380nm, 
425nm, 440nm and 470nm. Both the absorption and emission spectrum of non-
functionalised NP and MNP solutions at an optimal dilution were measured using a High 
Precision Cell Quartz Suprasil 10mm cuvette (Hellma Analytics, Germany).  
 
2.3.2.2.1 Determining optimum dilution for testing absorption and 
emission profiles 
Standard non-functionalised NPs were produced as described in 2.3.1. To determine the 
optimum NP dilution for testing emission spectra, non-functionalised NPs were diluted in 
distilled water in 0.25µg/ml increments to form a series of dilutions ranging from 3µg/ml 
to 5µg/ml CN-PPV. The absorption and emission spectra for all dilutions was measured 
as described in 2.3.2.2. 
 
2.3.3 Testing the effect of centrifugation on nanoparticle 
characterisation 
The conjugation between the recognition molecule and the maleimide functionalised NP 
initially required the MNP to undergo chemical modifications. Therefore, investigations 
were conducted to determine whether these modifications would have any effect on the 
hydrodynamic diameter or fluorescent emission of the MNP. 
99 
 
To investigate the effect of centrifugation on the MNP, two series of 1500μl optimal 
dilution bare 25% maleimide functionalised NP were centrifuged from 1,000g to 10,000g 
at increments of 1,000g at room temperature. The supernatant was discarded and MNPs 
resuspended in 1500μl distilled water. Series 1 was centrifuged for 5 minutes, whereas 
series 2 was centrifuged for 30 minutes. Following resuspension, the MNPs were 
characterised as per 2.3.2.1 and 2.3.2.2. The control was 1500μl of optimal dilution bare 
25% maleimide functionalised NP that had not been subjected to centrifugation. 
 
2.3.3.1 Testing effects of repeated centrifugation on nanoparticle 
characterisation 
To investigate the effect of repeated centrifugation on MNPs, 1500μl optimal dilution 
bare 25% maleimide functionalised NP was centrifuged at 6,000g for 30 minutes at room 
temperature and the supernatant discarded. The MNPs were resuspended in1500μl 
distilled water and characterised as per 2.3.2.1 and 2.3.2.2. The MNPs were then 
centrifuged for a further 30 minutes at room temperature, the supernatant discarded and 
the MNPs resuspended in 1500μl distilled water. This process was then repeated twice. 
Following each round of centrifugation and resuspension the MNP was characterised as 
per 2.3.2.1 and 2.3.2.2. 
 
2.3.4 Cell viability after exposure to bare maleimide 
functionalised nanoparticle 
2.3.4.1 Cell counting for seeding 96-well plates 
LoVo, HEK293 and EA.hy926 cells were passaged as described in 2.2.1.2 and 10μl of 
cell suspension solutions were mixed with 10μl Trypan blue (Life Technologies Europe, 
Bleiswijk, Netherlands). 10μl of this solution was placed into an Invitrogen cell counting 
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slide (Life Technologies Europe, Bleiswijk, Netherlands) and the cell concentration was 
determined using a Countess II Automated Cell Counter (Life Technologies, Carlsbad, 
California, USA). A concentration of 2.5 x 104 cells/ml was then created and100μl of cells 
in suspension were then added to each well in 96-well plates and placed into incubation. 
 
2.3.4.2 MTT Assay 
LoVo, HEK293 and EA.hy926 cells were prepared in 96-well plates (Corning Inc., New 
York, USA) as described in 2.3.4.1. After 24 hours, total cell media was exchanged with 
cell media containing 10-fold dilutions of bare 25% maleimide functionalised NPs and left 
for either 24, 48 or 72 hours. Plates also contained a media only control. After 24, 48 or 
72 hours, the media was replaced with a 1mg/ml solution of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, MO 63103, USA) in cell media 
and incubated for 4 hours. Excess unmetabolised MTT solution was discarded and 
formazan crystals were completely dissolved in propan-1-lol (Fisher Scientific, 
Loughborough, UK). Dissolved formazan absorbance values were determined at 570nm 
using a Mithras LB 940 Microplate Reader (Berthold Technologies Ltd., Harpenden, UK).  
 
2.3.5 Testing for non-specific binding of nanoparticle to cell 
lines 
 LoVo, HEK293 and EA.hy926 cells were prepared in 96-well plates as described in 
2.3.4.1. A control of appropriate cell media was compared against dilated bare non-
functionalised NP and the different ratios of diluted maleimide functionalised NPs (25%, 
50%, 75% and 100% MNP) in appropriate cell media. 100μl of either control, diluted 
non-functionalised NP or diluted MNP were added to wells and plates were incubated for 
24 hours at 37°C and 5% CO2. Cell media was then removed and the plates were 
subjected to three wash cycles lasting 5 minutes each with PBS (Sigma-Aldrich, MO 
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63103, USA). Plates were left overnight at room temperature protected from light. 200μl 
10% sodium dodecyl sulfate (SDS) was added to each well for 2-3 minutes and then 
centrifuged at room temperature for 5 minutes at 400g. 150μl of the supernatant from the 
wells were transferred into a new plate and fluorescence was measured (Excitation: 
470nm, Emission: 650nm) on the microplate reader. 
 
This method was repeated with the addition of cysteine to investigate whether blocking 
the unoccupied maleimide functional group had any impact on non-specific binding of 
the MNP to cells. A 10mM solution of cysteine was created in appropriate cell media and 
used to dilute the bare non-functionalised NP and different ratio bare maleimide 
functionalised NPs. The control, NP and different ratio MNP dilutions were left in the 
10mM cysteine cell media solution for an hour prior to adding to the wells to allow the 
cysteine to block the maleimide functional groups. 
 
2.4 Conjugation 
2.4.1 Conjugating anti-CEA antibody to heterobifunctional 
crosslinker 
To confirm the conjugation of oxidised antibodies through binding of aldehyde groups to 
hydrazide functional groups on the heterobifunctional crosslinker, a fluorescent 
sulfhydryl-reactive dye was used. DylightTM 488 Maleimide (ThermoFisher Scientific, 
Rockford, USA) is a maleimide activated fluorescent dye that labels unoccupied 
sulfhydryl groups.  
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2.4.1.1 Testing antibody – dye labelled crosslinker conjugate against 
cell lines using 0.5% skimmed milk as the blocking agent 
DylightTM 488 Maleimide and PDPH were dissolved in dimethyl sulfoxide (DMSO) to 
concentrations of 1.6mg/ml and 2.4mg/ml respectively. 250l of each solution were 
mixed together and incubated for 2 hours at room temperature, protected from light, 
allowing the dye to label the crosslinker. The anti-CEA antibody was oxidised as per the 
protocol described in 2.2.2.5 and 500l mixed with 280l of the dye-labelled crosslinker. 
This mixture was incubated in the dark for an hour at room temperature. Excess 
reagents were extracted from the antibody-dye-labelled crosslinker conjugate by gel 
filtration through a PBS-equilibrated 50K Amicon Ultra centrifugal filter. The filtrate was 
recovered and diluted in 780l PBS. The antibody-dye-labelled crosslinker conjugate 
was then tested on LoVo, HEK293 and EA.hy926 cell lines using the 
immunofluorescence protocol described in 2.2.1.4. 0.5% skimmed milk blocking and 
unconjugated oxidised antibody served as controls. Due to the presence of the 
fluorescent Dylight 488 molecules a secondary fluorescent antibody was not needed. 
 
2.4.1.2 Testing antibody – dye labelled crosslinker conjugate against 
cell lines using 0.1% bovine serum albumin as blocking the agent 
The protocol described above in 2.4.1.1 was repeated using a different blocking method 
(Avidin/Biotin blocking). LoVo, HEK293 and EA.hy926 cell lines were prepared and fixed 
in 6-well plates as described in 2.2.1.3. Cells were rehydrated in PBS for 5 minutes. The 
PBS was then discarded and an avidin-containing reagent (Vector Laboratories Ltd, 
Peterborough, UK) was added to cells and incubated at room temperature for 15 
minutes. Cells were then washed with PBS and a biotin solution (Vector Laboratories 
Ltd, Peterborough, UK) was added to cells and incubated at room temperature for 15 
minutes. A blocking solution containing 0.1% bovine serum albumin was then added to 
the cells and incubated for 30 minutes. The following steps were conducted as described 
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in 2.2.1.4. 0.1% bovine serum albumin blocking and unconjugated oxidised antibody 
served as controls. Due to the presence of the fluorescent Dylight 488 molecules a 
secondary fluorescent antibody was not needed for experiments. 
 
2.4.1.3 Testing components of antibody – dye labelled crosslinker 
conjugate 
To identify components which may potentially be responsible for non-specific binding to 
cell lines each of the following components were tested against LoVo, HEK293 and 
EA.hy926 cell lines using the immunofluorescence technique as described in 2.4.1.2 with 
the additional control of unmodified PDPH: 
• Oxidised anti-CEA antibody 
• PDPH 
• Dye labelled PDPH 
• Unblocked DylightTM 488 Maleimide dye 
• Blocked DylightTM 488 Maleimide dye 
To block the DylightTM 488 Maleimide the dye was added to a 10mM cysteine solution 
and left to incubate for an hour to allow the cysteine to block maleimide functional 
groups. 
 
2.4.2 Conjugation of antibody recognition molecule to maleimide 
functionalised nanoparticle  
Conjugation of the anti-CEA antibody to the 25% maleimide functionalised NP through 
the use of the heterobifunctional crosslinker, PDPH, was investigated. For subsequent 
experiments the non-functionalised PLGA-PEG used in the NP system was the 2KDa 
PEG chain length. 
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2.4.2.1 Conjugating heterobifunctional crosslinker to maleimide 
functionalised nanoparticle 
To ascertain the length of time for the heterobifunctional crosslinker to bind to the 
maleimide functional group on the MNP, the following binding assay was performed. 
 
LoVo cells were passaged as per 2.2.1.2 and seeded into 96-well plates as per 2.3.4.1. 
The plates were incubated overnight at 37°C, 5% CO2 and 95% Relative Humidity (RH).  
 
Equal volumes of 0.1mg/ml PDPH and 25% bare maleimide functionalised NP were 
mixed for 30 minutes, 1 hour and 2 hours at room temperature. Excess PDPH was 
removed by gel filtration through a 50K Amicon Ultra centrifugal filter that had been 
equilibrated with distilled water. The anti-CEA antibody was oxidised and filtered as per 
2.2.2.5. 
 
The oxidised anti-CEA antibody and each PDPH-NP conjugate were mixed at a ratio of 
20:1 for 1 hour at room temperature. Excess oxidised anti-CEA antibody was removed 
from each solution by centrifuging the mixture at 6,000g for 30 minutes, carefully 
removing the supernatant and resuspending in an original volume of PBS.  
 
1 in 100 dilutions of bare 25% maleimide functionalised NPs, 30 minute anti-CEA 
antibody-NP conjugate, 1 hour anti-CEA antibody-NP conjugate and 2 hour anti-CEA 
antibody-NP conjugate were created in appropriate cell media. Cell media in the 96-well 
plates was exchanged with 100l cell media of either the bare 25% maleimide 
functionalised NP or the various anti-CEA antibody-NP conjugates. Plates also 
contained a media only control. Plates were incubated for 24 hours at 37°C, 5% CO2 and 
95% Relative Humidity (RH).  
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Cell media was then removed and the plates were subjected to three wash cycles lasting 
5 minutes each with PBS. Plates were left overnight at room temperature protected from 
light. 200μl 10% sodium dodecyl sulfate (SDS) was added to each well for 2-3 minutes 
and then centrifuged at room temperature for 5 minutes at 400g. 150μl of the 
supernatant from the wells were transferred into a new plate and fluorescence was 
measured (Excitation: 470nm, Emission: 650nm) on the microplate reader. 
 
2.4.2.2 Testing anti-CEA antibody – nanoparticle conjugate against 
LoVo cell line 
LoVo cells were passaged as per 2.2.1.2 and seeded into 96-well plates as per 2.3.4.1. 
The plates were incubated overnight at 37°C, 5% CO2 and 95% Relative Humidity (RH).  
 
The anti-CEA antibody was oxidised and filtered as per 2.2.2.5. Equal volumes of 
0.1mg/ml PDPH and 25% bare maleimide functionalised NP were mixed for 30 minutes 
at room temperature. Excess PDPH was removed by gel filtration through a 50K Amicon 
Ultra centrifugal filter that had been equilibrated with distilled water. The filtrate was 
recovered and made up to the 50% of the original volume of solution filtered using 
distilled water so that the MNP concentration did not alter. 
 
Equal volumes of the oxidised anti-CEA antibody and PDPH-MNP conjugate were mixed 
for 1 hour at room temperature. Excess oxidised anti-CEA antibody was removed by 
centrifuging the mixture at 6,000g for 30 minutes, carefully removing the supernatant, 
and resuspending in an original volume of PBS.  
 
Cell media in the 96-well plates was exchanged with 100l cell media containing either 
bare non-functionalised, bare 25% maleimide functionalised or anti-CEA antibody-
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conjugated MNPs; each a 1 in 100 dilution. Plates also contained a media only control. 
Plates were incubated for 24 hours at 37°C, 5% CO2 and 95% Relative Humidity (RH).  
 
Cell media was then removed and the plates were subjected to three wash cycles lasting 
5 minutes each with PBS. Plates were left overnight at room temperature protected from 
light. 200μl 10% sodium dodecyl sulfate (SDS) was added to each well for 2-3 minutes 
and then centrifuged at room temperature for 5 minutes at 400g. 150μl of the 
supernatant from the wells were transferred into a new plate and fluorescence was 
measured (Excitation: 470nm, Emission: 650nm) on the microplate reader. 
 
The anti-CEA antibody-conjugated NP was also tested against the target cell line, LoVo, 
as described in 2.2.1.4. 
 
2.4.2.3 Testing target (anti-CEA) and control (anti-CD31) antibody – 
nanoparticle conjugates against target and control cell lines 
LoVo, HEK293 and EA.hy926 cell lines were passaged as per 2.2.1.2 and seeded into 
96-well plates as per 2.3.4.1. Plates were incubated overnight at 37°C, 5% CO2 and 95% 
Relative Humidity (RH).  
 
Both the target (anti-CEA) and control (anti-CD31) antibodies were oxidised and filtered 
as per 2.2.2.5. Equal volumes of 0.1mg/ml PDPH and 25% bare maleimide 
functionalised NPs were mixed for 30 minutes at room temperature. Excess PDPH was 
removed by gel filtration through a 50K Amicon Ultra centrifugal filter that had been 
equilibrated with distilled water. The filtrate was recovered and made up to the original 
volume of 25% bare maleimide functionalised NP using distilled water to maintain MNP 
concentrations. Equal volumes of the oxidised target and control antibodies were mixed 
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with PDPH-MNP conjugates for 1 hour at room temperature. Excess oxidised target and 
control antibodies were removed by centrifuging mixtures at 6,000g for 30 minutes. The 
supernatants were carefully removed and antibody-NP conjugates resuspended in PBS 
to the original volume.  
 
Cell media in the 96-well plates was exchanged with 100l cell media in the following 
conditions:  
i. Cell media only 
ii. Bare 25% maleimide functionalised NPs 
iii. Target antibody 
iv. Control antibody 
v. Target antibody-conjugated NPs 
vi. Control antibody-conjugated NPs 
 
All reagents were made up to 1 in 100 dilution in cell media. Cells were incubated with 
the different conditions for 24 hours at 37°C, 5% CO2 and 95% Relative Humidity (RH). 
Cell media was then removed and plates were subjected to three wash cycles with PBS 
for 5 minutes each. Plates were then left overnight at room temperature protected from 
light. 200μl 10% SDS was added to each well for 3 minutes and then centrifuged at room 
temperature for 5 minutes at 400g. 150μl of the supernatant from the wells were 
transferred into fresh 96-well plates and fluorescence intensities were measured 
(Excitation: 470nm, Emission: 650nm) using the microplate reader. 
 
The target and control antibody-conjugated NPs were also tested against fixed target 
and control cell lines as described in 2.2.1.4. 
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2.4.3 Optimising the protocol for conjugating antibodies to 
maleimide functionalised nanoparticle 
Different aspects of the antibody-NP conjugation process were investigated to optimise 
the work flow system. The following methods (categorised into steps) are based on the 
master protocol described in 2.4.2.3 and detail the aspects of the protocol that had been 
altered. For optimisation protocols only the target (anti-CEA) antibody was tested against 
LoVo, HEK293 and EA.hy926 cell lines. 
 
2.4.3.1 Optimisation step 1: Comparing different extraction techniques 
to remove excess antibody from antibody-nanoparticle conjugates 
The protocol in 2.4.2.3 was followed with the only alteration being the method for 
extracting excess oxidised antibodies from antibody-NP conjugates. Cell media in the 
96-well plates was exchanged with 100l cell media in the following conditions:  
i. Cell media only 
ii. Bare 25% maleimide functionalised NPs 
iii. Target antibody-NP conjugates with no extraction of excess antibodies 
iv. Target antibody-NP conjugates with extraction of excess antibodies by 
centrifugation 
v. Target antibody-NP conjugates with extraction of excess antibodies by dialysis 
vi. Target antibody-NP conjugates with extraction of excess antibodies by 
magnetism 
 
2.4.3.1.1 Extraction of excess antibody by dialysis 
A 1ml Spectra/Por Float-A-Lyzer G2 dialysis tube (Merck KGaA, Darmstadt, Germany) 
was used to extract excess oxidised antibodies from antibody-NP conjugates through 
dialysis. The Float-A-Lyzer G2 membrane was primed using 10% ethanol and then 
flushed with distilled water. After allowing the oxidised antibody and the magnetic PDPH-
MNP conjugate to mix for 1 hour, the mixture was carefully placed at the bottom of the 
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membrane and the dialysis tube was placed in PBS. The PBS dialysate buffer was 
refreshed at 2 hours, 6 hours and 10 hours then left overnight. Antibody-NP conjugates 
were then retrieved from the dialysis tube. 
 
2.4.3.1.2 Extraction of excess antibody by magnetism 
A magnetic CN-PPV/FeO4 lipid NP was kindly supplied by the Department of Physics 
(Photonics & Nanotechnology Group, Faculty of Natural and Mathematical Sciences, 
Kings College London, UK). 
 
After allowing the oxidised antibody and the magnetic PDPH-NP conjugate to mix for 1 
hour, the mixture was placed into a DynaMagTM-2 Magnet (ThermoFisher Scientific, 
Rockford, USA) (Figure 2.2) and left overnight at 4°C. The supernatant was removed 
and antibody-NP conjugates resuspended in PBS to the original volume.  
 
 
Figure 2.2. Image showing separation of magnetic maleimide functionalised NP 
from solution using DynaMagTM-2 Magnet magnetic separator. Orange 
sediment represents magnetic maleimide functionalised CNPPV/PLGA-PEG NP 
that has been separated from distilled water using the magnetic separator. 
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2.4.3.2 Optimisation step 2: Galactose-mediated blocking of 
unoccupied hydrazide groups on crosslinker 
The monosaccharide, Galactose, can be oxidised to block unoccupied hydrazide 
functional groups on the heterobifunctional crosslinker, PDPH. Galactose was therefore 
chosen as a blocking agent. Cell media in the 96-well plates was exchanged with 100l 
cell media in the following conditions:  
i. Cell media only 
ii. Bare 25% maleimide functionalised NPs 
iii. PDPH - 25% maleimide functionalised NP conjugates 
iv. PDPH - 25% maleimide functionalised NP conjugates with galactose 
v. Target antibody-NP conjugates 
vi. Target antibody-NP conjugates with galactose 
 
2mg galactose was dissolved into 1ml Glycolink Coupling Buffer solution. 2.1mg sodium 
meta-periodate (Sigma Aldrich) was added to 500l Glycolink Coupling Buffer solution. 
Equal volumes of the sodium meta-periodate and 2mg/ml galactose solutions were 
mixed and incubated for 30 minutes at room temperature whilst being protected from the 
light. Equal volumes of the oxidised galactose were added to PDPH - 25% maleimide 
functionalised NP conjugates and anti-CEA antibody-NP conjugates. These mixtures 
were left for 1 hour at room temperature, to allow galactose to block unoccupied 
hydrazide groups on PDPH. Excess oxidised galactose was removed by gel filtration 
through a 50K Amicon Ultra centrifugal filter that had been equilibrated with the Glycolink 
Coupling Buffer solution. The filtrate was recovered and made up to the original volume 
of conjugate using PBS. 
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2.4.3.3 Optimisation step 3: Assessing the effect of conjugation time 
between oxidised antibody and PDPH-MNP conjugate 
Oxidised anti-CEA antibodies and the PDPH-maleimide functionalised NP conjugates 
were incubated at room temperature for different lengths of time. Cell media in the 96-
well plates was exchanged with 100l cell media in the following conditions:  
i. Cell media only 
ii. Bare 25% maleimide functionalised NPs 
iii. Target antibody-NP conjugates – 1 hour incubation 
iv. Target antibody-NP conjugates – 2 hour incubation 
v. Target antibody-NP conjugates – 4 hour incubation 
vi. Target antibody-NP conjugates – 8 hour incubation 
 
2.4.3.4 Optimisation step 4: Investigating the effect of increasing the 
amount of Target (anti-CEA) antibodies incubated with PDPH-MNP in 
conjugation reactions 
The amount of oxidised target antibody mixed with the PDPH – maleimide functionalised 
NP conjugates was increased and compared to the original ratio. PDPH-blocking with 
galactose and filtration of the excess galactose were also examined. Cell media in the 
96-well plates was exchanged with 100l cell media in the following conditions: 
i. Cell media only 
ii. Bare 25% maleimide functionalised NP 
iii. Target antibody-NP conjugate – 1x Ab in reaction 
iv. Target antibody-NP conjugate – 2x Ab in reaction 
v. Target antibody-NP conjugate – 2x Ab in reaction with blocking agent 




2.4.3.5 Optimisation step 5: Investigating optimum dilution of 
maleimide functionalised nanoparticle in conjugation reaction 
Prior to conjugation with the oxidised target antibody different concentrations of the 
PDPH-maleimide functionalised NPs were created using PBS as the diluent. The target 
antibody-NP conjugates (of different MNP concentration) were tested against the cell 
lines as per 2.4.2.3. Cell media in the 96-well plates was exchanged with 100l cell 
media in the following conditions: 
i. Cell media only 
ii. Bare 25% maleimide functionalised NP 
iii. Undiluted target antibody-NP conjugate 
iv. 90% dilution target antibody-NP conjugate 
v. 80% dilution target antibody-NP conjugate 
vi. 70% dilution target antibody-NP conjugate 
 
2.4.3.6 Optimisation step 6: The influence of wash cycles following the 
incubation of cells with conjugates 
As per the protocol described in 2.4.2.3, cells were subjected to three wash cycles 
lasting 5 minutes each with PBS after 24 hours incubation with conjugates. Therefore, 
the impact of multiple wash cycles was investigated (2-4 wash cycles). Cell media in the 
96-well plates was exchanged with 100l cell media in the following conditions and 
plates subjected to 2-4 wash cycles: 
i. Cell media only 
ii. Bare 25% maleimide functionalised NP 
iii. Target antibody-NP conjugate 
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2.4.3.7 Optimisation step 7: Investigating the different parameters of 
incubation 
Different parameters (time and temperature) of incubation for the target antibody-NP 
conjugates on cells were investigated to determine the optimum incubation settings. Cell 
media in the 96-well plates was exchanged with 100l cell media in the following 
conditions and plates incubated for either 1 hour or overnight at 4C, room temperature 
or 37C: 
i. Cell media only 
ii. Bare 25% maleimide functionalised NP 
iii. Target antibody-NP conjugate 
iv. Blocked target antibody-NP conjugate 
 
2.4.4 Testing target and control antibody – nanoparticle 
conjugates against target and control cell lines using streptavidin 
functionalised nanoparticle 
The streptavidin functionalised variant of the CNPPV/PLGA-PEG NP was kindly supplied 
by the Department of Physics (Photonics & Nanotechnology Group, Faculty of Natural 
and Mathematical Sciences, Kings College London, UK). LoVo, HEK293 and EA.hy926 
cell lines were passaged as per 2.2.1.2 and seeded into 96-well plates as per 2.3.4.1. 
Plates were incubated overnight at 37°C, 5% CO2 and 95% Relative Humidity (RH). Both 
the target and control antibodies were biotinylated and filtered as per 2.2.2.6. Equal 
volumes of the biotinylated target and control antibodies were mixed with the streptavidin 
functionalised NPs for 1 hour at room temperature. Excess biotinylated target and 
control antibodies were removed by centrifuging at 6,000g for 30 minutes. The 
supernatants were carefully removed and antibody-SNP conjugates resuspended in PBS 
to the original volume. Cell media in the 96-well plates was exchanged with 100l cell 
media in the following conditions:  
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i. Cell media only 
ii. Bare streptavidin functionalised NPs 
iii. Target antibody 
iv. Control antibody 
v. Target antibody-streptavidin functionalised conjugated NPs 
vi. Control antibody-streptavidin functionalised conjugated NPs 
 
All reagents were made up to 1 in 100 dilution in cell media. Cells were incubated with 
the different conditions for 24 hours at 37°C, 5% CO2 and 95% Relative Humidity (RH). 
Cell media was then removed and plates were subjected to three wash cycles with PBS 
for 5 minutes each. Plates were then left overnight at room temperature protected from 
light. 200μl 10% SDS was added to each well for 3 minutes and then centrifuged at room 
temperature for 5 minutes at 400g. 150μl of the supernatant from the wells were 
transferred into fresh 96-well plates and fluorescence intensities were measured 
(Excitation: 470nm, Emission: 650nm) using the microplate reader. 
 
2.4.5 Conjugation of anti-CEA affimer to maleimide 
functionalised nanoparticle 
2.4.5.1 Preparing anti-CEA affimers 
The control and anti-CEA affimers used in this project were kindly supplied by the 
Department of Biotechnology (School of Molecular and Cellular Biology, Faculty of 
Biological Sciences, University of Leeds, UK). Two anti-CEA affimers, anti-CEA II and 
anti-CEA III, were assessed. A yeast SUMO-binding affimer (ySUMO) was used as the 
control affimer. 
 
Concentration of affimers was determined by calculating the optical density absorbance 
value at 280nm using a NanoDrop 1000 Spectrophotometer (Thermo Fisher). The value 
obtained was the divided by the extinction coefficient of that specific affimer. The 
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Nanodrop was initially blanked and calibrated using elution buffer as described in 
2.1.2.4.5.1. Once concentrations of affimers were determined, elution buffer was added 
to affimer samples so the concentrations of control and anti-CEA affimers were equal. 
 
2.4.5.2 Testing variants of anti-CEA affimer-maleimide functionalised 
nanoparticle conjugates 
Target (LoVo) and control (HEK293) cell lines were passaged as per 2.2.1.2 and seeded 
into 96-well plates as per 2.3.4.1. Plates were incubated overnight at 37°C, 5% CO2 and 
95% Relative Humidity (RH).  
 
Initially, both target and control affimers were reduced using immobilised TCEP Disulfide 
Reducing Gel (ThermoFisher Scientific, Rockford, USA) making cysteine functional 
groups available for conjugation to maleimide functionalised NPs. The immobilised 
TCEP Disulfide Reducing Gel was prepared using Eppendorf LoBind protein 
microcentrifuge tubes (Merck KGaA, Darmstadt, Germany) and centrifuged at 1,000g for 
1 minute. The supernatant was removed and the gel was washed three times with PBS 
supplemented with 1mM ethylenediaminetetraacetic acid (EDTA). 4l PBS with 50mM 
EDTA was added to the immobilised TCEP Disulfide Reducing Gel. Each affimer was 
added to double the volume of prepared immobilised TCEP Disulfide Reducing Gel and 
incubated for 1 hour at room temperature on a centrifuge tube rotator. Reduced affimer 
was recovered by centrifuging at 1,000g for 1 minute and extracting the clear 
supernatant containing the affimer.  
 
Affimer conjugated NPs were prepared by mixing equal volumes of reduced affimer and 
25% bare maleimide functionalised NPs and incubated overnight at room temperature. 
Excess affimer was removed by gel filtration through a 50K Amicon Ultra centrifugal filter 
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that had been equilibrated with elution buffer. The filtrate was recovered and 
resuspended in PBS to the original volume of reduced affimer and 25% bare maleimide 
functionalised NP. Cell media in the 96-well plates was exchanged with 100l cell media 
in the following conditions:  
i. Cell media only 
ii. Bare 25% maleimide functionalised NPs 
iii. Control affimer-conjugated NPs 
iv. Anti-CEA II affimer-conjugated NPs 
v. Anti-CEA III affimer-conjugated NPs 
vi. Equal mixture of anti-CEA II and anti-CEA III affimer-conjugated NPs 
 
All reagents were made up to 1 in 100 dilution in cell media. Cells were incubated with 
the different conditions for 24 hours at 37°C, 5% CO2 and 95% Relative Humidity (RH). 
Cell media was then removed and plates were subjected to three wash cycles with PBS 
for 5 minutes each. Plates were then left overnight at room temperature protected from 
light. 200μl 10% SDS was added to each well for 3 minutes and then centrifuged at room 
temperature for 5 minutes at 400g. 150μl of the supernatant from the wells were 
transferred into fresh 96-well plates and fluorescence intensities were measured 
(Excitation: 470nm, Emission: 650nm) using the microplate reader. 
 
2.4.5.3 Comparing different incubation settings for affimer-conjugated 
nanoparticle  
Different parameters (time and temperature) of incubation for the target (anti-CEA) 
affimer-NP conjugates on LoVo cells were investigated to determine the optimum 
incubation settings. The protocol described in 2.4.5.2. was followed, however, 
differences in incubation conditions of 96-well plates containing cells exposed to affimer-
conjugated NPs were made. Cell media in the 96-well plates was exchanged with 100l 
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cell media in the following conditions and plates incubated for either 2 hours or overnight 
at 4C or room temperature: 
i. Cell media only 
ii. Bare 25% maleimide functionalised NP 
iii. Target anti-CEA II/III affimer-NP conjugate 
 
2.4.5.4 Testing target and control affimer – nanoparticle conjugates 
against target and control cell lines 
The protocol described in 2.4.5.2 was followed with the exception that once the target 
and control affimer-conjugated NPs had been added to target and control cell lines the 
96-well plates were incubated overnight at room temperature. Cell media in the 96-well 
plates was then exchanged with 100l cell media in the following conditions:   
i. Cell media only 
ii. Bare 25% maleimide functionalised NPs 
iii. Control affimer-NP conjugates 
iv. Target anti-CEA II/III affimer-NP conjugates 
 
The target and control affimer-conjugated NPs were also tested against fixed target and 







2.5 Statistical analysis 
Statistical analysis was performed using Graphpad Prism 8 (Graphpad Software Inc, 
California, USA). One-way ANOVA and student’s t-test were used for statistical 
analyses. P-values equal to and less than 0.05 (p ≤ 0.05) are considered to show 
statistically significant differences. The statistical methods used for gene expression 
analysis were principal component analysis and hierarchical clustering; analysis was 
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3 Next Generation of Laparoscopic intraoperative Lymph node 
staging for Stratified colon cancer surgery (GLiSten) clinical trial 
3.1 Introduction 
A major limitation in the current standards of colorectal cancer surgery is the tendency to 
unnecessarily overtreat lymph node (LN) negative patients and undertreat LN positive 
patients(9). This is attributed to the inability to accurately predict and stage the presence 
of metastatic disease in LNs prior to surgical resection(31,33,34). Consequently, radical 
surgery will expose LN negative patients to unnecessary increased surgical risks (29), 
whilst LN positive patients will be at risk of disease progression if resection is not radical 
enough. This is an unmet clinical need and advances need to be made to accurately 
identify the presence of metastatic disease in LNs prior to surgical resection. 
 
As discussed in 1.3.3, fluorescence guided surgery is a potential option to improve 
disease-free survival following colorectal cancer surgery through fluorescence-mediated 
intraoperative identification of the tumour and LN metastases(11,12,94,96–102,104–
108,234,235). Various fluorescent dyes and probes, including indocyanine green (ICG) 
and 5-aminolevulinic acid (5-ALA), have been investigated across different surgical 
specialties for their efficacy in intraoperatively identifying tumour location and the 
presence of metastatic disease.  
 
Exogenously administered 5-ALA is metabolically converted intracellularly in the 
mitochondria into the fluorescent photosensitiser, PPIX. The Next Generation 
intraoperative Lymph node staging for Stratified colon cancer surgery (GLiSten) study(9) 
was designed to determine the feasibility of potentially using PPIX from exogenous 5-
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ALA as a fluorescent probe to detect the presence of LN metastases in colon cancer. 
The use of PPIX as a fluorescent marker to detect and identify the location of colonic 
tumours and the presence of LN metastases is a novel approach that has not been 
previously explored.  
 
The trial design is outlined in 2.1.1. The primary objective of the study was to determine 
the optimal dosage of 5-ALA for the intraoperative detection of metastases in LNs in 
adult colon cancer patients undergoing elective surgery. As a pre-defined criteria, a 
minimum of 2/10 (20%) patients in a single cohort needed to be accurately identify with 
metastatic LN to confirm the optimal dose of 5-ALA. 
 
The secondary objectives of this study were to establish a repeatable and consistent 
methodology by the standardisation of: 
I) Pre-operative computerised tomography (CT) LN reporting  
II) Laparoscopic segmental colonic resection with D3 lymphadenectomy  
III) Histopathological examination of resected specimens  
 
In addition to the primary and secondary objectives, data was collated relating to the 





3.2.1 GLiSten study results 
A total of 44 patients were recruited to the GLiSten study and no patients withdrew. 18/44 
participants were assigned to cohort 1 and 26/44 to cohort 2. 26 male and 18 female 
patients participated in the trial with a mean of 72 years (range: 52-88 years). The mean 
BMI was 27.3 (range: 19.1-37.8) with a median ASA grade of 2. There were no significant 
differences in the baseline characteristics between the two cohorts (Table 3.1). 
 
 
In cohort 1, patients were treated with a dose of 20mg/kg of 5-ALA. The identification of 
at least 2 patients with LN positive disease, as observed through fluorescence at 
20mg/kg of 5-ALA, was not achieved. Subsequently, cohort 2 received a higher dosage 
(30mg/kg) of 5-ALA.  
 
41/44 (93.2%) patients underwent blue-light laparoscopy. From these, 40/41 (97.6%) 
patients also had subsequent histopathological examination of the specimen. One 
patient (1/41) who underwent blue-light laparoscopy was found to have irresectable 
Table 3.1. Patient Demographics 
Cohort 1 Cohort 2 
Number of participants (n) 18 26 
Sex (ratio of male : female) 10 : 8 16 : 10 
Age (years) 
[Mean (range)] 
69.3 (52 - 85) 71.8 (53 - 88) 
BMI (kg/m2) 
[Mean (range)] 
26.1 (21 - 35) 28 (19 - 38) 
ASA 
Grade 
I 9 5 
II 8 13 
III 1 8 
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disease at the time of surgery and no oncological specimen was taken for 
histopathological examination. 3/44 (6.8%) patients did not undergo blue-light 
laparoscopy as 2/3 patients were cancelled on the planned day of surgery and the 
fluorescent laparoscopic equipment was unavailable for 1/3 patients. 
 
3.2.2 Primary objective: Diagnostic accuracy of intraoperative 5-
ALA fluorescence 
Of the 41 patients who underwent blue-light laparoscopy, 13/41 (31.7%) had fluorescent 
primary tumours and 7/13 (53.8%) of these patients also had fluorescent LN (Table 3.2). 
In either cohort, fluorescent LNs were observed in addition to fluorescent primary 
tumours. No fluorescent LNs were observed in the absence of fluorescent tumours. 
 
3.2.2.1 Cohort 1 
In cohort 1, 17/18 (94.4%) patients received blue-light laparoscopy. One (1/18) operation 
was cancelled. All 18 patients received 20mg/kg of 5-ALA. 6/17 (35.3%) patients had a 
fluorescent primary tumour and 3/6 (50%) of these patients had additional fluorescent LN 






Of the 3 patients with both fluorescent primary tumour and LN in cohort 1, one (1/3) 
patient had confirmed metastatic disease in the LN as confirmed by standard 
histopathological examination. Therefore, 1/17 (5.88%) patient in cohort 1 who received 
Table 3.2. Fluorescence results in 
Cohort 1 
✓ x 
Received blue-light laparoscopy 17 1 
Fluorescent primary tumour observed 6 11 
Fluorescent primary tumour AND 
fluorescent LN observed 
3 3 
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5-ALA and blue-light laparoscopy had confirmed fluorescent LN positive disease. Cohort 
1 did not meet the success detection criteria of 5-ALA, which is defined as 
histopathology confirmed metastatic disease in fluorescence LN in at least 2 for every 10 
node positive patients (20%).  
 
Equations 3.1A and 3.1B were used to calculate the sensitivity and specificity rates of 5-
ALA mediated fluorescence respectively. 
𝑨. 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 (%) = (
𝑁𝑜. 𝑜𝑓 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑡 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐴𝑁𝐷 ℎ𝑖𝑠𝑡𝑜𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐿𝑁
𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 ℎ𝑖𝑠𝑡𝑜𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐿𝑁
) × 100 
𝑩. 𝑺𝒑𝒆𝒄𝒊𝒇𝒊𝒄𝒊𝒕𝒚 (%)
= (
𝑵𝒐. 𝒐𝒇 𝒇𝒍𝒖𝒐𝒓𝒆𝒔𝒄𝒆𝒏𝒕 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝑨𝑵𝑫 𝒉𝒊𝒔𝒕𝒐𝒑𝒂𝒕𝒉𝒐𝒍𝒐𝒈𝒚 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝑳𝑵
𝑻𝒐𝒕𝒂𝒍 𝒏𝒐. 𝒐𝒇 𝒉𝒊𝒔𝒕𝒐𝒑𝒂𝒕𝒉𝒐𝒍𝒐𝒈𝒚 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝑳𝑵
)
× 𝟏𝟎𝟎 
Equation 3.1.Determining 5-ALA mediated fluorescence sensitivity and 
specificity 
 
In cohort 1, 5-ALA mediated fluorescence demonstrated a sensitivity of 11.1% and 
specificity of 75% for determining the pathological outcome of LN assessment (Table 
3.3). 
 
Table 3.3. Comparison of 
fluorescence and 






POSITIVE 1 2 3 
NEGATIVE 8 6 14 
Total 9 8 17 
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As shown in Table 3.3, 9 patients in cohort 1 were identified with disease in the LNs, 
instead of the required 10, as per the trial protocol outlined in 2.1.1. This is due to the 
accuracy of 5-ALA mediated fluorescence being determined by LN status on the basis of 
individual patients rather than the individual LN. Two patients in cohort 1 that were 
observed with fluorescent positive LNs were found to have benign disease (histology 
negative) upon standard histopathological examination of the fluorescent LN (Table 3.3) 
(false positive). Of these two patients, the first patient had no malignant LNs in their 
specimen including the fluorescent LN i.e. all LNs were found to be benign. The second 
patient was found to have six histopathology confirmed positive LNs in non-fluorescent 
LNs (false negative), out of a total of 23 LNs examined within the pathological specimen. 
However, the fluorescent LN did not contain any metastatic disease upon standard 
histopathological examination. This patient could therefore be placed in either the 
fluorescence positive & histopathology negative group (false positive), OR fluorescence 
negative & histopathology positive group (false negative). As the primary outcome of this 
study was to determine the accuracy of fluorescence in predicting LN involvement this 
patient was placed in the former (fluorescence positive & histopathology negative) group 
for data analysis. Therefore, the total number of patients in cohort 1 with histopathology 
positive LNs is calculated to show 9, instead of 10. 
 
Summary of findings from cohort 1: 
1. 18 patients were treated with a dose of 20mg/kg 5-ALA 
2. 17/18 received blue-light laparoscopy 
3. 6/17 (35.3%) patients showed fluorescence within the tumour 
4. 9/17 (52.9%) patients were found to be histopathology confirmed LN positive 
5. 1/9 (11.1%) of these patients had correctly identified node positive disease via 
fluorescence 
6. Cohort 1 did not meet the pre-defined criteria for acceptable 5-ALA sensitivity 
(actual: 1/9, 11.1% vs pre-defined: 2/10, 20%). 
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7. The sensitivity for the detection of involved LNs was inadequate and, therefore, 
as per the study protocol cohort 2 received the increased dose of 30mg/kg 5-
ALA.  
 
3.2.2.2 Cohort 2 
In cohort 2, 24/26 (92.3%) patients underwent blue-light laparoscopy. Two (2/26) 
patients did not undergo blue-light laparoscopy. All 26 patients received 30mg/kg of 5-
ALA. One (1/24) patient who underwent blue-light laparoscopy was found to have 
irresectable disease.  Excluding this one patient, 23/24 patients who underwent surgery 
had histopathological examination of their specimens. As summarised in Table 3.4, of 
the patients who underwent blue-light laparoscopy surgery 7/24 (29.2%) patients had a 
primary fluorescent tumour and 4/7 also had fluorescent LNs. 
 
None of the patients with fluorescent LNs were found to contain metastatic disease upon 
standard histopathological examination (Table 3.5). In cohort 2, 5-ALA mediated 
fluorescence demonstrated a sensitivity of 0% and specificity of 75% for determining the 





Table 3.4. Fluorescence results in Cohort 2  
✓ x 
Received blue-light laparoscopy 24 2 
Fluorescent primary tumour observed 7 17 




Table 3.5. Comparison of 
fluorescence and 






POSITIVE 0 4 4 
NEGATIVE 7 12 19 
Total 7 16 23 
 
In cohort 2, 9 patients had histopathology confirmed metastatic LN disease. 4 patients 
had fluorescent positive LNs but none of the fluorescing LNs were found to contain 
metastatic disease (false positive). 2/4 had no histopathology confirmed evidence of 
metastatic disease in any LNs. The other 2/4 patients had metastatic disease found in 
non-fluorescent LNs and the fluorescent LN were found to contain benign disease upon 
histopathological examination. This is similar to the observations seen in cohort 1. 
Therefore, the latter two patients were placed in the fluorescence positive & 
histopathology negative group for of data analysis. Hence the total number of patients 
with histopathology positive LNs in cohort 2 is calculated to show 7, instead of 9. 
 
Summary of findings from cohort 2: 
1. 26 patients were treated with a dose of 30mg/kg of 5-ALA 
2. 24/26 received blue-light laparoscopy 
3. 7/24 (29.2%) patients showed fluorescence within the tumour 
4. 7/26 (26.9) patients were found to be histopathology confirmed LN positive 
5. 0/4 (0%) patients had correctly identified node positive disease via fluorescence 
6. Cohort 2 did not meet the pre-defined criteria for acceptable 5-ALA sensitivity 
(actual: 0/4, 0% vs pre-defined: 2/10, 20%). 
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3.2.3 Secondary objectives: Preoperative CT imaging 
Surgical resection with blue-light laparoscopy was performed in 41/44 patients. Pre-
operative CT imaging and pathology staging was compared in these patients. Pre-
operative CT imaging was in concordance with histopathological findings in reporting 
non-involved (N0) and involved (N1/2) LN in 23/41 (56.1%) patients. Pre-operative CT 
reported over-staged and under-staged LN status in 11/41 (26.8%) and 7/41 (17.1%) 
patients respectively (Table 3.6). 
 
Table 3.6. Preoperative CT 
prediction of LN stage 
compared with 
histopathology 
LN staging in histopathology 
Total 
N1/2 N0 
LN staging in CT 
N1/2 13 11 24 
N0 7 10 17 
Total 20 21 41 
 
Equations 3.2A and 3.2B were used to calculate the sensitivity and specificity rates in 
preoperatively predicting LN stage using CT imaging. 
𝑨. 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 (%) = (
𝑁𝑜. 𝑜𝑓 𝐶𝑇 𝑁1/2 𝐴𝑁𝐷 ℎ𝑖𝑠𝑡𝑜𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 𝑁1/2
𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 ℎ𝑖𝑠𝑡𝑜𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 𝑁1/2
) × 100 
𝑩. 𝑺𝒑𝒆𝒄𝒊𝒇𝒊𝒄𝒊𝒕𝒚 (%) = (
𝑵𝒐. 𝒐𝒇 𝑪𝑻 𝑵𝟎 𝑨𝑵𝑫 𝒉𝒊𝒔𝒕𝒐𝒑𝒂𝒕𝒉𝒐𝒍𝒐𝒈𝒚 𝑵𝟎
𝑻𝒐𝒕𝒂𝒍 𝒏𝒐. 𝒐𝒇 𝒉𝒊𝒔𝒕𝒐𝒑𝒂𝒕𝒉𝒐𝒍𝒐𝒈𝒚 𝑵𝟎
) × 𝟏𝟎𝟎 
Equation 3.2. Determining preoperative CT imaging sensitivity and 
specificity for LN staging 
 
The sensitivity and specificity of preoperative CT imaging, to predict LN staging were 
65% and 47.6% respectively.  
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Pre-operative CT imaging, as confirmed by histopathology examination, was also 
conducted to detect for the presence of extramural vascular invasion (EMVI). EMVI is 
defined as the invasion of tumour cells into the veins beyond the muscularis 
propria(236). In colon cancer patients, EMVI is an indicator of poor prognosis and the 
presence of EMVI positively correlates with potential recurrence of disease(237). In this 
study EMVI was detected in 14/41 (34.1%) patients using histopathology. 27/41 (65.9%) 
patients were accurately identified as EMVI positive or negative on preoperative CT scan 
(Table 3.7).  
 
Table 3.7. Preoperative CT 
prediction of EMVI 
compared with 
histopathology  





EMVI in CT 
POSITIVE 14 5 19 
NEGATIVE 9 13 22 
Total 23 18 41 
 
Equations 3.3A and 3.3B were used to calculate the sensitivity and specificity rates in 
preoperatively detecting EMVI using CT imaging. 
𝑨. 𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 (%) = (
𝑁𝑜. 𝑜𝑓 𝐶𝑇 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐸𝑀𝑉𝐼 𝐴𝑁𝐷 ℎ𝑖𝑠𝑡𝑜𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐸𝑀𝑉𝐼
𝑇𝑜𝑡𝑎𝑙 𝑛𝑜. 𝑜𝑓 ℎ𝑖𝑠𝑡𝑜𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑦 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐸𝑀𝑉𝐼
) × 100 
𝑩. 𝑺𝒑𝒆𝒄𝒊𝒇𝒊𝒄𝒊𝒕𝒚 (%)
= (
𝑵𝒐. 𝒐𝒇 𝑪𝑻 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝑬𝑴𝑽𝑰 𝑨𝑵𝑫 𝒉𝒊𝒔𝒕𝒐𝒑𝒂𝒕𝒉𝒐𝒍𝒐𝒈𝒚 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝑬𝑴𝑽𝑰
𝑻𝒐𝒕𝒂𝒍 𝒏𝒐. 𝒐𝒇 𝒉𝒊𝒔𝒕𝒐𝒑𝒂𝒕𝒉𝒐𝒍𝒐𝒈𝒚 𝒏𝒆𝒈𝒂𝒕𝒊𝒗𝒆 𝑬𝑴𝑽𝑰
)
× 𝟏𝟎𝟎 
Equation 3.3. Determining preoperative CT imaging sensitivity and 
specificity for detecting EMVI 
 
The sensitivity and specificity of preoperative CT detection for the presence of EMVI 
were 60.9% and 72.2% respectively. 
130 
For the purpose of this study, patients were selected for recruitment on the basis of 
having suspected locally advanced disease as defined by FOxTROT pre-operative CT 
imaging criteria (see 2.1.1). Pre-operative CT imaging accurately identified tumour 













 T0/1 T2 T3 T4 Total 
T2 1 0 0 1 2 
T3 0 6 16 9 31 
T4a 0 1 2 4 7 
T4b 0 0 0 1 1 
Total 1 7 18 15 41 
 
3.2.4 Secondary objectives: Histopathology 
Forty-one patients underwent blue-light laparoscopy. From these, only 1 patient was 
found to have unresectable cancer and a specimen for histopathological examination 
was not taken. 40 patients who underwent blue-light laparoscopy also had subsequent 
histopathological examination of the resected specimen. Quality of the resected 
specimens were judged on the plane of resection. In total, 26/40 (65%) specimens were 
resected in the mesocolic plane with a larger proportion of mesocolic resections 




Table 3.9. Comparison of resection 
procedures between cohorts 
Cohort 1 (n=17) Cohort 2 (n=24) 
Resection plane 
Mesocolic 8 18 
Intramesocolic 8 5 
Muscularis propria 1 0 
Missing data 0 1 
 
3.2.5 Complications relating to surgery and 5-ALA 
administration 
Known risks of 5-ALA administration in humans include photosensitivity reactions, 
derangement of liver function tests, nausea, vomiting, tachycardia and hypotension. In 
addition to these specific risks relating to 5-ALA administration, patients were also 
counselled regarding the normal risks of major colorectal surgery and general 
anaesthesia (Table 3.10).  
 
Table 3.10. Major risks associated with major laparoscopic colorectal surgery 
• Venous thromboembolism 
• Bleeding 
• Infection including chest, wound, urine etc 
• Myocardial infarction or cerebral vascular accident 
• Conversion to open surgery 
• Injury to intra-abdominal structures such as intra-abdominal organs, major 
blood vessels, bowel, ureter, nerve etc 
• Anastomotic leak 
• Death 
• Formation of stoma 
• Ileus 
 
There were no serious adverse events related to 5-ALA in the trial however, minor side 
effects were observed in eight patients. Two patients experienced mild self-limiting 
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photosensitivity reactions beginning within 48 hours of surgery and resolving by the fifth 
postoperative day. This was thought to be related to their planned postoperative 
admission to a high dependency unit which has brighter ambient lighting than the 
general surgical ward. No intervention was required other than topical skin emollient 
cream. Mild derangement of liver function was noted in four patients within the 
immediate postoperative period and all four cases resolved within 3 days. The final two 
patients were both noted to have slight derangement of their renal function however, this 
could have been related to other factors such as their surgery and cannot be definitely 
attributed to receiving 5-ALA. Both patients renal function returned to normal without any 
intervention.  
 
Risks of major colorectal surgery are highlighted in Table 3.10. The anastomotic leak 
rate and conversion rate from laparoscopic to open surgery within the trial was 4.5% and 
14.2% respectively. One incidence of organ perforation (stomach) occurred within the 
trial with two incidences of major intra-abdominal haemorrhages (inferior vena cava and 
a peripancreatic vessel), one of which required conversion to open surgery. These 
figures should be considered in context of the patient selection process where patients 
with advanced disease were recruited for the trial and are therefore likely to be at a 
higher risk of a more difficult procedure increasing the risk of complications such as leak 
and conversion. Two patients were managed for postoperative ileus. Three patients 
were readmitted to hospital within 30 days of their discharge home; one for a chest 
infection, one for an acute kidney injury and one for a post-operative ileus. None of these 
complications requiring readmission were felt to be related to 5-ALA administration. 
 
There was a single death within 30 days of surgery in the GLiSten trial which was 
reviewed by the Data Monitoring and Ethics Committee (DMEC) and Trial Steering 
Committee (TSC), both of whom felt that 5-ALA was not implicated in the cause of death. 
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This individual was a high-risk surgical candidate with multiple co-morbidities and 
suffered an anastomotic leak with subsequent myocardial infarction and multi-organ 
failure, from which he succumbed. 
 
3.2.6 Gene expression analysis 
In addition to resecting tumour specimens for histopathology, normal and malignant 
colonic mucosa was also taken from resected specimens for further analysis and 
preserved as described in 2.1.2.1.  
 
Tumour samples were processed and cryoscrolls produced and stained for further 
analysis as described in 2.1.2.2 and 2.1.2.3. This was done to identify tumours with high 
yields of malignant cells making them suitable for gene microarray analysis. 12 patient 
samples were selected; 6 from cohort 1 and 6 from cohort 2. Patient demographics were 
kept as close as possible between both fluorescent and non-fluorescent groups (Table 
3.11). 6 fluorescent and 6 non-fluorescent tumours were selected and were equally 
distributed between both cohorts. The proportion of malignant cells in each tumour 










Table 3.11. Patient demographics of 






Number of samples (n) 6 6 
Sex (ratio of male : female) 5:1 3:3 
Age (years) 
[Mean (range)] 
65 (53-77) 76.8 (68-83) 
BMI (kg/m2) 
[Mean (range)] 
26.35 (22-35) 26.75 (24.7-28) 
ASA Grade 
I 2 1 
II 2 4 
III 2 1 
Tumour Site (Right : Left colon) 4:2 5:1 
Tumour 
differentiation 
Well/Moderate 6 4 
Poor 0 1 
Mucinous 0 1 
T stage 
3 5 4 
4 1 2 
M stage 
0 1 1 
X 5 4 
Yield of malignant cells (%) 
[Mean (range)] 
76.7 (60-85) 76.7 (60-90) 
 
Prior to extracting RNA from specimens, the optimal RNA extraction technique was 
determined. Cryoscrolls were taken from a single randomly selected benign tissue 
specimen and three different RNA extraction protocols were compared and evaluated as 
described in 2.1.2.4. The protocol that produced the best quality RNA was used to 
extract RNA from the 12 selected patient samples.  
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3.2.6.1 Comparison of RNA extraction techniques 
The RNA integrity number (RIN) is an algorithm-based method for determining the 
degree of degradation of RNA extracted from samples and has been identified as the 
preferred method of assessing RNA quality(238). Samples are assigned a number from 
1 to 10 (1 =  Most degraded and 10 = Least degraded). The RIN and concentration of 
RNA were used to compare the outcomes of the three protocols (Figure 3.1). 
 
 
Figure 3.1. Comparison of the quality of RNA extraction from GLiSten trial 
specimens. A) The concentrations of RNA extracted from the tissue using the 
three different protocols. B) The RIN values of RNA extracted using the three 
different protocols. Data represents means with standard deviation of 3 
independent experiments. See 2.1.2.4 in Materials and Methods for detailed 
protocols. Protocol 3 gave the highest RNA concentration whereas Protocol 2 
produced the highest RIN value. 
 
Using the three different RNA extraction protocols, Protocol 3 (see 2.1.2.4.4 in Materials 
and Methods for the detailed protocol) using the Qiagen RNeasy Mini Kit gave the 
highest concentration of RNA (Protocol 3: 82.37ng/l vs. Protocol 2: 15.22ng/l, p < 
0.0001) (Figure 3.1A). Protocol 2 was found to have the highest RIN value but the 
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difference in comparison to Protocol 3 was not significant (Protocol 3: 6.5 vs. Protocol 2: 
6.9, p = 0.22) (Figure 3.1B). 
 
3.2.6.2 Gene expression analysis report 
Gene expression analysis was performed to identify differentially expressed genes 
between fluorescent and non-fluorescent tumours after the administration of 5-ALA. 
Extracted RNA samples using the protocol described in 2.1.2.4.4 were processed and 
hybridised to the Affymetrix Human Transcriptome Array (HTA) 2.0. All 12 samples 
passed quality control measures and were used for analysis. 
 
Data from gene micro-array was assessed to identify any associations between 
biological and technical factors. Exploratory analysis using principal component analysis 
(PCA) and hierarchical clustering showed a partial difference based on gender however, 
no clear difference in gene expression between the fluorescent and non-fluorescent 
tumours was found (Figure 3.2). Due to the potential confounding effect based on 
gender, any probes located on the sex chromosomes were then removed from statistical 
analysis. A single-factor comparison was then performed to identify any significant 
differences in expression levels between fluorescent and non-fluorescent tumours.  
 
Figure 3.2 shows that the RIN value (technical factor) had the strongest effect on the 
gene expression data and this would have no influence on the observed fluorescence or 
non-fluorescence of the tumour sample. Figure 3.2 also shows that gender, tumour 
differentiation, the T and M stage of the tumour were all associated with either the 
second or third principal component indicating these biological factors may have some 
influence on the data variance. However, given the small sample size (Table 3.11) any 




Figure 3.2. Heatmap showing the strength of association between technical and 
clinical factors within the study samples. Taken from Tendeng et al.(239). 
Biological and technical factors within the experimental design were tested using a 
single-factor comparison to identify any significant differences between fluorescent 
and non-fluorescent tumours. Entries were considered significant at p<0.05. RIN 
value (PC1), gender (PC2), tumour differentiation (PC3), T-stage (PC3) and M-
stage (PC2) were found to be have statistically significant different levels of 
expression between fluorescent and non-fluorescent tumours. 
 
Using single-factor comparison with the recommended statistical threshold of p<0.05, no 
significant markers were identified. Relaxing the threshold to p<0.01 with fold-change cut 
off 1.3 to enable pathway analysis identified 217 differentially expressed genes 
comparing fluorescent verses non-fluorescent tumour samples. However, relaxation of 
the threshold increases the rates at which false-positives are highlighted. Therefore the 
217 genes identified should be validated using independent experimental techniques. 
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Pathway analysis using the relaxed threshold criteria, identified the upregulation of 
genes in the fluorescent group, that were primarily associated with the immune response 
system (Figure 3.3) and in particular olfactory transduction. Down-regulated genes that 
were identified, were mainly involved in cellular metabolic processes eg. Glycerolipid, 
lipoprotein or amino acid metabolism (Figure 3.3).  
 
 
Figure 3.3. KEGG Enrichment Analysis of A) upregulated and B) downregulated 
enriched KEGG pathways. Taken from Tendeng et al.(239). Only KEGG 
pathways with an enrichment p<0.05 are included in this figure. Up- and 
downregulated enrichments are shown separately as different components of a 
given KEGG pathway could be up- and downregulated within a single comparison. 
Colour (red for upregulated and blue for downregulated) is assigned based on the 
enrichment p-value, with white implying less significant enrichment. Genes 
associated with olfactory transduction were upregulated and those associated with 











−log10(p) of enrichment −log10(p) of enrichment 
0.0 0.0 0.50.5 1.0 1.0 1.51.5 2.0 2.0 2.52.5 3.0 3.0 3.5
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3.3 Discussion 
The GLiSten study is the first human clinical trial of intraoperative 5-ALA mediated 
fluorescence-guided surgery in colon cancer. A total of 44 patients were recruited, 41 
patients had intra-operative blue-light laparoscopy and of these, 13 primary tumours 
(31.7%) showed intraoperative fluorescence. 6 fluorescing tumours in cohort 1 (35.3%) 
and 7 fluorescing tumours in cohort 2 (29.2%) (Table 3.3). Seven out of 19 patients with 
LN positive disease exhibited LN fluorescence, 3 in cohort 1 (17.6%) and 4 in cohort 2 
(16.7%). All patients with fluorescent LN also had fluorescent tumours. Only one patient 
with fluorescent positive LN was found to have LN metastases. Neither dose of 5-ALA 
(20mg/kg and 30mg/kg) demonstrated adequate accuracy and sensitivity to support 
further investigation for the use of 5-ALA as an intraoperative fluorescent probe for LN 
staging in colorectal cancer surgery. Therefore, the trial did not proceed to a subsequent 
evaluation phase. Following surgery, patients received standard post-operative care and 
continued to receive routine follow-up and surveillance as per NICE guidelines(240).  
 
Similar to the GLiSten study, Kondo et al.(241) attempted to evaluate the use of 5-ALA 
mediated fluorescent diagnosis of peritoneal metastases in colon cancer patients. In this 
study, 12 patients were recruited on the basis of suspected peritoneal disease upon CT 
examination. 8/12 (66.7%) patients showed accurate fluorescence in the peritoneum 
confirming metastatic disease. This study did not comment on fluorescence of the 
primary tumour, LNs or any non-peritoneal metastatic deposits. Therefore, a direct 
comparison with the findings from our study is not possible. Nakamura et al.(106) 
evaluated 5-ALA mediated fluorescence in guiding endoscopic resections of early stage 
gastric and colorectal tumours. Of the 3 patients in this study with colorectal cancerous 
lesions only one showed fluorescence (33.3%). It is not possible to draw a strong 
conclusion between the GLiSten study and this study given that the latter only recruited 
three patients with colorectal tumours. To date, there are no additional studies that can 
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be compared to the GLiSten study evaluating the use of 5-ALA mediated fluorescence 
diagnosis in patients with colonic cancer. 
 
Aside from colorectal cancers, 5-ALA mediated fluorescence has been evaluated for the 
detection of other cancers. A study by Rink et al. assessing the use of 5-ALA in non-
muscle invasive bladder cancer surgery found that the sensitivity of tumour detection 
ranged between 76-97% with a specificity of 56%(96). It was suggested that 5-ALA 
fluorescence diagnosis might reduce the risk of residual disease. As detailed in chapter 
1, neurosurgeons use exogenous 5-ALA to improve tumour detection and clearance of 
resection margins in brain tumours. A Cochrane review by Barone et al.(235) reviewing 
the use of visual assistance and guidance during neurosurgery for brain tumours found 
that the evidence supporting the use of 5-ALA fluorescence assisted neurosurgery is 
possibly not as strong as previously expected. However, there was a significant 
improvement in complete tumour resection rates when using 5-ALA mediated 
fluorescence (65%) as compared to standard resection procedures (36%).  
 
In comparison to other malignancies, such as urological and neurological cancers, 5-
ALA appears to be less sensitive for the fluorescent detection of colorectal tumours. 
Although the timing and doses of 5-ALA administration in the GLiSten study were similar 
to other published studies with similar patient characteristics, different factors could have 
potentially influenced the findings. This includes i) autofluorescence of the surrounding 
tissue (false positive)(108,241,242), ii) quenching(108) and iii) photobleaching of the 
tumour by white light laparoscopy performed at the beginning of the procedure, reducing 
the intensity of fluorescence over time(96).  
 
Of the 41 patients that underwent blue-light laparoscopic resection, 19 patients had LN 
disease and 7/19 (36.8%) of these patients exhibited intra-operative 5-ALA/PPIX 
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fluorescence of the LN. Only one fluorescent LN was found to contain metastatic 
disease, suggesting non-specific fluorescence in the other fluorescent LNs. Clinical 
studies evaluating 5-ALA mediated fluorescent diagnosis in other malignancies have not 
focused on the detection of LN metastases, and currently the only studies for 
comparison are pre-clinical in vivo studies using animal models. 
 
Kato et al. conducted a study using murine models of colorectal cancer(11) that were 
administered intraperitoneal 5-ALA. Of the 10 mice that were treated, 3/10 (30%) mice 
exhibited fluorescent LN and all fluorescent LN contained metastatic disease as 
confirmed by histopathological examination. Histopathological examination of mice 
without fluorescent LN was not performed and sensitivity and specificity values were not 
obtained. A study by Harada et al. investigated 5-ALA mediated fluorescence in 
detecting LN metastases in freshly excised colonic tumour resections from 14 
patients(108). The study used a spectral unmixing method to reduce the 
autofluorescence from collagen masking true PPIX fluorescence. 12/14 patients had 
stage III disease and 9/14 patients were found to have LN positive disease. No 
fluorescent benign LNs were observed in this study and the sensitivity and specificity for 
detecting LN metastatic disease were 88.3% and 92% respectively, which is comparably 
higher than sensitivity and specificity rates from the GLiSten study. However, in this 
study 5-ALA fluorescence was examined ex-vivo and further details of LN fluorescence, 
including any non-fluorescent LNs containing metastatic disease, was not reported. In 
addition, the only reported patient demographic was the age range, not permitting the 
direct comparison of baseline characteristics with the GLiSten study. 
 
The GLiSten study found that although 5-ALA can be administered without serious 
adverse effects, it is not sensitive enough to detect LN metastasis and is not to be 
recommended for intra-operative fluorescence mediated staging of colonic cancers. The 
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results from this study suggest that 5-ALA mediated fluorescence in colonic cancers is 
not as effective as previously expected. To date, this is the only study that has clinically 
examined 5-ALA for intra-operative fluorescent diagnosis of colonic LN metastases. 
Another outcome of this study is that the application of intraoperative fluorescence in 
clinical practice is feasible and a viable strategy for intraoperative LN staging. For future 
applications, a fluorescent probe and/or photosensitising agent with high sensitivity and 
specificity for colorectal cancers would be highly beneficial.  
In this study, the sensitivity and specificity for detecting colorectal metastatic LN using 
pre-operative CT imaging were 65% and 47.6%, respectively(Table 3.6). This is 
comparable to the sensitivity (64-70%) and specificity (53-78%) for detecting colorectal 
metastatic LN using pre-operative CT imaging as reported in other studies(33,34). Based 
upon the findings from this study, 5-ALA fluorescence diagnosis did not demonstrate an 
improved ability to detect LN metastases as compared to pre-operative CT imaging. 
 
A clinical study by Dighe et al. evaluated the accuracy of CT imaging in stratifying 
patients into different prognostic groups(33). The presence of EMVI was examined as a 
potential prognostic marker. The sensitivity and specificity were 61% and 79% 
respectively. These results are similar to the sensitivity and specificity for EMVI detection 
on pre-operative CT imaging in the GLiSten study, which were 60.9% and 72.2% (Table 
3.7) respectively. The authors of the study argue that preoperative CT imaging is 
ineffective for detecting EMVI due to the poor sensitivity. This is potentially due to the 
subjective evaluations of pathologists creating discrepancies between CT imaging and 
pathological examinations. EMVI is still being reviewed as a clinical marker of prognosis 
in colon cancer patients and will benefit from simultaneous improvements in both the 
standards of CT imaging and pathological examination. 
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In the GLiSten study, 5-ALA fluorescence was observed in ~30% of the primary tumours 
which may be indicative of differences in the pharmacokinetics (uptake and clearance), 
metabolism of 5-ALA, and production of PPIX by different tumours(243–245). Given the 
low rates of tumour fluorescence observed, the tumour biology was investigated in an 
attempt to further explain the findings. Gene microarray analysis was performed to 
identify any differences at a gene expression between different colonic tumours, which 
might explain the differences that were observed in fluorescence of the primary tumour. 
From the 3 methods that were evaluated to extract RNA, Protocol 3 (Qiagen RNeasy 
Mini Kit ) produced the highest concentration of RNA per sample (Figure 3.1A). It also 
had the second highest RIN value of 6.5 (Figure 3.1B) which shows moderate 
degradation of the RNA within the sample(238). This was, therefore, the protocol 
selected to extract RNA from the tumour samples that were selected for gene expression 
analysis.  
 
Principal component analysis simplifies complex data whilst retaining patterns within the 
data set without knowledge of the different groups being compared(246). It transforms 
the data into fewer dimensions and projects onto lower dimensions called principal 
components to find the best summary of the data. In essence it is a data analysis tool 
that identifies the main axes of variance in a data set as well as understanding the key 
variables and spotting outliers. There are limitations with this data analysis tool however, 
the data must be linear, highly correlated patterns may not be identified as the principal 
components are uncorrelated and may miss clusters(246). On statistical analysis using 
single-factor comparison with the recommended threshold of p<0.05, no significant 




In summary, the GLiSten study was unable to support the use of 5-ALA/PPIX mediated 
fluorescence for intraoperative LN staging during colon cancer surgery. This study did 
show that 5-ALA fluorescence-guided surgery is an acceptable intervention to improve 
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4 Cancer targeting agents 
4.1 Introduction 
Monoclonal antibodies are one of the most commonly used recognition molecules used 
to actively target cancers(119). This is due to their high binding affinity and specificity for 
target antigens. The cell membrane marker, CEA, is commonly overexpressed in 
colorectal cancer cells(143,146,149) and, therefore, for this research project an anti-CEA 
antibody was chosen as the targeting agent. The recombinant chimeric IgG murine 
monoclonal anti-CEA antibody, A5B7, as described in 2.2.2, was used. A similar 
chimeric murine monoclonal antibody, CD31, was chosen as the control antibody. CD31 
is a single chain transmembrane protein that is expressed on endothelial cells(232).  
 
Affimers are short single-stranded RNA or DNA oligonucleotides that have been 
developed and are of interest as an alternative to monoclonal antibodies as active 
targeting agents(144,161,172,174). Given the overexpression of CEA in colorectal 
cancer cells an anti-CEA affimer was chosen for comparison as a targeting agent 
against the anti-CEA antibody. The anti-CEA affimer described in 2.2.3 was used for 
experiments described in this chapter.  
 
The three cell lines chosen for this project were LoVo, EA.hy926 and HEK293. LoVo 
cells are derived from a human metastatic colonic adenocarcinoma and are known to 
have high expression levels of CEA(247) on their cell surface membrane with negligible 
expression of CD31. The EA.hy926 cell line originates from primary human umbilical 
vein cells and is an endothelial cell line. EA.hy926 cells have high expression levels of 
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CD31(248) with a low expression levels of CEA. HEK293 is an epithelial cell line derived 
from human embryonic renal tissue and does not express either CEA or CD31(249). 
 
4.2 Results 
4.2.1 Antibody testing on fixed cells 
The three cell lines were cultured as described in 2.2.1.1 - 2.2.1.2 and prepared for 
immunofluorescence as described in 2.2.1.3. 
 
4.2.1.1 Testing target and control antibodies on fixed cells 
To demonstrate anti-CEA and anti-CD31 targeting on LoVo, EA.hy926 and HEK293 
cells, immunofluorescence was performed as described in 2.2.1.4. As shown in Figure 
4.1, green fluorescence was observed when LoVo cells were incubated with the anti-
CEA antibody and no fluorescence was observed when incubated with the anti-CD31 
antibody, suggesting that the LoVo cell line was an appropriate choice for the target cell 
line. For EA.hy926 cells, green fluorescence was only observed when incubated with the 
anti-CD31 antibody, suggesting that this cell line is an appropriate cell line to 
demonstrate that the anti-CD31 is correctly binding and as a control for the anti-CEA 
antibody. No green fluorescence was observed in HEK293 cells incubated with either 
antibody indicating that HEK293 cells are an appropriate control cell line for both the 





Figure 4.1. Binding of target and control antibodies on target and control cell lines 
using immunofluorescence on fixed cells. Blue fluorescence is DAPI. Green 
fluorescence is Alexa Fluor 488 using FITC filter.  Magnification x63. Scalebar = 
10 m. 0.5% skimmed milk blocking served as the control. Images in this figure are 
representative of at least 3 independent experiments. See 2.2.1.4 of Materials and 
Methods for the detailed protocol. The target anti-CEA antibody binds selectively to 
the LoVo cell line and the control anti-CD31 antibody binds selectively to the 
EA.hy926 cell line. Neither the target nor the control antibody bind selectively to 
the HEK293 cell line. 
 
4.2.1.2 Testing oxidised antibodies on fixed cells 
Antibodies underwent an oxidative process to enable conjugation to the MNP as 
described in 2.2.2.5. To investigate whether oxidising the anti-CEA and anti-CD31 
antibodies changed their affinities and specificities for their target cell surface markers, 
the oxidised antibodies were prepared and tested as described in 2.2.1.4. Green 
fluorescence was only observed when EA.hy926 and LoVo cell lines were incubated with 
the oxidised anti-CD31 and anti-CEA antibodies respectively. No fluorescence was 
detected in HEK293 cells incubated with either oxidised antibodies (Figure 4.2). This 
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suggests that the oxidation process did not influence the binding of either antibodies to 
their respective cell surface markers.  
 
Figure 4.2. Binding of oxidised target and control antibodies on target and control 
cell lines using immunofluorescence on fixed cells. Blue fluorescence is DAPI. 
Green fluorescence is Alexa Fluor 488 using FITC filter.  Magnification x63. 
Scalebar = 10 m. 0.5% skimmed milk blocking served as the control. Images in 
this figure are representative of at least 3 independent experiments. See 2.2.1.4 of 
Materials and Methods for the detailed protocol. The oxidised target anti-CEA 
antibody binds selectively to the LoVo cell line and the oxidised control anti-CD31 
antibody binds selectively to the EA.hy926 cell line. Neither the  oxidised target nor 
the oxidised control antibody bind selectively to the HEK293 cell line. 
 
4.2.1.3 Testing biotinylated antibodies on fixed cells 
Biotinylation of both antibodies was performed as described in 2.2.2.6. This was 
performed to identify this technique as a potential alternative conjugation route for 
binding the antibodies to the MNP. To investigate whether biotinylation had an impact on 
antibody binding, biotinylated antibodies were prepared and tested as described in 
2.2.1.4. Green fluorescence was only observed when EA.hy926 and LoVo cell lines were 
incubated with the biotinylated anti-CD31 and anti-CEA antibodies respectively. No 
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fluorescence was detected in HEK293 cells incubated with either biotinylated antibodies 
(Figure 4.3). This suggests that the biotinylation process did not influence the binding of 
either antibodies to their respective cell surface markers. 
 
 
Figure 4.3. Binding of biotinylated anti-CEA and anti-CD31 antibodies on target 
and control cell lines using immunofluorescence on fixed cells. Blue 
fluorescence is DAPI. Green fluorescence is Alexa Fluor 488 using FITC filter.  
Magnification x63. Scalebar = 10 m. 0.5% skimmed milk blocking served as the 
control. Images in this figure are representative of at least 3 independent 
experiments. See 2.2.1.4 and 2.2.2.6 in Materials and Methods for the detailed 
protocols. The biotinylated target anti-CEA antibody binds selectively to the LoVo 
cell line and the biotinylated control anti-CD31 antibody binds selectively to the 
EA.hy926 cell line. Neither the biotinylated target nor the biotinylated control 
antibody bind selectively to the HEK293 cell line. 
 
4.2.2 Gel electrophoresis of reduced antibody 
To create the antibody-NP conjugate, a half-antibody fragment was created by cleaving 
the di-sulphide bonds between the two heavy chains of the antibody in order to control 
its orientation in the conjugate. The half-antibody fragment would then be conjugated to 
the MNP via cysteine-maleimide conjugation chemistry. It was therefore important to 
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determine the most appropriate reducing agent as well as confirming the presence of a 
half-antibody fragment with an available cysteine group following reduction of the anti-
CEA antibody. Three reducing agents (TCEP, 2-ME and 2-MEA) were investigated using 
the protocol described in 2.2.2.1 and gel electrophoresis was performed on the reduced 
target antibody as described in 2.2.2.2 to identify the presence of half-antibody 
fragments following reduction. The molecular weight of the half-antibody fragment should 
be ~75kDa. As shown in Figure 4.4, no band was seen at 75kDa following TCEP 
reduction (Lane 2). Following 2-ME and 2-MEA mediated reduction of the anti-CEA 
antibody, bands were observed at 75kDa (Lanes 3 and 4).  
 
 
Figure 4.4. Developed gel electrophoresis membrane depicting weights of 
antibody fragments following reduction with different reduction agents. Lane 
1 – Molecular weight Markers (kDa), Lane 2 - TCEP, Lane 3 - 2-ME, Lane 4 - 2-
MEA. Images in this figure are representative of at least 3 independent 
experiments. See 2.2.2.1 and 2.2.2.2 of Materials and Methods for the detailed 
protocols. None of the three reducing agents produced a band at the 75kDa 
molecular weight indicating that low volumes of half-antibody fragments were 
produced with each reducing agent. 
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Densitometry analysis was performed on gels to estimate the percentage volume of the 
reduced antibody fragments in the total volume of antibody and summarised in Table 1. 
Densitometry analysis of the reduced antibody fragments revealed that reduction with 
TCEP produced negligible half-antibody fragments with no band detection around 
75kDa. Reduction with 2-ME and 2-MEA were found to produce half-antibody fragments 
(Figure 4.4 and Table 4.1). Densitometry analysis showed that the overall volume was 
around 5% for 2-ME (combination of peaks at 69 and 73 kDa representing half-antibody 
fragments) and around 3% for 2-MEA (peak at 66kDa). This shows that reduction of the 
anti-CEA antibody to produce half-antibody fragments using TCEP, 2-ME or 2-MEA is 
inefficient and alternative conjugation techniques would need to be explored.  
 
Table 4.1. Densitometry analysis of the resulting anti-CEA antibody fragments 
following reduction with TCEP, 2-ME and 2-MEA. Height represents the peak 
height above baseline for the signal and the raw volume is the area under the 





Height Raw volume Total volume % 
TCEP 
113 1524 3180391 2 
49 21684 99368232 56 
26 20919 74281152 42 
2-ME 
93 18822 64296488 54 
73 2532 2067259 2 
69 2313 3017554 3 
25 20749 50056264 42 
2-MEA 
88 14913 43676720 47 
66 1260 2614556 3 
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25 12041 38209272 41 
22 5644 8235290 9 
4.2.3 Testing for presence of glycoprotein on antibody 
The use of a linker between the antibody and the MNP was explored. 3-(2-
pyridyldithio)propionyl hydrazide (PDPH) is a heterobifunctional cross linker with 
sulfhydryl-reactive pyridyldithiol and carbonyl-reactive hydrazide groups. Many 
monoclonal antibodies contain glycoprotein side chains on their heavy chains. If this is 
present on the A5B7 anti-CEA antibodies then oxidising this glycoprotein on the antibody 
would allow for conjugation of PDPH via its hydrazide group. Dot blotting was performed 
to verify the presence of a glycoprotein side chain on the anti-CEA antibody as described 
in 2.2.2.3. Biotinylation of the oxidised anti-CEA antibody was successful confirming the 
presence of a glycoprotein chain that could be exploited as a site for conjugation to the 
MNP (Figure 4.5). 
 
 
Figure 4.5. Dot blot highlighting the biotinylation of oxidised anti-CEA antibody 
and non-oxidised anti-CEA antibody control. Images in this figure are 
representative of at least 3 independent experiments. See 2.2.2.3 of Materials and 
Methods for detailed protocol. Biotinylation of the oxidised anti-CEA antibody was 
successful whereas biotinylation did not occur with the non-oxidised anti-CEA 
antibody indicating that the antibody does possess a glycoprotein side chain. 
 
    Oxidised anti-CEA antibody        Non-oxidised anti-CEA antibody 
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4.2.3.1 Western blotting 
The configuration of an antibody, depicted Figure 1.13, shows the glycoprotein chain 
projecting out from the heavy chain. Western blotting of the biotinylated antibody was 
performed as per the protocol described in 2.2.2.4 to deduce the location of the 
glycoprotein chain. This was conducted in order to identify the orientation of the antibody 
after conjugation to the MNP. In agreement with Figure 4.5, Figure 4.6 shows that 
biotinylation of the untreated antibody was not detected (Lane 2). The largest band of 
reduced biotinylated antibody was detected around 35-40kDa (Figure 4.6. Lane 3). It is 
difficult to identify accurately which specific fragment of the anti-CEA antibody this band 




Figure 4.6. Western Blot showing biotinylation of oxidised and non-oxidised anti-
CEA antibody. Lane 1 - Molecular weight Markers (kDa), Lane 2 - Untreated 
antibody, Lane 3 - Treated antibody. Images in this figure are representative of at 
least 3 independent experiments. See 2.2.2.4 of Material and Methods for the 
detailed protocol. The largest band occurred at a molecular weight of 35-40kDa. 
 
4.2.4 Testing biotinylated affimers 
Following the unsuccessful characterisation of the anti-CEA antibody, an anti-CEA 
affimer was subsequently evaluated as a potential targeting agent. To assess the 
binding of the anti-CEA affimer, it was biotinylated as described in 2.2.3 and 
immunofluorescence was performed on LoVo, EA.hy926 and HEK293 cells. The affimer 
was designed with a free cysteine (sulfhydryl) group at the base enabling conjugation 
through cysteine-maleimide chemistry. In order to confirm that the anti-CEA affimer 
bound specifically to the target cell line only a biotin-maleimide dye was conjugated to 
the affimer resulting in biotinylation. The biotin was therefore available for binding to the 
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fluorescent protein, Streptavidin Dylight 488. As shown in Figure 4.7, noticeable green 
fluorescence was observed in anti-CEA affimer treated LoVo cells. 
 
 
Figure 4.7. Binding of biotinylated anti-CEA affimer on target and control cell lines 
compared to BSA control using immunofluorescence on fixed cells. Blue 
fluorescence is DAPI. Green fluorescence is Streptavidin Dylight 488 using FITC 
filter.  Magnification x63. Scalebar = 10 m. 0.1% bovine serum albumin blocking 
served as the control. Images in this figure are representative of at least 3 
independent experiments. See 2.2.3 of Materials and Methods for the detailed 
protocol. The target anti-CEA affimer binds selectively to the LoVo cell line. 
 
4.3 Discussion 
Antibodies are commonly used as recognition molecules and affimers are of increasing 
interest for targeting. For my research project, I had to identify a suitable anti-CEA 
targeting candidate that could be used to functionalise the MNP and improve the 
targeting of colorectal cancers in addition to identifying an appropriate control recognition 
molecule. The anti-CEA (target) and anti-CD31 (control) antibodies were initially 
evaluated in this project for their suitability.  
 
Immunofluorescence of both the target and control antibodies was performed on the 
three selected cell lines (Figure 4.1). The target antibody was found to selectively bind to 
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the target cell line, LoVo, which overexpresses the cell surface marker of interest (CEA). 
The control antibody was found to bind only to the control cell line, EA.hy926. Neither the 
target nor the control antibody was found to bind to the second control cell line, HEK293, 
which does not express either CEA or CD31. This demonstrated that the target and 
control cell lines, as well as the target and control antibodies, were suitable for further 
experiments.  
 
Due to the unique structure of antibodies a variety of functional groups are available that 
can be exploited for conjugation(233). For this research project, the different conjugation 
methods via functional groups were considered as potential mechanisms for antibody 
conjugation to the NP. For example, free amine and carboxyl groups are commonly 
found on the tertiary structures of antibodies(233). However, exploiting these groups for 
conjugation could result in random orientation of the antibody on the NP and potentially 
affect the antigen-binding ability of the antibody-NP conjugate(155,250,251). Balevicius 
et al.(252) investigated the differences in the antigen-binding abilities of an antibody-
based immunosensor. The antigen-binding abilities of fragmented antibodies was 
compared to whole non-fragmented intact antibodies. Whole intact antibodies were 
conjugated to the biosensors via covalent bonding of the free carboxyl groups and 
resulted in random orientation of the intact antibody once conjugated to the biosensors. 
Half-antibody fragments were formed through the reduction of whole intact antibodies 
using 2-ME as the reducing agent. Half-antibody fragments were conjugated to the 
biosensors using the free sulfhydryl groups (created through 2-ME mediated reduction) 
resulting in a more controlled orientation and conjugation of half-antibody fragments to 
the biosensors and without compromising the antigen-binding site. Half-antibody 
fragment-conjugated immunosensors were found to bind 2.5-fold higher to their 
respective antigens as compared to whole intact antibody-conjugated immunosensors. 
Findings from this study suggest that random orientation of antibodies could potentially 
compromise and decrease the antigen-binding abilities of the antibodies. Orientated 
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conjugation is where the chosen functional group to be used for conjugation is located at 
a specific site on the antibody and can preserve the ability of the antibody to bind 
specifically to its antigen(155,233,250,252,253). Dulay et al.(254) developed an 
antibody-based immunosensor for the diagnosis of the bacterial infectious disease, 
Tularemia. The authors compared whole intact antibodies against half-antibody 
fragments. Whole intact antibodies were conjugated using carboxyl groups resulting in 
random orientation of the antibodies and hindering the antigen-binding sites. Half-
antibody fragments were correctly orientated and conjugated through sulfhydryl groups. 
The half-antibody fragment-conjugated immunosensors were found to be more sensitive 
in antigen-binding as compared to whole intact antibody conjugates. The authors 
attributed this difference in binding sensitivities to better presentation of the antigen-
binding site enabling improved antigen binding.  
 
Two commonly used orientated conjugation strategies are i) selective cleaving of 
antibodies into half-antibody fragments using a reducing agent(155,233) and ii) the 
oxidation of glycoprotein side chains on the heavy chain of antibodies and using a 
crosslinker to form the desired conjugate(233). Biotinylation of antibodies is also a 
common strategy used for antibody conjugation(233) as it takes advantage of the strong 
binding chemistry between avidin and biotin. Due to the proven track record of the 
chemical reduction, oxidation and biotinylation processes for facilitating antibody 
conjugation they were chosen and investigated in this project. 
 
In order to conjugate the antibody to the NP, the antibody would initially undergo 
reduction or chemical modification. Monoclonal antibodies are susceptible to becoming 
inactivated through this process as the site of conjugation could potentially be located at 
the antigen binding site(155,233). Oxidation or biotinylation are methods of chemically 
modifying antibodies for conjugation and it was vital to identify whether these processes 
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altered the binding properties of both the target and control antibodies. Figure 4.2 and 
Figure 4.3 confirm that modifying the antibodies did not influence their antigen binding 
abilities. Modified target antibody only bound to LoVo cells and modified control antibody 
only bound to EA.hy926. After determining that oxidation and biotinylation did not affect 
the binding abilities of the antibodies these processes were investigated for forming 
antibody-NP conjugates. 
 
Initially, it was proposed that half-antibody fragments would be ideal candidates as 
recognition molecules for conjugation. Half-antibody fragments have free cysteine 
groups formed through the cleavage of disulfide covalent bonds in the hinge region by a 
reducing agent(155,233). The cysteine groups are then available to bind to maleimide 
functionalised NPs. Antibodies would need to undergo chemical reduction first in order to 
produce half-antibody fragments. The ideal reducing agent as well as the quantity of 
half-antibody produced from this process was therefore investigated. Firstly, the 
reduction of the anti-CEA antibody was carried out using TCEP, 2-ME and 2-MEA, to 
identify which of these reducing agents would produce half-antibody fragments. These 
reducing agents were chosen as they possess varying potencies in reduction. 2-MEA is 
the mildest reducing agent, 2-ME has moderate reducing abilities and TCEP is the 
strongest reducing agent(155). All three reducing agents have previously been used 
successfully to produce half-antibody fragments as identified in the literature. 
Dithiothreitol (DTT) is another strong and potent antibody reducing agent. However, DTT 
is known to possibly degrade structures and denature monoclonal antibodies(255).  
As highlighted in Figure 4.4, the ideal reducing agent for producing half-antibody 
fragments for MNP conjugation was not successfully identified. Although reduction with 
2-ME and 2-MEA did result in the production of half-antibody fragments, they constituted 
an inadequate fraction of the overall volume. Further optimisation of reducing conditions 
could potentially improve the production yield of half-antibody fragments. This was 
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suggested by Makaraviciute et al.(155), who, showed that optimisation of variables such 
as the type of reducing agent, concentration of reducing agent, pH, and also the type of 
antibody, can influence the production yields of half-antibody fragments.  
 
The low volumes of anti-CEA half-antibody fragments produced through chemical 
reductions using 2-ME and 2-MEA means that large quantities of the anti-CEA antibody 
would be needed in order to generate adequate amounts of half-antibody fragments for 
MNP conjugation. Given that the anti-CEA antibody is not commercially available and 
had been gifted to our research laboratory by Cancer Research UK Biotherapeutics 
Development Unit, the total volume of antibody available for experiments was 
substantially limited. In addition, the same quantity of the control antibody would have 
also been required which was not financially feasible. This meant that reducing 
antibodies to produce half-antibody fragments was impractical and therefore not pursued 
further. 
 
The use of a chemical linker between the glycoprotein side chain on the antibody and 
the MNP was then explored. A heterobifunctional crosslinker has different reactive 
groups at either end enabling conjugation to different functional groups(233). A carbonyl-
reactive and sulfhydryl-reactive crosslinker would be an ideal choice for conjugating the 
antibody to the MNP and is discussed in more detail in Chapter 6. IgG monoclonal 
antibodies are typically glycosylated meaning they possess a polysaccharide 
glycoprotein side chain which protrudes from the heavy chain. The glycoprotein side 
chain on the antibody could be oxidised(233) creating a reactive aldehyde group. The 
aldehyde group formed would then bind to the carbonyl-reactive end of 
heterobifunctional crosslinkers, with the maleimide functionalised NP binding to the other 
end. PDPH is a heterobifunctional crosslinker that has a carbonyl-reactive hydrazide 
group and a sulfhydryl-reactive pyridyldithiol group on either ends. The pyridyldithiol 
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group is displaced by maleimide in its presence, subsequently allowing functionalised 
MNPs to bind to the linker and creating an antibody-NP conjugate. Other carbonyl-
reactive and sulfhydryl-reactive crosslinkers which are commonly used include 4-(4-N-
maleimidophenyl)butyric acid hydrazide (MPBH) and 4-(N-
maleimidomethyl)cyclohexane-1-carboxyl-hydrazide (M2C2H). Both of these crosslinkers 
utilise a maleimide functional group at the sulfhydryl-reactive end, which would not be 
compatible and would be unable to conjugate to the maleimide functionalised NP. PDPH 
was therefore selected as it has previously been used to conjugate antibodies(256).  
 
The anti-CEA antibody used in this research project is not commercially available and 
the molecular structure of the antibody is unknown. Therefore, dot blotting was 
performed to confirm the presence of a glycoprotein side chain and western blotting to 
identify its location on the target antibody(Figure 4.6 and Figure 4.7). Dot blotting 
showed that the oxidised target antibody was biotinylated whereas the control non-
oxidised target antibody was not biotinylated. This indicates the presence of a 
glycoprotein side chain on the antibody as suggested by successful oxidation and 
subsequent biotinylation. Western blotting was performed to identify the presence of the 
glycoprotein side chain which would have been expected to be located on the heavy 
chain fragment (refer to Figure1.13), producing a biotinylated band at 50kDa. As shown 
in Figure 4.6, the largest band of reduced biotinylated anti-CEA antibody was found to be 
between 35-40kDa. This does not correlate to a specific antibody fragment (refer to 
Figure 1.14), but could possibly represent a mixture of heavy and light chain fragments. 
Bands of heavy chain fragments are expected at ~50kDa and light chain fragments at 
~25kDa.  A possible explanation for this was the use of DTT as the reducing agent when 
preparing samples to be resolved via gel electrophoresis. As highlighted earlier, DTT is a 
strong reducing agent, which may have degraded the heavy chain fragment into further 
smaller partial fragments resulting in the band observed between 35-40kDa. Western 
blotting was therefore unable to identify the specific location of the glycoprotein side 
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chain on the oxidised target antibody. However, no discrete band was seen at 25kDa 
which is the expected weight for single light chain fragments, suggesting that the 
glycoprotein chain was not present on the light chains of the antibody. Therefore, using 
the glycoprotein chain to conjugate the antibody to the MNP should not interfere with the 
binding of the antibody to its target antigen.  
 
An anti-CEA affimer that had been designed with a free cysteine group in the base of the 
scaffold that is available for binding was also investigated as an alternative to the anti-
CEA antibody. This would eliminate the need for a linker in the conjugation of targeting 
agent to the MNP and rely on the cysteine-maleimide reaction chemistry. The targeting 
and binding properties of the anti-CEA affimer was evaluated. Figure 4.7 shows that 
FITC fluorescence was predominantly observed in LoVo cells incubated with the 
biotinylated anti-CEA affimer. 
 
In summary, this chapter describes the work that was done in order to identify a suitable 
candidate that could be used as an anti-CEA targeting agent and conjugated to the 
MNP. Both the anti-CEA antibody and affimer were found to bind specifically to the 
target cell line (LoVo) and not to the control cell lines (EA.hy926 and HEK293). The anti-
CD31 antibody was also identified as a suitable control antibody. Gel electrophoresis 
and densitometry analysis showed that generating half-antibody fragments of the anti-
CEA antibody as targeting agents was not feasible. The presence of a glycoprotein side 
chain on the target antibody was identified that could potentially be oxidised and used for 
conjugation. Modifying both the anti-CEA and anti-CD31 antibodies by oxidation did not 
alter their ability to bind to their respective cell surface antigens. Although the precise 
location of the glycoprotein side chain was not determined on the anti-CEA antibody, it is 
unlikely to be located on the light chain fragment and therefore should not be present in 
the antigen-binding site. Therefore, using the glycoprotein side chain for conjugation to 
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the MNP should not alter the antibody’s ability to bind to its target antigen. This was 

















Nanoparticles (NPs) and nanomedicines are versatile tools that can assist in the 
diagnosis and treatment of cancers. Due to the unique physiology of tumours and their 
microenvironments, NPs can utilise the EPR (see 1.1.4.1) effect to accumulate within the 
tumour vicinity (191,192) or be modified to specifically target and bind to cancers such 
as their application in fluorescence-guided cancer surgery. The ideal characteristics for 
NPs designed for fluorescent diagnosis, as detailed in 1.4.3.3, includes bright 
fluorescence, effective tissue penetration, negligible photobleaching and 
chemical/physical stability(53,215,216) with a high degree of sensitivity and specificity for 
the target tissue. Ideal fluorescent NPs have peak light emission within the near-infrared 
(NIR, ≥650nm) region thereby improving fluorescent emission through multiple layers of 
tissue and reduced autofluorescence(16,215,229). Semi-conducting organic polymer 
NPs, that emit in the NIR range, are potential candidates that can be applied for 
fluorescent diagnosis and fluorescent-guided surgery. These NPs are photostable, 
physically small in size (200nm) for effective tumour penetration, fluorescently bright, 
exhibit minimal cellular toxicity and large Stokes shift(226). A large Stokes shift is 
important because it improves the sensitivity of distinguishing fluorescent signals above 
non-specific background fluorescence, whereas a narrow Stokes shift can make it 
challenging to differentiate between true NPs fluorescent and background fluorescence 
i.e. tissue autofluorescence(257).  
 
PEGylation involves the surface functionalisation of NPs with polyethylene glycol (PEG) 
polymer chains which helps them evade elimination via the mononuclear phagocyte 
system (MPS). PEGylation also allows NPs to be easily modified enabling the 
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conjugation of NPs to targeting moieties (170,191,209). PEGylation also reduces the 
‘clumping’ and aggregation of NPs and decreases immunogenicity(53). 
 
For this research project, a semi-conducting organic self-assembling NP was developed, 
comprised of a CN-PPV fluorescent core surrounded by a PLGA-PEG shell (Figure 5.1 
and 1.14). CN-PPV is physically hydrophobic and the PLGA-PEG shell allows the NPs to 
be soluble in water (hydrophilic). As described above, the presence of PEG chains on 
the surface enables surface modification for conjugation to a targeting moiety for the 
active targeting of tumour tissue. 
 
 
Figure 5.1 Fluorescent imaging of NIR fluorescent CN-PPV dye-doped PLGA-PEG 
semiconducting polymer NP. This image shows the red emission of bare non-
functionalised CN-PPV dye-doped PLGA-PEG NPs when exposed to an excitation 
wavelength of 405nm. Image in this figure is representative of 3 independent 




5.2.1 Nanoparticle characterisation 
Bare non-functionalised (standard) and bare maleimide functionalised NPs were 
fabricated and characterised as described in 2.3.1 and 2.3.2 respectively. 
 
5.2.1.1 Characterisation of nanoparticle sizes 
Characterisation of the sizes of NPs was carried out as described in 2.3.2.1. Figure 5.2 
shows the sizes of CN-PPV/PLGA-PEG non-functionalised NPs and MNPs with varying 
amounts of maleimide PLGA-PEG that were stored in solution over time. Firstly, no 
significant changes in the hydrodynamic diameters of 0% (p=0.45), 25% (p=0.24), 50% 
(p=0.07) and 75% (p=0.09) maleimide functionalised NPs that were stored was observed 
over time (Figure 5.2A-5.2D). However, a 31d.nm reduction in hydrodynamic diameter 
was observed in 100% maleimide functionalised NPs when comparing sizes at Day 0 
and Day 84 (p=0.002) (Figure 5.2E). Increasing the overall amount of maleimide PLGA-
PEG content within the MNPs resulted in increasing mean hydrodynamic diameters of 
the MNPs (Figure 5.2F). 
 
Figure 5.3 shows sizes of non-functionalised and 25% MNPs with long (5,000 Da) and 
short (2,000) PEG polymer chains that were stored in solution over time. 25% maleimide 
functionalised CN-PPV/PLGA-PEG NPs with both long and short PEG polymer chains 
were found to be stable in size over time (long PEG chain: p=0.09, short PEG chain: 
p=0.1). In addition, 25% maleimide functionalised NPs were found to have larger 
hydrodynamic diameters as compared to their non-functionalised counterparts. On Day 
0, long PEG chains = 24d.nm increase in size, p<0.0001 and short PEG chain = 28d.nm 
increase, p<0.0001.  
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A. 0% B. 25%
C. 50% D. 75%
E. 100% F.
 
Figure 5.2. Mean hydrodynamic diameters of CN-PPV/PLGA-PEG NPs over time. 
A) Bare non-functionalised NP. B) Bare 25% maleimide functionalised NP. C) Bare 
50% maleimide functionalised NP. D) Bare 75% maleimide functionalised NP. E) 
Bare 100% maleimide functionalised NP. F) Day 0 sizes of NPs with varying 
amounts of maleimide PLGA-PEG. Data represents means with standard deviation 
of 5 independent experiments. Experiments were performed in triplicate. See 
2.3.2.1 of Materials and Methods for the detailed protocol. Hydrodynamic 
diameters of bare non-functionalised (0% MNP) and bare 25% - 75% maleimide 
functionalised NPs (MNPs) remained stable over time; There was a decrease in 
the hydrodynamic diameter of 100% MNP over time. Increasing the concentration 
of functionalised maleimide PLGA-PEG in the NP increased the hydrodynamic 
diameter. 
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Figure 5.3. Mean hydrodynamic diameters of long and short PEG polymer chain 
functionalised CN-PPV/PLGA-PEG NPs. A) NPs with long PEG chains 
(5,000Da) B) NPs with short PEG chains (2,000Da). Data represents means with 
standard deviation of 3 independent experiments. Experiments were performed in 
triplicate. See 2.3.2.1 of Materials and Methods for the detailed protocol. The 
hydrodynamic diameter of bare non-functionalised and bare 25% maleimide 
functionalised NPs with long and short PEG chains remained stable over time. The 
hydrodynamic diameter of both forms of 25% MNP was larger than both forms of 
0% MNP. 
 
Figure 4 shows the polydispersity index of non-functionalised NPs (0% MNP), MNPs 
with varying amounts of maleimide PLGA-PEG (25% - 100% MNPs) as well as non-
functionalised (0% MNP) and 25% MNPs with long (5,000 Da) and short (2,000) PEG 
polymer chains over time. Values of below 0.2 are commonly deemed acceptable for 




Figure 4. Mean polydispersity index of CN-PPV/PLGA-PEG NPs over time. Data 
represents means with standard deviation of 5 independent experiments. 
Experiments were performed in triplicate. See 2.3.2.1 of Materials and Methods for 
the detailed protocol. All different types of CN-PPV/PLGA-PEG NPs characterised 
over time showed polydispersity index values of less than 0.2. 
 
5.2.1.2 Absorption and emission spectra 
The absorption and emission spectra for non-functionalised NPs and all MNPs were 
mapped out as described in 2.3.2.2.  
 
5.2.1.2.1 Optimum dilution of nanoparticles 
In order to deduce the optimal emission spectrum profile of NPs the concentration of 
NPs yielding a maximum absorbance of 0.1A.U. needs to be identified. There are two 
known factors that can influence the absorption and emission spectrum profiles when 
testing NPs using a spectrometer; scattering and reabsorption. On exposing NPs larger 
than 50nm to electromagnetic plane waves a phenomenon known as Mie scattering can 
contribute to the absorption spectrum profile. Mie scattering describes the scattering of 
light by a homogeneous sphere(258). The contribution from Mie scattering can be of the 
same magnitude or larger than the fluorescent material being studied. Reabsorption 
describes the effect of scattered light interacting with a second sample particle. If the 
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sample NP concentration was high, then light can interact with an initial NP, scatter but 
can then inadvertently interact and re-scatter from a second NP. The rescattered light 
could then potentially be detected by the spectrometer impacting on the spectrum profile. 
If the sample NP concentration is low enough then the scattered light from the interaction 
with the initial NP will be less likely to interact with a second NP and therefore the 
scattered light is not detected. The optimal concentration of NPs was therefore studied to 
determine the dilution/concentration that minimised strong contributions from Mie 
scattering in addition to reducing effects seen from reabsorption. A maximum absorption 
of 0.1A.U. is the empirical value used as absorbance at this peak seems to reduce these 
two factors across a wide range of NP systems. The absorption should be linearly 
proportional to the concentration of the NP, however this is not the case seen in Figure 
5.5. There is increasing background at increased NP concentrations which would 
suggest that there is contribution to the spectrum profile from scattering. 
 
Serial dilutions of non-functionalised CN-PPV/PLGA-PEG NPs were created and their 
absorption spectra were mapped out as described in 2.3.2.2.1. As shown in Figure 5.5, a 
maximal absorption of 0.1A.U. was achieved at 3.5g CN-PPV/ml. For the other 
concentrations of non-functionalised NPs, the maximal absorption readings were - 5g 
CN-PPV/ml: 0.1625A.U., 4.75g CN-PPV/ml: 0.145A.U., 4.5g CN-PPV/ml: 0.1375A.U., 
4.25g CN-PPV/ml: 0.1275A.U., 4g CN-PPV/ml: 0.115A.U., 3.75g CN-PPV/ml: 
0.1075A.U., 3.25g CN-PPV/ml: 0.0975A.U. and 3g CN-PPV/ml: 0.0825A.U. Following 





Figure 5.5. Absorption profiles of serial dilutions of non-functionalised CN-
PPV/PLGA-PEG NPs. Data represents means with standard deviation of 3 
independent experiments. Experiments were performed in triplicate. See 2.3.2.2.1 
of Materials and Methods for the detailed protocol. An absorption of 0.1A.U. was 
achieved at 3.5g CN-PPV/ml. 
 
5.2.1.2.2 Absorption and emission spectra for non-functionalised 
nanoparticles 
Figure 5.6 illustrates the normalised absorption and emission spectra for non-
functionalised NPs at 3.5g CN-PPV/ml. Peak light absorption was found at the 
excitation wavelength of 470nm. Emission spectra was then mapped out at four different 
excitation wavelengths (380nm, 425nm, 440nm and 470nm) which all showed maximal 
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peak emission around 650nm. The absorption and emission spectra for the non-
functionalised NPs did not appear to change over time. 
 
 
Figure 5.6. Absorption and emission profiles of non-functionalised CN-PPV/PLGA-
PEG NPs at optimum dilution over time. Data represents means with standard 
deviation of 3 independent experiments. Experiments were performed in triplicate. 
See 2.3.2.2 of Materials and Methods for the detailed protocol. Peak absorption 
occurred at an excitation wavelength of 470nm. Peak emission occurred at 650nm 
at all four excitation wavelengths tested. The absorption and emission spectra for 
0% MNP remained stable over time. 
 
5.2.1.2.3 Absorption and emission spectra for maleimide functionalised 
nanoparticles 
Figure 5.7 shows the normalised absorption and emission spectra for maleimide 
functionalised NPs. Peak light absorption was found at the excitation wavelength of 
470nm. Emission spectra was then mapped out at four different excitation wavelengths 
(380nm, 425nm, 440nm and 470nm) which all showed maximal peak emission around 
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650nm. The absorption and emission spectra for all maleimide functionalised NPs 
remained comparable over time. These findings are similar to non-functionalised NPs.  
 
 
Figure 5.7. Absorption and emission profiles for maleimide functionalised CN-
PPV/PLGA-PEG NPs. A) Bare 25% maleimide functionalised NP. B) Bare 50% 
maleimide functionalised NP. C) Bare 75% maleimide functionalised NP. D) Bare 
100% maleimide functionalised NP. Data represents means with standard 
deviation of 3 independent experiments. Experiments were performed in triplicate. 
See 2.3.2.2 of Materials and Methods for the detailed protocol. Peak absorption 
occurred at an excitation wavelength of 470nm for all MNPs. Peak emission 
occurred at 650nm at all four excitation wavelengths tested for all MNPs. The 
absorption and emission spectra for all MNPs remained stable over time. 
 
5.2.1.2.4 Absorption and emission spectra for short PEG nanoparticles 
The normalised absorption and emission spectra for the non-functionalised and 
maleimide functionalised short PEG NPs are illustrated in Figure 5.8. Peak light 
absorption was found at the excitation wavelength of 470nm. Emission spectra was 
mapped out at four different excitation wavelengths (380nm, 425nm, 440nm and 470nm) 
which all showed maximal peak emission around 650nm. The absorption and emission 
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spectra for these short PEG NPs and short PEG MNPs remained comparable over time. 
These findings are similar to the non-functionalised and maleimide functionalised NPs.  
 
 
Figure 5.8. Absorption and emission profiles for non-functionalised and 
maleimide functionalised short PEG CN-PPV/PLGA-PEG NPs. A) Bare non-
functionalised NP with short PEG chains. B) Bare 25% maleimide functionalised 
NP with short PEG chains. C) Bare 50% maleimide functionalised NP with short 
PEG chains. D) Bare 75% maleimide functionalised NP with short PEG chains. E) 
Bare 100% maleimide functionalised NP with short PEG chains. Data represents 
means with standard deviation of 3 independent experiments. Experiments were 
performed in triplicates. See 2.3.2.2 of Materials and Methods for the detailed 
protocol. Peak absorption occurred at an excitation wavelength of 470nm for all 
short PEG MNPs. Peak emission occurred at 650nm at all four excitation 
wavelengths tested for all short PEG MNPs. The absorption and emission spectra 




5.2.1.3 Testing the effects of conjugation processes on nanoparticle 
characterisation 
To form an efficient antibody-NP conjugate system the excess oxidised antibody must 
initially be removed from the solution. This procedure involves centrifuging the conjugate 
and it is important to determine the effects that centrifugation would have on the MNPs. 
The effects of different centrifuging parameters, such as G-force and time, were 
investigated and the results are shown in Figure 5.9. 
 
Figure 5.9A shows that centrifuging for 5 minutes at lower centrifugal forces (2-8G) 
caused larger changes in the hydrodynamic diameters of the bare maleimide 
functionalised NPs as compared to bare maleimide functionalised NPs centrifuged for 30 
minutes: 1G – 3.1% difference in hydrodynamic diameters (p=0.8957), 2G – 8.9% 
(p<0.0001), 3G – 9.5% (p<0.0001), 4G – 8.2% (p<0.0001), 5G – 8.4% (p<0.0001), 6G – 
7.5% (p<0.0001), 7G – 6.8% (p<0.0001), 8G – 4.5% (p=0.0178), 9G – 3.0% (p>0.9999), 
10G – 0.1% (p>0.9999). Figure 5.9B shows that centrifuging for 5 minutes decreased 
fluorescence emission of bare maleimide functionalised NPs more than centrifuging for 
30 minutes: 1G - 5.4% reduction in fluorescent emission was observed between 5 and 
30 minutes (p<0.0001), 2G - 32.3% (p<0.0001), 3G - 40.2% (p<0.0001), 4G - 38.1% 
(p<0.0001), 5G - 43.8% (p<0.0001), 6G - 56.0% (p<0.0001), 7G - 41.4% (p<0.0001), 8G 




Figure 5.9. Effects of centrifugation on NPs A) Changes in hydrodynamic diameter B) 
changes in the intensity of fluorescent emission of bare maleimide functionalised 
NPs. Data represents means with standard deviation of 3 independent 
experiments. Experiments were performed in triplicate and results are relative to 
non-centrifuged bare maleimide functionalised NPs control. Fluorescent excitation 
= 470nm and emission = 650nm). See 2.3.3 of Materials and Methods for the 
detailed protocol. Centrifugation of the NP increased the hydrodynamic diameter; 
centrifuging at 6G for 30 minutes caused the smallest increase in hydrodynamic 
diameter. Centrifugation of the NP reduced the emitted fluorescence; centrifuging 




Repeated wash steps as part of the protocols for synthesising antibody-conjugated NPs 
also involves centrifugation per wash. Therefore, the effects of repeated centrifugation at 
6G per repeated wash step were investigated. Figure 5.10 shows that repeated 
centrifugation of MNPs after each wash step resulted in increasing hydrodynamic 
diameters of MNPs. 8% increase in the hydrodynamic diameter was observed after 
Wash 1 (p<0.0001), 14.3% after Wash 2 (p<0.0001) and 18.3% after Wash 3 (p<0.0001) 
as compared to non-centrifuged bare MNPs. Increasing reduction in fluorescent 
emission was also observed after each subsequent wash step; 22.3% reduction in 
fluorescence emission was observed after Wash 1 (p<0.0001), 49.8% after Wash 2 
(p<0.0001) and 83.1% after Wash 3 (p<0.0001) as compared to non-centrifuged bare 
MNPs. It is possible that the reduction in fluorescence emission is due to the loss of 




Figure 5.10. Effects of repeated centrifugation on hydrodynamic diameters and 
fluorescent emission on bare maleimide functionalised NPs. Data represents 
means with standard deviation of 3 independent experiments. Experiments were 
performed in triplicate and results are relative to non-centrifuged bare maleimide 
functionalised NPs control. Fluorescent excitation = 470nm and emission = 
650nm). See 2.3.3.1 of Materials and Methods for the detailed protocol. Repeated 
centrifugation of the NP at 6G increased the hydrodynamic diameter and reduced 
the emitted fluorescence.  
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5.2.2 Investigating cell viability after exposure to bare maleimide 
functionalised nanoparticles 
Cell viability assays were performed on HEK293, EA.hy926 and LoVo cell lines after 
incubation with 10-fold dilutions of bare 25% maleimide functionalised NPs (for example, 
1 in 10 refers to a dilution of 1ml of bare 25% maleimide functionalised NPs in 9ml of 
appropriate cell media, 1 in 100 refers to a dilution of 1ml of bare 25% maleimide 
functionalised NPs in 99ml of appropriate cell media etc) using the protocol described in 
2.3.4. Cell viability measurements were taken at 24, 48 and 72 hours. Figure 5.11 shows 
cell viability after incubation with bare 25% maleimide functionalised NPs normalised to 
cell only (no MNPs) controls. 
 
In HEK293 cells (Figure 5.11A), 26% (p=0.6635) and 28% (p=0.7545) reduction in cell 
viability (compared to cell media only) was observed at 1 in 10 MNPs (highest 
concentration) incubated for 24hrs and 72hrs respectively. HEK293 cell viability 
improved with further MNPs dilutions (1 in 100000 NPs: 3.7%% (p>0.9999) and 7.0% 
(p>0.9999) reduction in cell viability (compared to cell media only) was observed at 
24hrs and 72hrs respectively). In LoVo cells (Figure 5.11B), 3% (p>0.9999) and 3% 
(p>0.9999) reduction in cell viability was observed at 1 in 10 MNPs incubated for 24hrs 
and 72hrs respectively. In EA.hy926 cells (Figure 5.11C), 10% (p=0.0097) and 16% 
(p<0.0001) reduction in cell viability was observed at 1 in 10 MNPs incubated for 24hrs 




Figure 5.11. Cell viability in cell lines after being exposed to varying 
concentrations of bare NPs containing the maleimide terminal group. A) 
HEK293 B) LoVo and C) EA.hy926 cell lines. Data represents means with 
standard deviation of 3 independent experiments. Experiments were performed in 
triplicate. p<0.05 (*) and p<0.0005 (**). See 2.3.4 of Materials and Methods for the 
detailed protocol. Moderate toxicity was observed in HEK293 cells at the highest 
MNPs concentration (1 in 10). No major toxicities was observed in the HEK293 cell 
line at lower MNP concentrations. Np major toxicities were observed in either the 
EA.hy926 and LoVo cell lines. 
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5.2.3 Non-specific binding of nanoparticles 
To ensure that binding of antibody-conjugated NPs to target cells is mediated through 
active antibody targeting only, the non-specific binding of NPs was investigated. Bare 
non-functionalised and maleimide functionalised NPs were tested against HEK293, 
EA.hy926 and LoVo cell lines as described in 2.3.5. Figure 5.12 shows changes in 
fluorescent emission after cells were incubated with bare non-functionalised and 
maleimide functionalised NPs, as compared to cell only (no NPs) controls. No significant 
difference in fluorescent emission was observed in all cell lines with any dilution of the 
different bare non-functionalised NPs or bare maleimide functionalised NPs when 
compared to a media only control. 1 in 10 at 0% MNP vs control: LoVo = p>0.9999, 
HEK293 = p>0.9999 and EA.hy926 = p>0.9999. 1 in 10 at 100% MNP vs control: LoVo = 




Figure 5.12. Fluorescence in cell lines after incubation of bare non-functionalised 
(0% MNP) and maleimide functionalised NPs with varying concentrations of 
maleimide PLGA-PEG (25% MNP to 100% MNP). A) HEK293 B) EA.hy926 and 
C) LoVo cell lines. Data represents means with standard deviation of 8 
independent experiments. See 2.3.5.1 of Materials and Methods for the detailed 
protocol. Non-functionalised and maleimide functionalised NPs exhibited very little 
non-specific binding to HEK293, LoVo and EA.hy926 cells.  
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To determine whether blocking unoccupied maleimide functional groups on the NPs 
provided any additional benefit in reducing non-specific binding, cysteine was added as 
described in protocols 2.3.5. Figure 5.13 shows changes in fluorescent emission after 
cells were co-incubated with bare non-functionalised and maleimide functionalised NPs 
and maleimide-blocking cysteine, as compared to cell only (no NPs and cysteine) 
controls. No significant difference in fluorescent emission was seen in all cell lines 
incubated with any dilutions of the cysteine-blocked different bare non-functionalised 
NPs or bare maleimide functionalised NPs when compared to a media only control. 1 in 
10 at cysteine-blocked 0% MNP vs control: LoVo = p>0.9999, HEK293 = p>0.9999 and 
EA.hy926 = p>0.9999. 1 in 10 at cysteine-blocked 100% MNP vs control: LoVo = 




Figure 5.13. Fluorescence in cell lines after incubation with varying 
concentrations of cysteine-blocked bare non-functionalised (0% MNP) and 
maleimide functionalised NPs with varying concentrations of maleimide 
PLGA-PEG (25% MNP to 100% MNP). A) HEK293 B) EA.hy926 and C) LoVo cell 
lines. Data represents means with standard deviation of 8 independent 
experiments. Experiments were performed in triplicate. See 2.3.5.1 of Materials 
and Methods for the detailed protocol. Cysteine-blocked non-functionalised and 
maleimide functionalised NPs exhibited very little non-specific binding to HEK293, 




The characterisation of the physical properties, specifically the stability of sizes, of both 
non-functionalised and maleimide functionalised NPs was conducted as part of this 
research project. Changes in NPs sizes over time, especially clinically-related 
nanomedicines, has previously been shown to influence their kinetics profiles and 
applications(259,260). Measurements of the hydrodynamic diameters of all NPs were 
recorded to highlight the physical stability of NPs and MNPs over extended periods of 
time. The hydrodynamic diameter of the non-functionalised NPs ranged between 
103.3nm and 121.7nm. Over the course of 56 days the hydrodynamic diameter of the 
non-functionalised NPs remained stable in aqueous solution (Figure 5.2A). This is in 
concordance with previously published data regarding this self-assembling NP system. 
Kemal et al. (229) compared the hydrodynamic diameters of CN-PPV/PLGA-PEG NPs 
comprised of different ratios of CN-PPV to PLGA-PEG over time. The study found that 
the hydrodynamic diameters of NPs with varying ratios of CN-PPV:PLGA-PEG increased 
with increasing concentrations of PLGA-PEG in NPs. Overall diameters ranged between 
110nm and 140nm. Differences in hydrodynamic diameters was primarily attributed to 
the 5,000Da long chain PEG. This study also compared the colloidal stability of CN-PPV-
only NPs with 1:1 ratio CN-PPV/PLGA-PEG NPs by measuring the hydrodynamic 
diameters of both systems over 60 days. Similar to the findings in this research project, 
the authors found that the hydrodynamic diameters of both systems remained stable 
over 60 days.  
 
As shown in Figure 5.2, the hydrodynamic diameters of the maleimide functionalised 
NPs remained stable over 84 days in aqueous solution. Maleimide functionalised NPs 
were found to be consistently larger than non-functionalised NPs and hydrodynamic 
diameters increased with increasing maleimide content within the NPs (Figure 5.2F). The 
hydrodynamic diameter of maleimide functionalised NPs ranged between 124nm and 
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158nm. On Day 0 (day of MNPs fabrication) the ranges of hydrodynamic diameters of 
maleimide functionalised NPs were: 
i. 25%: 124 – 131nm 
ii. 50%: 129 – 137nm 
iii. 75%: 130 – 140nm 
iv. 100%: 139 – 158nm 
 
In this research project, the maleimide functionalisation of CN-PPV/PLGA-PEG NPs is a 
novel innovation. To date, no study has been conducted which can be used to draw 
comparisons on the physical properties of maleimide functionalised NPs. Following the 
characterisation of non-functionalised and maleimide functionalised NPs sizes over time, 
further experiments were conducted comparing non-functionalised and maleimide 
functionalised NPs. For these experiments 25% maleimide functionalised NPs (124.2nm 
– 130.6nm) were chosen as they were the closest in overall MNPs sizes to non-
functionalised NPs (103.3nm - 121.7nm). 
 
As discussed in 1.4.3.2, PEGylation is the most efficient strategy enabling NPs to evade 
MPS by inhibiting the adhesion of opsonin proteins(202,261). To achieve this, linear 
PEG chains block protein binding sites to shield the surfaces of NPs. The lengths and 
molecular weights of PEG chains that are used to block surface protein binding sites are 
important factors in PEGylation(197). Longer and heavier PEG chains have previously 
been shown to increase systemic circulation times of PEGylated NPs putatively 
indicating their evasion to MPS mediated elimination(262). However, excessive 
PEGylation can negatively affect NPs pharmacokinetics through hindering cellular 
uptake by interfering with the NPs ability to bind to targeted antigens(261). To highlight 
the influence of the length of PEG chains on NPs Pozzi et al.(261) conducted a study, 
investigating the effect of various lengths (and weights) of PEG chains in a liposomal 
drug delivery system. The authors compared non-PEGylated liposomes to PEGylated 
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liposomes functionalised with 1,000Da (short), 2,000Da (medium) and 5,000Da (long) 
PEG chains. The uptake of liposomes into the prostate cancer cell line, PC3, was 
evaluated between the four different liposomal formulations. The study found that the 
1,000Da and 2,000Da PEGylated liposomes had higher cellular uptake as compared to 
non-PEGylated liposomes. The heaviest (5,000Da) PEGylated liposomes were found to 
have the lowest cellular uptake of all four liposomal formulations. The study also 
investigated the degree of protein binding to the surface of liposomes, and found that 
moderate PEGylation on the 2,000Da PEGylated liposomes provided the most effective 
shielding from protein adsorption. Therefore, in this project, to further enhance the 
binding to targeting moieties and reduce protein adsorption, a lighter and shorter PLGA-
PEG (PEG 2,000Da) was used to create maleimide functionalised PLGA-PEG NPs. 
Figure 5.3 demonstrates that the hydrodynamic diameters of lighter and shorter PEG 
non-functionalised and maleimide functionalised NPs followed a similar trend in stability 
in sizes, as compared to their heavier and longer PEG counterparts. Overall, maleimide 
functionalised NPs remained heavier than non-functionalised NPs. 
 
The ultimate application of the CN-PPV/PLGA-PEG NPs being investigated in this 
research project is optical medical imaging via fluorescent diagnosis. Characterising the 
light absorption and emission profiles of NPs is important to define their excitation and 
emission parameters during clinical application(74). The absorption and emission 
spectra profiles for both non-functionalised and maleimide functionalised NPs were 
found to be similar (Figure 5.6 and Figure 5.7). Both have peak absorption at 470nm 
which is optimal for clinical application(69,213,223). When excited at 470nm, both exhibit 
bright fluorescence at 650nm. Although this is not considered to be within the NIR, the 
emission of non-functionalised and maleimide functionalised NPs is within the deep-red 
region of the spectrum and is an emission wavelength that can be detected with existing 
laparoscopic equipment therefore this NP system represents good potential probes for 
fluorescence-guided surgery. An additional three excitation wavelengths were also 
188 
chosen to map out the emission spectra of NPs and MNPs. Endoscopic multispectral 
fluorescence camera system technologies such as the KARL STORZ D-Light P System 
and The Stryker ENV System, are commonly used in clinics as imaging platforms to 
assist in fluorescence-guided surgery and fluorescence angiography(83,263,264). These 
imaging platforms typically emit fluorescent light between 380nm and 440nm with peak 
at 425nm. Therefore, these three excitation wavelengths (380nm, 425nm and 440nm) 
were chosen in addition to the optimum excitation wavelength for the CN-PPV/PLGA-
PEG NPs and MNPs, which is 470nm (Figure 5.6). Similar to the emission profile at 
470nm excitation, the fluorescent emission profiles at the three additional wavelengths 
showed peaks in the near-infrared range positively indicating the suitability of the CN-
PPV/PLGA-PEG NPs and MNPs with existing surgical and clinical imaging platforms. 
 
As described earlier, multiple washing steps is performed as part of the protocols 
developed for creating antibody-conjugated NPs. Changes in the hydrodynamic 
diameters and fluorescence emission of NPs subjected to centrifuging has previously 
been reported in the literature(265–268). Biswas et al.(265) found that increasing the 
length of time that colloidal silicon NPs are subjected to centrifugation resulted in 
diminishing intensity of luminescence from NPs. The colour of luminescent emission also 
changed from white to blue/green. The authors also found that the sizes of silicon NPs 
reduced in correlation with the length of times under centrifugation. Another study 
investigating the effects of centrifugation on tin NPs found that increasing centrifugal 
force from 6,000g to 12,000g resulted in increasing agglomeration of NPs(266). Similar 
to this research project, Kemal et al.(229) investigated CN-PPV based semi-conducting 
NPs and found that low centrifugal forces caused irreversible aggregation of NPs. La 
Spina et al.(267) investigated the influence of repeated centrifugation on the surface 
chemistry of gold NPs. Centrifugation is used as a method for extracting sodium citrate, 
a stabilising agent used during the manufacturing of gold NPs. Sodium citrate impedes 
functionalisation of gold NPs. This study found that although the amounts of sodium 
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citrate had substantially reduced after three wash cycles (involving centrifugation), NPs 
had aggregated after the third wash. The authors also found decreasing intensity in 
near-infrared light absorbance of gold NPs with each subsequent centrifugation/wash 
cycle. Shi et al.(268) investigated the effect of repeated centrifugation on fluorescence 
emission of gold nanorods. Gold nanorods were centrifuged from 5,500g to 8,500g up to 
three times, and the authors found a reduction in the longitudinal peak wavelength of 
emission, i.e. a blue-shift. The shortening of the longitudinal peak wavelength of 
emission correlated with the number of centrifugation cycles and with increasing 
centrifugal forces. 
 
To investigate the effects of centrifugation on our MNPs, they were subjected to a range 
of centrifugal forces ranging from 1,000g to 10,000g. The highest centrifugal force of 
10,000g is used for the modification and extraction of excess antibodies. Therefore, this 
was the highest centrifugal force that the MNPs would be subjected to. Figure 5.9 shows 
that centrifugation induced changes in the hydrodynamic diameters and fluorescence 
emission (Excitation: 470nm) in maleimide functionalised NPs. It also demonstrates that 
the percentage change in these characteristics was dependent on time under 
centrifugation and the centrifugal force applied.  Using these findings, it was decided that 
the MNPs would be centrifuged at 6,000g for 30 minutes when required during the 
conjugation process, as these settings yielded the smallest changes in size and 
fluorescent emission. Figure 5.10 demonstrates that repeated centrifugation also 
impacts the hydrodynamic diameter and emitted fluorescence of the bare maleimide 
functionalised NP. With each subsequent centrifugation the changes in size and 
fluorescence intensity got larger. Hence, it was decided not to perform serial wash steps 
after centrifuging MNPs at 6,000g for 30 minutes.  
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The biotoxicity of MNPs was investigated in different cell lines. Fluorescent NPs with 
specific medical imaging properties are designed with intent to be used as diagnostic 
agents. Adverse cytotoxicities induced by these NPs could ultimately lead to their failure 
during clinical trials with them being deemed unsafe for patient use(110,133,197,213). 
To investigate the cytotoxicities, MNPs were incubated with cells and cell viability was 
analysed. Moderate toxicity was observed in HEK293 cells at the highest MNPs 
concentration (1 in 10). However, cell viability improved with at lower MNPs 
concentrations. No major toxicities was observed in either EA.hy926 and LoVo cell lines 
(Figure 5.11). The findings from these results suggest that different cell lines have 
different levels of sensitivity to maleimide functionalised NPs. The optimal concentration 
of MNPs will need to be deduced which would yield the highest intracellular 
accumulation of MNPs and have negligible effects on cell viability. 
 
Non-specific binding and non-specific interactions between cells and PEGylated NPs 
have been previously been shown in the literature. A study by Vigor et al. used active 
CEA targeting of superparamagnetic iron oxide NPs to improve MRI imaging of CEA-
positive colorectal cancer cells. The authors found higher non-specific binding of NPs to 
control CEA-negative cell line, A375M (melanoma cell line) as compared to the LS174T 
CEA-positive cell line(157). This non-specific binding was also present with their bare 
unblocked NPs meaning that non-specific binding was not exclusively due to the 
targeting moiety used. The study also suggested that non-specific binding could be 
related to the negative surface charge of NPs produced by using negatively charged 
carboxylated PEG for conjugation purposes. Another study by Zhang et al.(269) found 
that by modifying their magnetite NPs by PEGylation reduced uptake into macrophage 
cells (part of the MPS) but also increased the non-targeted intracellular uptake of the NP 
into human breast cancer BT20 cells. They speculated that this increased uptake is due 
to the high solubility of PEG in the lipid bilayer of the cell surface membrane. In this 
research project, it was found that both bare (unblocked) and cysteine-blocked variants 
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of non-functionalised and maleimide functionalised NPs exhibited very little non-specific 
binding to HEK293, LoVo and EA.hy926 cells (Figure 5.12 and 5.13). 
 
In summary, the semiconducting organic polymer CN-PPV NPs is an ideal fluorescent 
probe to assist in fluorescent diagnosis and imaging. As shown in this chapter, the peak 
intensity of fluorescent emission of both non-functionalised and maleimide functionalised 
NPs is around 650nm. In addition, maximum light absorption occurs in the blue-violet 
range (<500nm) conferring a wide Stokes shift, meaning there is clear separation 
between their maximal absorption and emission peaks. The blue-violet excitation range 
is currently achievable with commercially available laparoscopic equipment making the 
NP system compatible with existing surgical imaging platform. The non-functionalised 
and maleimide functionalised NPs have also exhibited physical stability over time in an 
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6 Conjugation and binding assays 
6.1 Introduction 
Active targeting, by conjugating tumour-specific targeting agents to nanomedicines, can 
improve the binding and uptake into tumours by (118,192). Antibodies have been 
extensively investigated and used in multiple studies as targeting agents for conjugation 
to NPs to improve delivery (150,166–168,270). Affimers are emerging as alternative 
targeting agents to antibodies, given their potential advantages (144,172). The increased 
cell membrane expression of the carcinoembryonic antigen (CEA) has been identified as 
an ideal antigen for targeting colorectal cancers(143). Therefore, for this research project 
a monoclonal IgG anti-CEA antibody and an anti-CEA affimer were selected as potential 
targeting agents for conjugation to CN-PPV/PLGA-PEG fluorescent NPs. 
 
Conjugation of antibodies to NPs requires the availability of free functional groups to 
facilitate the conjugation process. PEG does not have functional groups to facilitate 
conjugation. One way this can be achieved is by using functionalised PEG that 
possesses free terminal groups, such as amine, carboxyl or maleimide. These functional 
groups allow multiple immunoglobulin antibody molecules to bind to a single NP, thereby 
increasing the binding affinity of NP-conjugates to target tumours(192,271). The 
‘cysteine-maleimide’ reaction is a strong and reliable covalent bond, which has 
previously been investigated in pharmaceutical applications, specifically in developing 
antibody-drug conjugates(233). To this end, the CN-PPV/PLGA-PEG fluorescent NP 
was fabricated with maleimide terminal groups for conjugation to targeting agents via 
‘cysteine-maleimide’ mediated bonding. 
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It was proposed that reducing the disulphide bonds in antibodies could make free 
cysteine groups available for binding(155,233). However, as discussed in 4.3, it became 
apparent that this was not a practical solution and an alternative pathway for conjugation 
of antibody to MNP was investigated. Oxidation of the antibody’s glycoprotein side chain 
(specifically sialic acid) generates a reactive aldehyde group which interacts with 
hydrazide groups to form stable hydrazone bonds. This enables the possibility of 
conjugating the antibody through the glycoprotein side chain to the MNP via a 
crosslinker(233). 
 
3-[2-pyridyldithio]propionyl hydrazide (PDPH) is a heterobifunctional crosslinker 
containing sulfhydryl-reactive pyridyldithiol and aldehyde-reactive hydrazide functional 
groups at either end of the molecule(272) (Figure 6.1). In the presence of maleimide, the 
pyridine-2-thione moiety in the sulfhydryl-reactive pyridyldithiol group is displaced 
allowing conjugation of maleimide to the heterobifunctional crosslinker. Through this 
reaction, PDPH is a suitable crosslinker between the reactive aldehyde group on the 





Figure 6.1. Chemical structure of heterobifunctional 3-(2-Pyridyldithio)propionyl 
hydrazide (PDPH) crosslinker(273). PDPH is a heterobifunctional crosslinker 
which contains a sulfhydryl-reactive pyridyldithiol group and an aldehyde-reactive 
hydrazide group. This crosslinker allows conjugation of glycoproteins to sulfhydryl-
containing peptides or proteins.  
 
6.2 Results 
6.2.1 Conjugation of target (anti-CEA) antibody to 
heterobifunctional crosslinker 
To demonstrate the conjugation of target (anti-CEA) antibody to the PDPH 
heterobifunctional crosslinker immunofluorescence was performed as described in 
2.4.1.1. As shown in Figure 6.2, green fluorescence was observed when LoVo cells 
(target cell line for the anti-CEA antibody) were incubated with the anti-CEA antibody – 
DyLightTM dye labelled PDPH crosslinker conjugate. No fluorescence was observed 
when LoVo cells were incubated with the anti-CEA antibody alone. Green fluorescence 
was also observed when HEK293 and EA.hy926 cells were incubated with the anti-CEA 
antibody – DyLightTM dye labelled PDPH crosslinker conjugate, suggesting that the 




Sulfhydryl-reactive pyridyldithiol group Aldehyde-reactive hydrazide group
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Figure 6.2. Binding of target antibody and target antibody - dye labelled PDPH 
heterobifunctional crosslinker on target and control cell lines using 
immunofluorescence on fixed cells. Blue fluorescence is DAPI. Green 
fluorescence is DyLightTM 488 using FITC filter.  Magnification x63. Scalebar = 
10 m. 0.5% skimmed milk blocking and unconjugated oxidised antibody served 
as controls. Due to the presence of the fluorescent DyLight 488 molecules, a 
secondary fluorescent antibody was not needed for experiments. Images in this 
figure are representative of at least 3 independent experiments. See 2.4.1.1 of 
Materials and Methods for the detailed protocol. The presence of green 
fluorescence in target (LoVo) and both control (EA.hy926 and HEK293) cell lines 
incubated with anti-CEA antibody–dye labelled PDPH conjugates suggests non-
specific binding of conjugates to cells. 
 
This experiment was repeated using bovine serum albumin as the blocking agent as 
described in 2.4.1.2. As shown in  Figure 6.3, green fluorescence was observed when 
LoVo cells were incubated with the anti-CEA antibody – DyLightTM dye labelled PDPH 
crosslinker conjugate. No fluorescence was observed when LoVo cells were incubated 
with the anti-CEA antibody alone. Green fluorescence was seen when HEK293 and 
EA.hy926 cells were incubated with the anti-CEA antibody – DyLightTM dye labelled 
PDPH crosslinker conjugate. The results shown in Figure 6.2 and  Figure 6.3 could 
represent non-specific binding of the target antibody-dye conjugate. 
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 Figure 6.3. Binding of target antibody and target antibody - dye labelled PDPH 
crosslinker on target and control cell lines using BSA blocking protocol on 
fixed cells. Blue fluorescence is DAPI. Green fluorescence is DyLightTM 488 using 
FITC filter.  Magnification x63. Scalebar = 10 m. 0.1% bovine serum albumin and 
unconjugated oxidised antibody served as controls. Due to the presence of the 
fluorescent DyLight 488 molecules, a secondary fluorescent antibody was not 
needed for experiments. Images in this figure are representative of at least 3 
independent experiments. See 2.4.1.2 of Materials and Methods for the detailed 
protocol. The presence of green fluorescence in target (LoVo) and both control 
(EA.hy926 and HEK293) cell lines incubated with anti-CEA antibody–dye labelled 
PDPH conjugates suggests non-specific binding of conjugates to cells despite 
blocking with BSA. 
 
To identify the cause of non-specific binding seen in  Figure 6.2 and  Figure 6.3, the 
individual components of the anti-CEA antibody – dye labelled PDPH heterobifunctional 
crosslinker were investigated as described in protocol 2.4.1.3. Figure 6.4 shows that no 
green fluorescence was observed when LoVo, HEK293 or EA.hy926 cells were 




Figure 6.4. Binding of different components of DyLight dye labelled anti-CEA 
antibody – PDPH heterobifunctional crosslinker conjugate on target and 
control cell lines using immunofluorescence on fixed cells. Blue fluorescence 
is DAPI. Green fluorescence is DyLightTM 488 using FITC filter.  Magnification x63. 
Scalebar = 10 m. 0.1% bovine serum albumin blocking, unconjugated oxidised 
antibody and unmodified PDPH served as controls. Due to the presence of the 
fluorescent DyLight 488 molecules, a secondary fluorescent antibody was not 
needed for experiments. Images in this figure are representative of at least 3 
independent experiments. See 2.4.1.3 of Materials and Methods for the detailed 
protocol. Green fluorescence is seen on both the target and control cell lines in the 
presence of DyLightTM 488 Maleimide dye, even when the maleimide functional 
group is blocked by PDPH or cysteine. No green fluorescence is seen with the 
oxidised anti-CEA antibody or PDPH. 
 
Green fluorescence in all three cell lines was observed when cells were incubated with 
the unblocked DyLightTM dye. Substantial fluorescence was also observed when all three 
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cell lines were incubated with the blocked DyLightTM dye and dye labelled PDPH. This 
could suggest that the DyLightTM 488 Maleimide dye is responsible for the non-specific 
binding of the target antibody-dye conjugate observed in Figure 6.2 and  Figure 6.3. 
 
6.2.2 Conjugation of antibody to maleimide functionalised 
nanoparticle using heterobifunctional crosslinker 
6.2.2.1 Conjugating heterobifunctional crosslinker to maleimide 
functionalised nanoparticles 
A binding assay was conducted as per 2.4.2.1 to determine the optimal length of 
incubation time to conjugate maleimide functionalised NPs to the heterobifunctional 
linker, PDPH (Figure 6.5). Target antibody-NP conjugates were incubated with the target 
cell line and fluorescence quantified, using bare maleimide functionalised NPs (MNP) as 
an additional control. 
 
A significant difference in the fluorescence compared to cell media only treated cells was 
observed when the heterobifunctional crosslinker was incubated with the bare 25% 
maleimide functionalised NP for 30 minutes; 12% increase in fluorescence (p=0.0048). 
No significant difference in fluorescence intensities were seen at 1 hour and 2 hours with 
6% (p=0.3839) and 7% (p=0.1868) increase in fluorescence intensities respectively. The 
results shown in Figure 6.5 suggest that the optimal time for conjugation between the 
bare 25% maleimide functionalised NP and PDPH was 30 minutes and therefore this 






Figure 6.5. Assessment of optimal incubation time for conjugation of maleimide 
functionalised NP (MNP) to heterobifunctional crosslinker. Results represent 
mean values of at least 3 independent experiments with SD. Experiments were 
performed in triplicate. Statistically significant difference of fluorescence 
normalised to cell media only treated cells was considered at p<0.05 (*). See 
2.4.2.1 of Materials and Methods for the detailed protocol. A significant increase in 
the fluorescence intensity was observed when MNP was incubated with the 
heterobifunctional crosslinker for 30 minutes. 
 
6.2.2.2 Testing anti-CEA antibody – nanoparticle conjugate against 
LoVo cell line 
In order to confirm conjugation of the antibody to the maleimide functionalised NP, a 
binding assay and an immunofluorescence study on the target (LoVo) cell line were 
performed as described in 2.4.2.2. A 1 in 100 dilution of anti-CEA antibody-NP conjugate 
was chosen as this concentration of bare maleimide functionalised NP was the highest 
that also yielded minimal cytotoxicity (Figure 5.10).  
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Figure 6.6 shows that a 402% increase in fluorescence was observed when anti-CEA 
antibody-NP conjugates were incubated with LoVo cells, as compared to cell media only 
treated cells (p<0.0001). 77% (p=0.6837) and 42% (p>0.9999) increase in fluorescence 
was observed when bare non-functionalised and bare 25% maleimide functionalised 
NPs respectively were incubated with LoVo cells as compared to cell media only treated 
cells. This shows that there was a higher degree of binding of target antibody-NP 
conjugates to LoVo cells in comparison to bare NPs and bare MNPs. Comparing the 
different variants of NPs, a 325% increase in fluorescence was observed in target 
antibody-NP conjugates as compared to bare non-functionalised NPs (p=0.0004). A 
360% increase in fluorescence was observed in target antibody-NP conjugates as 




Figure 6.6. Assessment of binding of bare NPs and antibody-NP conjugate 
(AbMNP) to LoVo cells. Results represent mean values of at least 3 independent 
experiments with SD. Experiments were performed in triplicate. Statistically 
significant difference of fluorescence normalised to cell media only treated cells 
was considered at p<0.05 (*). See 2.4.2.2 of Materials and Methods for the 
detailed protocol. A significant increase in the fluorescence intensity is seen when 
the target antibody-NP conjugate is incubated with LoVo cells compared to bare 
non-functionalised NPs and bare maleimide functionalised NPs. 
 
Figure 6.7 shows that green fluorescence was observed when LoVo cells were 
incubated with target antibody–NP conjugates. Red fluorescence from CN-PPV/PLGA-
PEG antibody-NP conjugates was also similarly observed in target LoVo cells. Taken 
together, this indicates successful binding of the target antibody to CN-PPV/PLGA-PEG 
MNPs and successful binding of target antibody-NP conjugates to the target cell line, 




Figure 6.7. Binding of target antibody-NP conjugate (Anti-CEA AbMNP) on target 
cell line using immunofluorescence on fixed cells. Blue fluorescence is DAPI 
using DAPI filter. Green fluorescence is Alexa Fluor 488 secondary antibody 
using FITC filter. Red fluorescence is CN-PPV NP using 5-ALA filter. Magnification 
x63. Scalebar = 10 m. 0.5% skimmed milk blocking served as control. Images in 
this figure are representative of at least 3 independent experiments. See 2.4.2.2 of 
Materials and Methods for the detailed protocol. Green and red fluorescence is 
observed when the target antibody-NP conjugate is incubated with LoVo cells 
indicating successful conjugation of antibody to MNP. 
 
6.2.2.3 Testing target and control antibody – nanoparticle conjugates 
against target and control cell lines 
The binding abilities of both the target and control antibody-NP conjugates (CEA AbMNP 
and CD31 AbMNP respectively) against LoVo, HEK293 and EA.hy926 cell lines was 







Figure 6.8 shows that a 16% increase in fluorescence intensity was observed when 
target antibody-NP conjugates were incubated with the target cell line (anti-CEA 
antibody-NP conjugate against LoVo cell line)(p<0.0001). However, a 17% (p<0.0001) 
and 20% (p<0.0001) increase in fluorescence intensities were also observed when 
target antibody-NP conjugates were incubated with HEK293 and EA.hy926 control cell 
lines. An increase in fluorescence intensities was also observed when control antibody-
NP conjugates were incubated with all three cell lines. HEK293: 18% (p<0.0001), 
EA.hy926: 17% (p<0.0001) and LoVo: 15% (p<0.0001)).  
 
No significant differences in fluorescence was observed between the binding of target 
antibody-NP conjugates and control antibody-NP conjugates on all three cell lines. 
HEK293: 1% difference in fluorescence (p=0.9995), EA.hy926: 2% (p=0.8088) and 
LoVo: 2% (p=0.9208). Figure 6.8 also shows a decrease in fluorescence when the two 
control cell lines were incubated with the bare 25% maleimide functionalised NP. 
HEK293: 9% (p=0.0081) and EA.hy926: 18% (p<0.0001). The anti-CEA antibody used to 
develop the target antibody-NP conjugates should preferentially bind to the CEA-positive 
LoVo cell line more than the control cell lines. However, no significant difference in 
fluorescence was found between LoVo and control cell lines when incubated with target 




Figure 6.8. Binding of target and control antibody-NP conjugates (AbMNP) against 
target and control cell lines. Results represent mean values of at least 3 
independent experiments with SD. Experiments were performed in triplicate. 
Statistically significant difference of fluorescence normalised to cell media only 
treated cells was considered at p<0.0001 (*). See 2.4.2.3 of Materials and Methods 
for the detailed protocol. Significant increases in fluorescence intensity are seen 
with both the target and control antibody-NP conjugates to all cell lines indicating 
non-specific binding. 
 
Figure 6.9 shows that green DyLight 448 fluorescence was observed when the target 
cell line, LoVo, was incubated with target (anti-CEA) antibody–NP conjugates. Red CN-
PPV/PLGA-PEG NP fluorescence was also seen in anti-CEA AbMNP incubated LoVo 
cells. No green DyLight 448 fluorescence was observed when the target cell line was 
incubated with control (anti-CD31) antibody–NP conjugates. However, red fluorescence 
from CN-PPV/PLGA-PEG NPs was observed suggesting non-specific binding of control 
antibody-NP conjugates to LoVo cells. This supports the findings seen in Figure 6.8. 
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Green DyLight 448 fluorescence and red CN-PPV/PLGA-PEG NP fluorescence was also 
observed when the control cell line EA.hy926, was incubated with control antibody–NP 
conjugates (Figure 6.9). However, green DyLight 448 fluorescence was seen when 
EA.hy926 cells were incubated with target (anti-CEA) antibody – NP conjugates 
suggesting non-specific binding of target antibody-NP conjugates to EA.hy926 cells. Red 
fluorescence from CN-PPV/PLGA-PEG NPs was also seen when control antibody-NP 




Figure 6.9. Binding of target and control antibody-NP conjugates on target and 
control cell lines using immunofluorescence on fixed cells. Blue fluorescence 
is DAPI using DAPI filter. Green fluorescence is Alexa Fluor 488 secondary 
antibody using FITC filter. Red fluorescence is CN-PPV NP using 5-ALA filter. 
Magnification x63. Scalebar = 10 m. 0.5% skimmed milk blocking served as 
control. Images in this figure are representative of at least 3 independent 
experiments. See 2.4.2.3 of Materials and Methods for the detailed protocol. Green 
and red fluorescence is observed when both the target and control antibody-NP 
conjugates to all cell lines indicating non-specific binding. 
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6.2.3 Optimisation of antibody-nanoparticle conjugation 
6.2.3.1 Optimisation step 1: Comparing different extraction techniques 
to remove excess antibody from antibody-nanoparticle conjugates 
Excess oxidised antibody needs to be removed from antibody-NP conjugates to prevent 
free oxidised antibodies from binding and blocking target antigens. This would allow the 
antibody-NP conjugates only to bind and occupy the target antigens. Three different 
extraction methods were compared as per the protocol described in 2.4.3.1. Target 
antibody-NP conjugates were incubated with HEK293, LoVo and EA.hy926 cell lines and 
fluorescence quantified. 
 
Centrifuging was found to be the most effective method in putatively removing free 
unconjugated antibodies. A 90% increase in fluorescence was found in centrifuged 
antibody-NP conjugate and free unconjugated antibodies mixture (p<0.0001). The use of 
magnetic forces to separate the mixture resulted in 24% increase in fluorescence 
(p=0.0048) and the use of a dialysis yielded 20% increase in fluorescence (p=0.0251) 
(Figure 6.10). When the three extraction methods are compared against no extraction, 
only centrifugation showed a significant difference in fluorescence. Centrifugation: 81.0% 
(p<0.0001), Magnetism: 15% (p=0.2190) and Dialysis: – 11% (p=0.8559). For all 





Figure 6.10. Assessment of binding of target antibody-NP conjugate to LoVo cells 
using different extraction methods to remove excess oxidised target 
antibody. Results represent mean values of at least 3 independent experiments 
with SD. Experiments were performed in triplicate. Statistically significant 
difference of fluorescence normalised to cell media only treated cells was 
considered at p<0.05 (*) and p<0.0001 (**). See 2.4.3.1 of Materials and Methods 
for the detailed protocol. These results show that centrifugation is the best 
extraction method to remove excess oxidised target antibody. 
 
When comparing the different extraction methods, Figure 6.10 shows a statistically 
significant increase in fluorescence between extraction using centrifugation and both 
dialysis and magnetism. Centrifugation vs. Magnetism: 67% difference in fluorescence 
(p<0.0001), Centrifugation vs. Dialysis: 71% (p<0.0001), Magnetism vs. Dialysis: 4% 
(p>0.9999). 
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6.2.3.2 Optimisation step 2: Galactose-mediated blocking of 
unoccupied hydrazide groups on crosslinker 
To reduce non-specific binding, the hydrazide functional groups on the heterobifunctional 
crosslinkers needs to be occupied by the aldehyde groups on oxidised antibodies or 
blocked by oxidised galactose. The blocking of unoccupied hydrazide functional groups 
by oxidised galactose was performed as per 2.4.3.2. Target antibody-NP conjugates 
were incubated with HEK293, LoVo and EA.hy926 cell lines and fluorescence quantified. 
 
Figure 6.11 demonstrates that significant increases in fluorescence were observed in 
LoVo cells incubated with both target antibody-NP conjugates (AbMNP) and galactose-
blocked target antibody-NP conjugate (Blocked AbMNP). AbMNP: 216% (p<0.0001) and 
Blocked AbMNP: 109% (p=0.0066).  
 
However, increase in fluorescence was also observed when both AbMNP and Blocked 
AbMNP conjugates were incubated with HEK293 cells. AbMNP: 184% (p<0.0001) and 
Blocked AbMNP: 118% (p=0.0001). In EA.hy926 cells, a 98% (p=0.0007) and 49% 
(p=0.0901) increase in fluorescence was observed with AbMNP and Blocked AbMNP 
respectively. Comparing AbMNP and Blocked AbMNP, increased fluorescence was 
observed in all three cell lines incubated with AbMNP. HEK293: 65% (p=0.0155), LoVo: 
106% (p=0.0082) and EA.hy926: 49% (p=0.0921). 
 
Additionally, a 170% increase in fluorescence was also observed when PDPH-25% 
maleimide functionalised NP conjugates were incubated with HEK293 cells (p<0.0001) 
(Figure 6.11). To highlight the impact of galactose-mediated blocking of hydrazide 
functional groups, no significant differences in fluorescence were detected when blocked 
PDPH - 25% maleimide functionalised NP conjugates were incubated with all three cell 
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lines. HEK293: 22% increase in fluorescence (p=0.7604), EA.hy926: 2% reduction 
(p>0.9999) and LoVo: 47% increase (p=0.4156) (Figure 6.11). 
 
Similar to the results described in 6.2.2.3, no significant differences in fluorescence were 
observed between the LoVo and control cell lines incubated with blocked target (anti-
CEA) antibody-NP conjugates. HEK293 vs. LoVo: 9% (p>0.9999) and EA.hy926 vs. 
LoVo: 60% (p=0.2488). 
 
 
Figure 6.11. Assessment of binding of target antibody-NP conjugate (AbMNP) 
against target and control cells using oxidised galactose to block 
unoccupied hydrazide functional groups on heterobifunctional crosslinker. 
Results represent mean values of at least 3 independent experiments with SD. 
Experiments were performed in triplicate. Fluorescence was normalised to cell 
media only treated cells. Statistically significant difference of fluorescence 
normalised to cell media only treated cells was considered at p<0.05 (*) and 
p<0.0001 (**). See 2.4.3.2 of Materials and Methods for the detailed protocol. 
Galactose-mediated blocking of unoccupied hydrazide functional groups did not 
appear to prevent non-specific binding of the antibody-NP conjugate to control cell 
lines. 
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6.2.3.3 Optimisation step 3: Assessing the effect of conjugation time 
between oxidised antibody and PDPH-MNP conjugate 
The oxidised anti-CEA antibody and PDPH-maleimide functionalised NP conjugates 
were incubated together for different time periods, to determine the optimum length of 
time for the conjugation reaction to occur as described in 2.4.3.3. Unconjugated anti-
CEA (target) antibodies were then removed from mixtures and the target antibody-NP 
conjugates were incubated with HEK293, LoVo and EA.hy926 cell lines and 
fluorescence quantified. 
 
Figure 6.12 shows that a significant increase (as compared to cell media only treated 
cells) in fluorescence intensities was found in all three cell lines that were incubated with 
target antibody-NP conjugates under conjugation reaction for all lengths of time (1, 2, 4 
and 8 hours)( (p<0.0001). 
 
Comparing the different cell lines, it was found that LoVo cells had increased 
fluorescence as compared to control cell lines, when incubated with antibody-NP 
conjugates under reaction for 1 and 2 hours. At 1hr - HEK293 vs. LoVo: 138% 
(p<0.0001) and EA.hy926 vs. LoVo: 66% (p=0.0001). At 2hr - HEK293 vs. LoVo: 124% 
(p<0.0001) and EA.hy926 vs. LoVo: 68% (p=0.0011). However, when LoVo cells were 
incubated with antibody-NP conjugates that were under reaction for longer (4 and 8 
hours), no significant increase in fluorescence was observed as compared to control cell 
lines . At 4hr - HEK293 vs. LoVo: 19% (p>0.9999) and EA.hy926 vs. LoVo: -20% 





Figure 6.12. Comparing binding of target antibody-NP conjugates where the 
antibody and PDPH-MNP have incubated for different time periods against 
target and control cell lines. Results represent mean values of at least 3 
independent experiments with SD. Experiments were performed in triplicate. 
Fluorescence was normalised to cell media only treated cells. Statistically 
significant difference of fluorescence between the target antibody-NP conjugates 
was considered at p<0.05 (*) and p<0.0001 (**). See 2.4.3.3 of Materials and 
Methods for the detailed protocol. Significant increases in fluorescence intensities 
was found in all three cell lines incubated with target antibody-NP conjugates at all 
incubation durations. 
 
6.2.3.4 Optimisation step 4: Investigating the effect of increasing the 
amount of Target (anti-CEA) antibodies incubated with PDPH-MNP in 
conjugation reactions 
The amount of oxidised anti-CEA (target) antibody mixed with the PDPH – maleimide 
functionalised NPs was increased (Increased Ab:MNP) to determine whether this 
practical step could improve the efficiency of the antibody-NP system. Blocking of 
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increased Ab:MNP with galactose as well as the additional step of extracting excess 
blocking agent were also evaluated as per 2.4.3.4. Antibody-NP conjugates were 
incubated with HEK293, LoVo and EA.hy926 cell lines and fluorescence quantified. 
 
Increase in fluorescence compared to cell media only treated cells was found when all 
three cell lines were incubated with increased Ab:MNP. HEK293: 31% (p=0.0104), 
EA.hy926: 56% (p=0.0115) and LoVo: 78% (p<0.0001) (Figure 6.13). Similarly, increase 
in fluorescence was also observed when all three cell lines were incubated with AbMNP 
of normal amount of oxidised anti-CEA. HEK293: 61% (p<0.0001), EA.hy926: 79% 
(p<0.0001) and LoVo: 97% (p<0.0001). 
 
With the inclusion of galactose-mediated blocking of increased Ab:MNP, the increased 
fluorescence in cells was retained. HEK293: 64% (p<0.0001), EA.hy926: 60% 
(p=0.0052) and LoVo: 45% (p=0.0018). However, when antibody-NP conjugates were 
filtered to remove excess galactose (blocking agent), fluorescence had reduced and no 
significant difference in fluorescence was observed as compared to cell media only 
treated cells. HEK293: 13% (p=0.7113), EA.hy926: 18% (p=0.8753) and LoVo: 18% 
(p=0.5981) (Figure 6.13). The increased amount of oxidised anti-CEA antibodies in 
increased Ab:MNP mixtures was done to ensure that all PDPH-MNP were conjugated to 
antibodies, and therefore increase AbMNP binding to LoVo (CEA-positive) cells. 
However, a 19% reduction in fluorescence was observed in increased Ab:MNP treated 
LoVo cells compared to AbMNP treated cells (p=0.5487). Galactose-mediated blocking 
reduced fluorescence by 52% (p=0.0002) in increased Ab:MNP treated LoVo cells and 




Figure 6.13. Comparison of the binding of target antibody-NP conjugates (AbMNP) 
with different ratios of antibody to PDPH – maleimide functionalised NP 
conjugates and different post conjugation processes against target and 
control cell lines. Results represent mean values of at least 3 independent 
experiments with SD. Experiments were performed in triplicate. Fluorescence was 
normalised to cell media only treated cells. Statistically significant difference of 
fluorescence normalised to cell media only treated cells was considered at p<0.05 
(*) and p<0.0001 (**). See 2.4.3.4 of Materials and Methods for the detailed 
protocol. Increases in fluorescence intensity were seen when all three cell lines 
were incubated with increased concentration of antibody-NP conjugate.  
 
6.2.3.5 Optimisation step 5: Investigating optimum dilution of 
maleimide functionalised nanoparticle in conjugation reaction 
Bare maleimide functionalised NPs were diluted with phosphate buffered saline (PBS) 
prior to conjugation with oxidised target (anti-CEA) antibodies, as described in 2.4.3.5. 
AbMNP refers to standard target antibody-NP conjugates with no dilution of maleimide 
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functionalised NPs prior to conjugation. Antibody-NP conjugates were incubated with 
HEK293, LoVo and EA.hy926 cell lines and fluorescence quantified. 
 
At all AbMNP dilutions, a significant increase in fluorescence was only observed in the 
CEA-positive LoVo cells as compared to cell media only treated cells. No dilution: 175% 
(p<0.0001), 90% dilution: 185% (p<0.0001), 80% dilution: 189% (p<0.0001) and 70% 
dilution: 173% (p<0.0001)(Figure 6.14). No differences in fluorescence were observed in 
the control cell lines. 
 
When comparing the different AbMNP dilutions, no significant differences in 
fluorescence were observed in LoVo cells. No dilution vs. 90% dilution: 10% difference in 
fluorescence (p=0.9982), vs. 80% dilution: 14% (p=0.9901), vs. 70% dilution: 2% 
(p=0.9999). 90% dilution vs. 80% dilution: 4% (p>0.9999), vs. 70% dilution: 12% 




Figure 6.14. Comparison of the binding of target antibody-NP conjugates (AbMNP) 
with different dilutions of maleimide functionalised NP used in the 
conjugation reaction against target and control cell lines. Results represent 
mean values of at least 3 independent experiments with SD. Experiments were 
performed in triplicate. Fluorescence was normalised to cell media only treated 
cells. Statistically significant difference of fluorescence normalised to cell media 
only treated cells was considered at p<0.0001 (**). See 2.4.3.5 of Materials and 
Methods for the detailed protocol. Significant increases in fluorescence intensity 
were only seen in target cell line with the target antibody-NP conjugate at all 
dilutions of MNP. 
 
6.2.3.6 Optimisation step 6: The influence of wash cycles following the 
incubation of cells with conjugates 
Plates of target (LoVo) and control (EA.hy926 and HEK293) cell lines were seeded as 
per 2.4.3.6 and subjected to different numbers of wash cycles with PBS from 2 cycles to 
4 cycles. Antibody-NP conjugates were incubated with HEK293, LoVo and EA.hy926 cell 
lines and AbMNP fluorescence was quantified following PBS wash steps. 
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After 2 wash cycles, a 16% increase in fluorescence was observed in LoVo cells 
incubated with target antibody-NP conjugates (AbMNP) (p=0.0006) as compared to cell 
media only treated cells. This increase in fluorescence (16%, p=0.0084) was also 
observed in one other control cell line, HEK293 (Figure 6.15). Further PBS washes were 
found to mildly reduce the intensity of fluorescence in the target cell line. 2 wash cycles 
vs. 3 wash cycles: 9% (p=0.2950). 2 wash cycles vs. 4 wash cycles: 8% (p=0.6094).  
 
 
Figure 6.15. Comparison of the binding of target antibody-NP conjugates (AbMNP) 
having undergone different numbers of wash cycles against target and 
control cell lines. Results represent mean values of at least 3 independent 
experiments with SD. Experiments were performed in triplicate. Fluorescence was 
normalised to cell media only treated cells . Statistically significant difference of 
fluorescence normalised to cell media only treated cells was considered at p<0.05 
(*) and p<0.0001 (**). See 2.4.3.6 of Materials and Methods for the detailed 
protocol. These results suggest that more than two wash cycles reduced 
fluorescence intensities in LoVo and both control cell lines. 
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6.2.3.7 Optimisation step 7: Investigating the different parameters of 
incubation 
Target (LoVo) and control (EA.hy926 and HEK293) cell lines were seeded as per 2.4.3.7 
and incubated under different conditions. Cells were either incubated for 1 hour or 
overnight at either 4C, room temperature or 37C. Antibody-NP conjugates were 
incubated with HEK293, LoVo and EA.hy926 cell lines and fluorescence quantified. 
 
Overnight incubation at 37C was found to yield optimal binding in LoVo cells incubated 
with both unblocked and galactose-blocked target antibody-NP conjugates (AbMNP), at 
45% and 49% increase in fluorescence as compared to cell media only treated cells 
(p<0.0001 for both unblocked and galactose-blocked AbMNP) (Figure 6.16F). However, 
increased fluorescence was also observed in both control cell lines incubated overnight 
at 37C with both unblocked and galactose-blocked AbMNP. HEK293-unblocked 
AbMNP: 39% (p=0.0002) and HEK293-blocked AbMNP: 46% (p<0.0001). EA.hy926-
unblocked AbMNP: 27% (p=0.0048) and EA.hy926-blocked AbMNP: 30% (p=0.0018) 
(Figure 6.16F). 
 
No significant differences in fluorescence intensities were observed for either AbMNP 
variations on the target cell line at any other incubation conditions (Figure 6.16A-E). 
Unblocked AbMNP: 1 hour at 4C – 2% (p>0.9999), 1 hour at room temperature – 2% 
(p>0.9999), 1 hour at 37C – 1% (p>0.9999), overnight at 4C – 9% (p=0.2744) and 
overnight at room temperature – 1% (p>0.9999). Galactose-blocked AbMNP: 1 hour at 
4C – 0% (p>0.9999), 1 hour at room temperature – 5% (p>0.9999), 1 hour at 37C – 





Figure 6.16. Comparison of the binding of unblocked and blocked target antibody-
NP conjugates (AbMNP) under different incubation conditions. A) Incubation 
for 1 hour at 4C, B) Incubation for 1 hour at room temperature, C) Incubation for 1 
hour at 37C, D) Incubation overnight at 4C, E) Incubation overnight at room 
temperature, F) Incubation overnight at 37C. Results represent mean values of at 
least 3 independent experiments with SD. Experiments were performed in 
triplicate. Fluorescence was normalised to cell media only treated cells. 
Statistically significant difference of fluorescence normalised to cell media only 
treated cells was considered at p<0.05 (*) and p<0.0001 (**). See 2.4.3.7 of 
Materials and Methods for the detailed protocol. Overnight incubation at 37C is 
the best incubation condition for antibody-NP conjugates on cells although non-
specific binding is still present and observed in both control cell lines, even with 
galactose-mediated blocking of unoccupied hydrazide functional groups. 
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In the control cell lines, a significant increase in fluorescence was only observed in 
EA.hy926 cells incubated with both unblocked and galactose-blocked AbMNP overnight 
at room temperature. Unblocked AbMNP: 20% (p=0.0006) and galactose-blocked 
AbMNP: 33% (p<0.0001) (Figure 6.16E). Apart from this, no significant differences in 
fluorescence was observed in control cell lines incubated with either AbMNP variants at 
the remaining incubation parameters (Figure 6.16). 
 
6.2.4 Testing target and control antibody – nanoparticle 
conjugates against target and control cell lines using streptavidin 
functionalised nanoparticle 
A different conjugation strategy utilising biotin – streptavidin conjugation chemistry was 
explored using streptavidin functionalised CN-PPV/PLGA-PEG NPs, supplied by KCL. 
Conjugation of the streptavidin functionalised NPs was achieved through biotinylated 
target (anti-CEA) and control (anti-CD31) antibodies. Biotinylation of the antibodies was 
carried out as per 2.2.2.6. The ability of this system to target the tissue of interest was 
investigated by testing both the target and control antibody-streptavidin functionalised 
NP conjugates (CEA AbSNP and CD31 AbSNP respectively) against LoVo, EA.hy926 
and HEK293 cell lines as described in protocol 2.4.4.  
 
As shown in Figure 6.17, a 37% increase in fluorescence was observed when CEA 
AbSNP was incubated with the target (LoVo, CEA-positive) cell line as compared to cell 
media only treated cells (p<0.0001). However, increase in fluorescence was also 
observed when the control cell lines were incubated with CEA AbSNP. HEK293: 17% 
(p=0.8103) and EA.hy926: 34% (p=0.0280). No significant differences in fluorescence 
was found between target and control cell lines. HEK293 vs. LoVo: 20% (p=0.3557) and 
EA.hy926 vs. LoVo: 3% (p>0.9999).  
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Similarly, an increase (24%) in fluorescence was observed when LoVo cells were 
incubated with the control CD31 AbSNP (p=0.0044). This increase was also observed in 
control cell lines incubated with CD31 AbSNP. HEK293: 19% (p=0.7350) and EA.hy926: 
31% (p=0.0486) (Figure 6.17). No significant differences in fluorescence was found 
between target and control cell lines. HEK293 vs. LoVo: 5% (p>0.9999) and EA.hy926 
vs. LoVo: 7% (p>0.9999). 
 
A non-significant 13% increase in fluorescence was found between CEA AbSNP and 
CD31 AbSNP incubated LoVo cells (p=0.1682). 
 
 
Figure 6.17. Binding of target and control antibody-streptavidin functionalised NP 
conjugates (AbSNP) against target and control cell lines. Results represent 
mean values of at least 3 independent experiments with SD. Experiments were 
performed in triplicate. Statistically significant difference of fluorescence 
normalised to cell media only treated cells was considered at p<0.05 (*) and 
p<0.0001 (**). See 2.4.4 of Materials and Methods for the detailed protocol. 
Significant increases in fluorescence intensity are seen with both the target and 
control AbSNPs to all cell lines indicating non-specific binding. 
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6.2.5 Conjugation of anti-CEA affimer to maleimide 
functionalised nanoparticle 
6.2.5.1 Testing target and control affimers on fixed cells 
Target (anti-CEA) and control (ySUMO) affimers underwent biotinylation for the purpose 
of testing against target (LoVo) and control (HEK293) cell lines. Immunofluorescence 
and fluorescent imaging was performed as described in 2.2.3.  
 
As shown in Figure 6.18, green fluorescence was observed when LoVo cells were 
incubated with the anti-CEA affimer and no fluorescence was observed when incubated 
with the control affimer. No affimer specific fluorescence was observed in HEK293 cells 




Figure 6.18. Binding of target and control affimers on target and control cell lines 
using immunofluorescence. Blue fluorescence is DAPI. Green fluorescence is 
Streptavidin DyLight 488 protein using FITC filter. Magnification x63. Scalebar = 
10 m. 0.1% bovine serum albumin served as a control. Images in this figure are 
representative of at least 3 independent experiments. See 2.2.3 of Materials and 
Methods for the detailed protocol. The target anti-CEA affimer binds selectively to 
the LoVo cell line and the control affimer does not bind selectively to either the 
control or target cell line. 
 
6.2.5.2 Testing variants of anti-CEA affimer maleimide functionalised 
nanoparticle conjugates 
Control (ySUMO), target (anti-CEA II)  and target (anti-CEA III) affimer-conjugated NPs 
(AffMNP), as well as a mixture of anti-CEA II and anti-CEA III affimer-conjugated NPs 
were incubated with target (LoVo) and control (HEK293) cell lines. Protocol was 
performed as per 2.4.5.1. Fluorescence from AffMNPs was measured and quantified. 
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As shown in Figure 6.19, a 9% (p>0.9999) and 32% (p>0.9999) increase in fluorescence 
intensity was observed in LoVo cells incubated with anti-CEA II AffMNP and anti-CEA III 
AffMNP as compared to cell media only treated cells. In addition, a 32% (p>0.9999) 
increase in fluorescence was also observed in anti-CEA II/III AffMNP incubated LoVo 
cells. No significant difference (7%) in fluorescence was observed in control AffMNP 
incubated LoVo cells (p>0.9999). 
 
In control HEK293 cells no significant fluorescence was observed when incubated with 
anti-CEA II AffMNP (3% increase, p>0.9999), anti-CEA III AffMNP (4% increase, 
p>0.9999) and anti-CEA II/III AffMNP (3% increase, p>0.9999). Upon comparing anti-
CEA II/III AffMNP incubated HEK293 and LoVo cells, a 29% (p=0.0338) increase in 
fluorescence was found in anti-CEA II/III AffMNP incubated LoVo cells (Figure 6.19). 
 
The anti-CEA affimers were found to be mildly specific in binding to LoVo cells when 
comparing control and anti-CEA AffMNP incubated LoVo cells. Control AffMNP vs. anti-
CEA II AffMNP: 16% increase in anti-CEA II AffMNP (p>0.9999). Control AffMNP vs. 
anti-CEA III AffMNP: 39% increase in anti-CEA III AffMNP (p>0.8499). Control AffMNP 
vs. anti-CEA II/III AffMNP: 39% increase in anti-CEA II/III AffMNP (p>0.8422) (Figure 
6.19). 
 




Figure 6.19. Comparison of binding of control and various target affimer-NP 
conjugates (AffMNP) against target and control cell lines. Results represent 
mean values of at least 3 independent experiments with SD. Experiments were 
performed in triplicate. Statistically significant difference of fluorescence 
normalised to cell media only treated cells was considered at p<0.05 (*) and 
p<0.0001 (**). See 2.4.5.1 of Materials and Methods for the detailed protocol. The 
increase in fluorescence intensity is greater when the target cell line was incubated 
with either anti-CEA III AffMNP or anti-CEAII/III AffMNP mixture, as compared to 
anti-CEA II AffMNP alone. There was also little non-specific binding of any of the 
target AffMNPs to the control cell line. 
 
6.2.5.3 Comparing different incubation settings for affimer-conjugated 
nanoparticle 
To determine the optimum incubation settings of anti-CEA II/III affimer-conjugated NPs 
on LoVo cells, a binding assay was carried out as per the protocol described in 2.4.5.2. 
 
Figure 6.20 shows that a significant increase in fluorescence was observed when LoVo 
cells were incubated overnight with anti-CEA II/III AffMNP at both temperatures as 
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compared to cell media only treated cells. Room temperature: 19% (p<0.0001) and 4C: 
17% (p=0.0003). No non-significant difference (2%) was observed between the two 
overnight temperatures (p=0.9844). 
 
No significant difference in fluorescence compared to cell media only treated cells was 
observed when LoVo cells were incubated with anti-CEA II/III AffMNP for 2 hours at 









Figure 6.20. Assessing optimum conditions for binding of affimer-conjugated NP 
(AffMNP) against the target (LoVo) cell line. Results represent mean values of 
at least 3 independent experiments with SD. Experiments were performed in 
triplicate. Fluorescence was normalised to cell media only treated cells. 
Statistically significant difference of fluorescence normalised to cell media only 
treated cells was considered at p<0.0001 (*). See 2.4.5.2 of Materials and Methods 
for the detailed protocol. Incubation of the AffMNP with the LoVo cells overnight at 
room temperature showed the greatest increase in fluorescence intensity. 
 
6.2.5.4 Testing target and control affimer–nanoparticle conjugates 
against target and control cell lines 
Control and target anti-CEA II/III affimer-conjugated NPs were tested against control 
(HEK293) and target (LoVo) cell lines using the protocol described in 2.4.5.3. 
 
Figure 6.21 shows that a 56% increase in fluorescence was observed when LoVo cells 
were incubated with anti-CEA II/III AffMNP as compared to cell media only treated cells. 
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(p<0.0001). No significant difference (14%, p=0.3348) was observed when HEK293 cells 
were incubated with anti-CEA II/III AffMNP. A significant difference of 42%, was found 
between HEK293 and LoVo cells incubated with anti-CEA II/III AffMNP (p<0.0001). 
 
No significant increase in fluorescence was observed when either cell lines were 
incubated with control AffMNP. LoVo: 16% (p=0.2953) and HEK293: 4% (p=0.9770) 
Figure 6.21. LoVo cells were found to be 40% more fluorescent when incubated with 
anti-CEA II/III AffMNP as compared to control AffMNP (p<0.0001). Whereas, a 11% 







Figure 6.21. Binding of target and control affimer-conjugated NPs (AffMNP) 
against target and control cell lines. Results represent mean values of at least 3 
independent experiments with SD. Experiments were performed in triplicate. 
Statistically significant difference of fluorescence normalised to cell media only 
treated cells was considered at p<0.0001 (**). See 2.4.5.3 of Materials and 
Methods for the detailed protocol. A significant increase in fluorescence intensity is 
seen only when the target AffMNP is incubated with the target cell line (LoVo). 
 
Figure 6.22 shows that red CN-PPV/PLGA-PEG NP fluorescence is seen in anti-CEA 
AffMNP incubated LoVo cells. No red CN-PPV/PLGA-PEG NP fluorescence was 
observed when the target cell line was incubated with control affimer–NP conjugates. 
Red fluorescence from CN-PPV/PLGA-PEG NPs was not seen when either the target or 
control affimer-NP conjugates were incubated with the control cell line HEK293, 




Figure 6.22. Binding of target and control affimer-NP conjugates (AffMNP) on 
target and control cell lines using immunofluorescence on fixed cells. Blue 
fluorescence is DAPI using DAPI filter. Red fluorescence is CN-PPV NP using 5-
ALA filter. Magnification x63. Scalebar = 10 m. 0.5% skimmed milk blocking 
served as control. Images in this figure are representative of at least 3 independent 
experiments. See 2.4.5.3 of Materials and Methods for the detailed protocol. The 
presence of red fluorescence indicates target affimer-NP conjugates selectively 
bind to LoVo cells, not the control HEK293 cell line. 
 
6.3 Discussion 
The maleimide functional group contains a reactive imide functional group that can 
undergo an addition reaction with sulfhydryl groups to form a very stable thioether 
linkage(233) which cannot be broken under normal physiological conditions. Maleimide 
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also reacts ~1000 fold faster with sulfhydryl groups than with amine groups between pH 
6.5-7.5 and is a popular choice for the conjugation of cysteine-containing compounds 
such as proteins(274). Chemical and structural stability with high degree of specificity 
and reactivity of this thioether bond are the reasons why maleimide was chosen in this 
research project as the terminal functional group for conjugating the targeting agents to 
CN-PPV/PLGA-PEG NPs. As discussed in 4.3, the reduction of antibodies to produce 
half-antibody fragments with free sulfhydryl groups was not a viable route for conjugation 
to maleimide functionalised NPs. Therefore, an alternative conjugation method through 
the potential use of a heterobifunctional crosslinker was assessed. 
 
Heterobifunctional crosslinkers have different chemically reactive groups at each end of 
the molecular structure, that can bind to different functional groups on target proteins or 
macromolecules. This is especially useful for site-directed and orientated conjugation 
reactions(275). As previously discussed in 4.3, orientated conjugation between NPs and 
targeting agents is desirable to maintain the ability of targeting agents to effectively bind 
to their target antigens without compromised binding affinity. The heterobifunctional 
crosslinker, 3-(2-pyridyldithio)propionyl hydrazide (PDPH), was chosen for this project as 
previous studies have successfully shown that it can be used in the preparation of 
antibody conjugates for clinical applications(276).  
 
One of the purposes of PDPH is to act as a thiolation reagent providing sulfhydryl 
functional groups for conjugation to oxidised glycoproteins(233). As shown in Figure 6.1, 
PDPH contains sulfhydryl-reactive pyridyldithiol and aldehyde-reactive hydrazide 
functional groups at either end of the molecule. Hydrazide functional groups will 
spontaneously react with oxidised glycoprotein side chains on antibodies forming stable 
hydrazone bonds. When the pyridyldithiol groups have been displaced, free sulfhydryl 
233 
groups become exposed and react with double bonds in maleimide functional groups 
subsequently forming thioether bonds. 
 
The conjugation of both anti-CEA and anti-CD31 antibodies to maleimide functionalised 
CN-PPV/PLGA-PEG NPs through the use of the PDPH heterobifunctional crosslinker 
was investigated. Immunofluorescence studies were performed to confirm the binding of 
oxidised antibodies to PDPH. Neither the oxidised antibodies nor the heterobifunctional 
crosslinker are inherently fluorescent, therefore fluorescence in cells should only be 
observed if oxidised antibodies have successfully bound to PDPH which had been 
labelled with a maleimide functionalised green fluorescent dye. The presence of green 
fluorescence in target (LoVo) and both control (EA.hy926 and HEK293) cell lines 
incubated with anti-CEA antibody–dye labelled PDPH conjugates suggests that non-
specific binding of conjugates to cells had occurred (Figure 6.2).  
 
This is further confirmed in  Figure 6.3, which shows non-specific binding of anti-CEA 
antibody–dye labelled PDPH conjugates to all cell lines despite bovine serum albumin 
being used to reduce the possibility of non-specific binding instead of 0.5% skimmed 
milk solution. The individual components of the conjugation process were then 
investigated in order to attempt to identify which part of the conjugate was responsible 
for the non-specific binding. 
 
Figure 6.4 shows that in the presence of the DyLightTM 488 Maleimide dye, green 
fluorescence is seen on both the target and control cell lines. This occurs even when the 
DyLightTM dye’s maleimide functional group is blocked by either PDPH or cysteine. 
Sulfhydryl groups are popular for conjugation as they are present in most proteins and 
are located in the side chains of the amino acid, cysteine(277–279). However, this could 
mean that the proteins within the cell surface membrane (i.e. tyrosine kinase receptors 
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such as the insulin and epidermal growth factor receptors, cell adhesion molecules and 
G protein coupled receptors such as the beta-2 adrenergic receptor) would be targets for 
any maleimide functional group. The findings depicted in Figure 6.4 could therefore 
represent the unintentional binding of unoccupied maleimide functional groups on the 
DyLightTM dye to these cell surface membrane bound proteins. The fluorescence seen 
with blocked DyLightTM 488 Maleimide dye and PDPH-DyLightTM 488 Maleimide dye 
conjugates are similar and less intense than fluorescence observed with the unblocked 
DyLightTM 488 Maleimide dye alone. This could indicate that molecules of DyLightTM dye 
had not been sufficiently saturated with either cysteine or PDPH, leaving unoccupied 
maleimide functional groups available to bind to the cell surface proteins. Figure 6.4 also 
shows that no fluorescence was seen with either the oxidised antibody alone nor the 
heterobifunctional crosslinker alone, confirming that neither of these are inherently 
fluorescent and are therefore not responsible for the aberrant fluorescence. Following 
this, the DyLightTM 488 Maleimide dye was no longer used for visualising the binding of 
antibody-PDPH to cells. The use of PDPH was continued in the antibody-NP conjugation 
process. 
 
Figure 6.5 demonstrates that the optimal conjugation time for the PDPH crosslinker to 
bind to maleimide functionalised NPs was 30 minutes, therefore this was used in all 
subsequent experiments. After determining this step of the conjugation protocol, binding 
assays and immunofluorescence studies were carried out to confirm the conjugation of 
anti-CEA antibodies to 25% maleimide functionalised NPs (Figure 6.6 and Figure 6.7). 
Conjugation was found to be successful using this approach  and therefore further 
assays and immunofluorescence studies were performed testing both the target (anti-
CEA) and control (anti-CD31) antibody-NP conjugates against all three cell lines (LoVo, 
EA.hy926 and HEK293) (Figure 6.8 and Figure 6.9). 
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In theory, anti-CEA conjugates should only bind to CEA-positive LoVo cells and anti-
CD31 conjugates should only bind to CD31-positive EA.hy926 cells. Neither antibody 
conjugates should bind to HEK293 cells. Figure 6.8 shows significant differences in 
fluorescence when the target (anti-CEA) and control (anti-CD31) antibody-NP 
conjugates are incubated with the target (LoVo) and control (EA.hy926 and HEK293) cell 
lines respectively. However, Figure 6.8 also shows significant differences in fluorescence 
when the target and control antibody-NP conjugates are incubated with their respective 
control cell lines indicating non-specific binding of both antibody-NP conjugates. 
 
To investigate the cause of non-specific binding of antibody conjugates to their control 
cell lines different optimisation steps of the conjugation protocol were investigated 
(Figure 6.10 to Figure 6.16). Due to logistical reasons, only the target antibody-NP 
conjugate was used for the optimisation experiments as there was a limited supply of the 
target antibody and it was not financially prudent to use large quantities of the control 
antibody for optimisation purposes. 
 
Firstly, different extraction methods to remove excess unbound oxidised anti-CEA 
antibodies were compared (Figure 6.10). Centrifugation was found to be the most 
effective method in removing excess oxidised anti-CEA antibody, thereby improving the 
binding of anti-CEA antibody-NP conjugates to LoVo cells by reducing the binding of free 
oxidised antibodies. This is in comparison to the use of no extraction methods where the 
low levels of difference in fluorescence between anti-CEA AbMNP/free unbound oxidised 
anti-CEA antibody mixture treated LoVo cells and cell media only LoVo cells were seen. 
This suggests that free oxidised anti-CEA antibodies are occupying cell surface CEA 
antigens and preventing the anti-CEA antibody-NP conjugates from being able to bind. 
Hydrazide functional groups in PDPH can react with free aldehyde groups if they are not 
occupied by oxidised glycoprotein side chains on antibodies. Therefore, unbonded 
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hydrazide functional groups could potentially and inadvertently react and bind to 
aldehyde groups found on glycoproteins within the extracellular domain of cell 
membranes, such as immunoglobulins(280). Therefore, the additional step of blocking 
unoccupied hydrazide functional groups with galactose was evaluated in the conjugation 
protocol (Figure 6.11). Non-specific binding of anti-CEA antibody-NP conjugates was 
seen on the two control cell lines. However, following the addition of galactose blocking 
to block unoccupied hydrazide functional groups a decrease in fluorescence was 
observed in both control cell lines. Although this did not improve specificity of anti-CEA 
antibody-NP conjugate binding to control cell lines, these findings indicate that 
unoccupied hydrazide functional groups on PDPH crosslinkers may partially be 
responsible for non-specific binding of anti-CEA antibody-NP conjugates to control cell 
lines. Furthermore, from the findings in Figure 6.11, the addition of galactose-mediated 
blocking reduced the ability of anti-CEA antibody-NP conjugates to bind to LoVo cells. 
The reasons for this phenomenon are currently unclear and did not offer a solution to 
improve antibody-NP conjugate binding specificity. 
 
Next, the optimum incubation time for conjugation when oxidised anti-CEA antibodies 
and PDPH-MNP conjugates are mixed together was determined (Figure 6.12). No 
substantial improvements in reducing non-specific binding were found by altering the 
length of time the antibodies had to conjugate and bind to the PDPH-MNP conjugates. A 
minor difference was found between 1 and 2 hours, therefore for all subsequent 
experiments the antibodies were mixed with PDPH-MNP conjugates for 1 hour. 
 
Following on, the next optimisation step was to assess whether increasing the amount of 
oxidised anti-CEA antibody in the conjugation mixture could improve the efficiency of the 
conjugation system. It was found that increasing the amount of anti-CEA antibody in the 
conjugation reaction did not improve anti-CEA antibody-NP conjugate binding to LoVo 
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cells and also did not decrease the non-specific binding of anti-CEA antibody-NP 
conjugates to control cell lines (Figure 6.13). The addition of galactose blocking agent to 
the increased anti-CEA antibody-NP conjugates was found to have further negatively 
impacted binding to LoVo cells, which is similar to the findings described above in the 
addition of galactose to block unoccupied hydrazide functional groups. In addition, 
galactose blocking of increased anti-CEA antibody-NP conjugates increased non-
specific binding to control cell lines. Subsequently, increasing the amount of oxidised 
anti-CEA antibody in conjugation reactions was not considered. 
 
The next optimisation step was to dilute the maleimide functionalised NPs used in 
conjugation reactions to assess whether this could improve the binding specificity of anti-
CEA antibody-NP conjugates (Figure 6.14). The results contradict the findings in Figure 
6.8. For every dilution of maleimide functionalised NPs used in this optimisation step, 
anti-CEA antibody-NP conjugates bound appropriately to LoVo cells with no significant 
binding to either of the two control cell lines. The only difference between the findings in 
Figure 6.8 and Figure 6.14 is the dilution of NPs. Therefore, it is not clear why specific 
binding was observed as the antibody-NP conjugates were only found to bind to LoVo 
cells. No significant difference in the intensity of fluorescence was measured between 
the different dilutions of the maleimide functionalised NPs. There was no clear 
advantage of diluting the MNPs in the conjugation process. 
 
The next step that was investigated was the influence of post-conjugation reaction PBS 
wash cycles (Figure 6.15). PBS-mediated washing of cells is important to remove 
unbound antibody-NP conjugates and to reduce non-specific binding and fluorescence in 
control cell lines only. As shown in Figure 6.15, it was found that the number of wash 
cycles exceeding two washes reduced fluorescence intensities in LoVo and both control 
cell lines. It could be postulated that the reasons for this finding may be that the anti-CEA 
238 
antibody-NP conjugates were not effectively binding to CEA antigens on LoVo cells. The 
fluorescence observed in control cell lines could have possibly been due to the 
inadequate removal of conjugates from cells following PBS washes. Although in this 
research project I was unable to examine the influence of one wash cycle or the possible 
use of another washing agent such as Hank's Balanced Salt Solution. These are factors 
to consider for future in vitro antibody-NP conjugation experiments that could address 
the non-specific binding that has been observed. 
 
Optimum conditions for incubation of anti-CEA antibody-NP conjugates on cell lines 
were also investigated (Figure 6.16). From the results, it is clear that overnight 
incubation at 37C resulted in the best incubation conditions for antibody-NP conjugates 
on cells. However, non-specific binding was still present and observed in both control 
cell lines, even following the addition of galactose to block unoccupied hydrazide 
functional groups. As described above, the addition of galactose decreased the change 
in fluorescence seen when blocked anti-CEA antibody-NP conjugates were incubated 
with all three cell lines as compared to unblocked anti-CEA antibody-NP conjugates 
(Figure 6.11). The inclusion of overnight incubation at 37C alongside galactose blocking 
further increased the change in fluorescence between blocked and unblocked antibody-
NP conjugates. 
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The purpose of the different optimisation steps of the antibody-NP conjugation process 
was an attempt to elucidate factors involved in the non-specific binding and varying 
levels of fluorescence. Unfortunately, definitive evidence of any underlying cause has not 
been found during the scope of this research project.  
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One potential factor that could be causing non-specific binding is the PEGylation of CN-
PPV/PLGA-PEG NPs. A disadvantage of NP PEGylation is that the steric hinderance 
and neutral surface charge, which helps PEGylated nanomedicines to evade MPS, can 
hinder extracellular interactions and reduce binding of the nanomedicines to target 
tissues and reduce intracellular uptake(281,282). A study by Woodle et al.(283) found 
that PEGylation of antibody-conjugated liposomes has an adverse effect on the 
antibody, preventing it from binding to its target antigen and the authors propose that 
alternative targeting agents such as peptides or oligosaccharides may improve binding 
to target tissues. Jokerst et al.(282) found that using functionalised PEG (such as 
succimide-, maleimide- or alkyne-functional groups) for conjugation to targeting agents 
could increase non-specific binding due to the electrical surface charges generated by 
the functional group on the terminal end of the PEG molecule. If the functional group 
causes the NP to become positively or, in particular, negatively charged, then the NP will 
non-specifically bind to protein structures(284). However, Schneider et al.(285) found 
that PEGylation of their antibody-NP conjugates reduced non-specific binding to cerebral 
extracellular matrix. Their study conjugated the monoclonal antibody, ITEM4, to 
PEGylated and non-PEGylated carboxylate-modified polystyrene NPs to actively target 
Fn14. Fn14 is a cell surface receptor that is upregulated in glioblastoma tumours. The 
authors tested both the non-PEGylated and PEGylated antibody-NP conjugates against 
rodent brain extracellular matrix components to determine whether non-specific binding 
was present. The non-PEGylated Fn14 antibody-NP bound irreversibly to the 
extracellular matrix components whereas minimal non-specific interactions between the 
PEGylated Fn14 antibody-NP conjugates and extracellular matrix components were 
observed. 
 
Another potential cause for non-specific binding of antibody-NP conjugates is the 
physical shape of the NP, which may influence the specificity and affinity of the 
antibody’s interactions with their target antigens. Barua et al.(286) compared the binding 
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of bare and Trastuzumab (anti-HER2 receptor monoclonal antibody)-coated antibody 
nanorods and nanospheres to HER2+ (BT-474 and SK-BR-3) and HER2- (MDA-MB-
231) breast cancer cell lines. Their study showed that the Trastuzumab-coated antibody 
nanorods exhibited increased binding to the HER2+ cell lines and decreased binding to 
HER2- cell lines, as compared to the Trastuzumab-coated antibody nanospheres. This 
study demonstrated that nanomedicines of similar chemical properties but different 
physical and structural properties can substantially influence the binding of the 
nanomedicines to target cells and antigens. 
 
During this research project, it was found that the average increase in fluorescence was 
187% (range: 90% – 252%) when anti-CEA antibody-NP conjugates were incubated with 
CEA-positive LoVo cells as compared to cell media only treated cells, when 
accumulating the results for optimisation steps 1 to 5. However, for optimisation steps 6 
and 7 the average increase in fluorescence was 37% (range: 16% - 49%). 
Characterisation of the non-functionalised NP was conducted over time (refer to Figure 
5.5) and there was no evidence of a decrease in the intensity of non-functionalised NP 
fluorescence. During this research project, non-functionalised NPs were stored in 
deionised distilled water and antibody-NP conjugates were stored in cell media solution. 
It would be interesting to observe the impact of the solutions used to store NPs on the 
absorption spectra of the functionalised CN-PPV/PLGA-PEG NPs over time. 
 
The results depicted in Figure 6.8 exhibit little non-specific binding of the bare 25% 
maleimide functionalised NP to all three cell lines, which is in keeping with the results 
from previous non-specific binding experiments (refer to Figure 5.11 and Figure 5.12). 
Substantial increased fluorescence was observed when bare 25% maleimide 
functionalised NPs were incubated with the three cell lines (Figure 6.14). Similarly, 
significant increase in fluorescence, as compared to cell media only treated cells, was 
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also seen when bare 25% maleimide functionalised NPs were incubated in all cell lines 
for all optimisation experiments (Figure 6.11, Figure 6.12, Figure 6.13 and Figure 6.15). 
However, no increase in fluorescence was observed when bare streptavidin 
functionalised NPs were incubated with the three cell lines (Figure 6.17). Figure 6.16F 
also shows that there was significant increase in fluorescence when bare maleimide 
functionalised NPs were incubated with HEK293 cells overnight at 37C. 
 
As previously discussed in 5.3, other studies have observed the non-specific binding of 
NPs to cell lines. These studies have proposed that this could be due to negatively 
charged PEG(157), or the high lipid solubility of PEG enabling it to be absorbed into the 
cell surface membrane(269). Although it was not explored in this research project, the 
effect of PEG and the binding of bare 25% maleimide functionalised CN-PPV/PLGA-
PEG NPs will need to be further investigated. 
 
A possible reason for non-specific binding of the antibody-NP conjugates and bare 
maleimide functionalised NPs could be the maleimide functional groups. Excess or 
unoccupied functional groups can lead to increased non-specific binding(287). Although 
maleimide reactions are exclusive to sulfhydryl groups in the pH range 6.5-7.5, if the cell 
media environment become more basic in pH>8, then the reactivity and likelihood of 
maleimide functional groups reacting with amine groups is significantly increased(233). 
The maleimide may then react with free amine groups on cell surface proteins. Some 
proteins within the cell surface membrane, such as the beta-2 adrenergic receptor and 
the epidermal growth factor receptor, have exposed free sulfhydryl groups(288) which 
may bind to unoccupied maleimide functional groups on antibody-NP conjugates leading 
to inappropriate and non-targeting agent mediated binding. Maleimide functional groups 
can also undergo hydrolysis (to an open maleamic acid form), rendering them unreactive 
to sulfhydryl groups(233) and preventing them from successfully conjugating NPs to 
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antibodies. To address this, the protein streptavidin, was bound to the CN-PPV/PLGA-
PEG NPs and conjugated to biotinylated antibodies to evaluate whether this could 
improve this nanomedicine platform. The added benefit of using streptavidin 
functionalised NPs is that the heterobifunctional crosslinker, PDPH, is no longer required 
as streptavidin will bind to the biotinylated antibodies. The removal of PDPH will exclude 
unoccupied hydrazide groups on the PDPH crosslinker as a source of inappropriate and 
non-specific binding. 
 
Figure 6.17 shows significant increase in fluorescence as compared to cell media only 
treated cells, when target (anti-CEA) and control (anti-CD31) antibody-streptavidin NP 
conjugates were incubated with the target and control cell lines respectively. However, 
Figure 6.17 also shows significant increase in fluorescence when the target and control 
antibody-streptavidin NP conjugates are incubated with their respective control cell lines, 
indicating inappropriate non-specific binding of both antibody-streptavidin functionalised 
NP conjugates. This is similar to the findings observed with maleimide functionalised 
antibody conjugates (Figure 6.8). These findings may represent unoccupied streptavidin 
functional groups on NPs reacting with proteins located on the cell surface membrane or 
potentially the same underlying disadvantages of PEGylation may be producing the 
inappropriate binding. The increase in fluorescence when anti-CEA antibody-streptavidin 
functionalised NP conjugates were incubated with LoVo cells was also low at 37%. This 
is in keeping with the increase in fluorescence seen in the latter optimisation steps with 
maleimide functionalised NP conjugates. 
 
A different recognition molecule was then investigated to see if this could resolve some 
of the issues surrounding non-specific binding detailed above. The use of antibodies was 
substituted for affimers. Immunofluorescence of both the target (anti-CEA) and control 
(ySUMO) affimers was performed on the target (LoVo) and control (HEK293) cell lines 
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(Figure 6.18). The target affimer (anti-CEA III) was found to selectively bind to the target 
LoVo cell line. The control affimer was found to not bind to either the target or the control 
cell line. This demonstrated that the target and control affimers were suitable for further 
experiments. Two separate anti-CEA affimers (anti-CEA II and anti-CEA III) had been 
investigated with the recommendation that a mixture of the two affimers may be more 
specific. A previous research project (289), also undertaken at the University of Leeds, 
investigated the development and application of anti-CEA affimer-based biosensors. In 
this study, it was observed that a polyclonal antibody-based biosensor system expanded 
the range and affinity for CEA detection, as compared to a monoclonal antibody-based 
biosensor. Similarly, a heterogenous mixture of affimers incorporated into a biosensor 
system composed of three different anti-CEA affimer clones (anti-CEA I, anti-CEA II and 
anti-CEA III) had a similar detection range to the polyclonal antibody biosensor system. 
 
Experiments were conducted to assess the ability of the target and control affimers to 
bind to the cell lines. Figure 6.19 shows that increase in fluorescence was greater when 
the target cell line was incubated with either anti-CEA III AffMNP or anti-CEAII/III AffMNP 
mixture, as compared to anti-CEA II AffMNP alone. There was also little non-specific 
binding of any of the target AffMNPs to the control cell line. The optimum incubation 
settings for AffMNP conjugates needed to be determined and for this the anti-CEA II/III 
AffMNP mixture was used. When exploring affimers for in vivo studies, the incubation 
temperatures reported in the literature are either at room temperature or 4-5C(290). 
Figure 6.20 shows that the optimum incubation conditions for the anti-CEA II/III AffMNP 
mixture on LoVo and HEK293 cell lines was overnight at room temperature. However, 
only further slight increase in fluorescence was seen when the target AffMNP mixture 
was incubated overnight at room temperature compared to overnight at 4C. The 
metabolic processes and enzyme viability of cells would be impaired at 4C, therefore 
incubation at room temperature was chosen as this would help to preserve the normal 
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physiological function of cells. Selected target and control affimer-NP conjugates were 
tested against the target and control cell lines using the optimum incubation parameters. 
Figure 6.21 demonstrates that target affimer-NP conjugates selectively bound to LoVo 
cells. This could represent a more accurate and specific targeted fluorescent probe than 
the antibody-NP conjugates. Tiede et al.(290) compared antibody and affimer binding to 
VEGFR2 (vascular endothelial growth factor receptor-2, a key mediator in the formation 
of new blood vessels) in human pancreatic tissue. Immunohistochemical analysis found 
increased staining of VEGFR2 using affimer, as compared to antibody binding and 
staining of VEGFR2. The authors hypothesised that the smaller sizes of affimers 
enabled efficient tissue penetration, and the affimer’s epitope (specific binding site of 
affimer on the receptor) may have been more readily accessible. Taken together, both of 
these factors may have allowed a larger number of affimers to bind to VEGFR2 as 
compared to the VEGFR2-targeting antibodies. Similar to this study, a similar 
comparison of anti-CEA antibody-NP and affimer-NP conjugates binding to target (LoVo) 
and control (HEK293 and EA.hy926) cell lines will need to be conducted to confirm 
which of the two recognition molecule bound NP systems is better. 
 
In summary, this chapter details and describes the work that was done to identify and 
conjugate a suitable targeting agent to the fluorescent semi-conducting polymer (CN-
PPV/PLGA-PEG) NPs. This was done in an effort to develop a fluorescent probe that 
can accurately target colorectal cancer cells. Despite both target (anti-CEA) and control 
(anti-CD31) antibodies being specific for the CEA and CD31 cell surface proteins, 
following conjugation to the MNP non-specific binding of both antibody-conjugates was 
observed. Despite taking optimisation steps towards eliminating non-specific binding no 
credible solution was found to address non-specific binding and differences in the 
change of fluorescence. Possible factors such as the binding of unoccupied maleimide 
functional groups, PEGylation of NPs, physical structure of NPs and storage conditions 
could have influenced the results. Streptavidin bound NPs were also investigated 
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however, similar non-specific binding was observed. Substituting antibodies for affimers 
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7 Research summary, conclusion, limitations and future work 
7.1 Summary and conclusions 
One of the major and currently unmet challenges in colorectal cancer surgery is the 
accuracy in determining the status of sentinel lymph nodes with metastatic disease. This 
is vital in order to appropriately stratify the extent of surgical resection. One potential 
method that has been investigated to address this is the use of fluorescent probes during 
laparoscopic surgery, to intraoperatively visualise and detect lymph node metastases. 
 
The aims of this research project were to 1) Evaluate the application of 5-aminolevulinic 
acid (5-ALA) mediated fluorescence in patients undergoing colorectal cancer surgery 
(GLiSten trial), 2) Evaluate CEA-targeting antibody and affimer for the development of a 
novel fluorescent probe, 3) Evaluate the semiconducting organic polymer CN-PPV as a 
fluorescent probe to detect colorectal cancer cells and 4) Test the binding of anti-CEA 
antibody/affimer-conjugated CN-PPV NPs in different cell types. 
 
As detailed in Chapter 3, the GLiSten trial demonstrated that 5-ALA did not meet the 
sensitivity and specificity requirements to be used as an accurate fluorescent probe that 
could be used for fluorescent-guided colorectal cancer surgery. In addition, no significant 
differences in gene expression between fluorescent and non-fluorescent tumours were 
found, which requires further exploration. Using current technologies being applied in 
surgery, fluorescent-guided colorectal cancer surgery and the detection of lymph node 
metastases is feasible. A newer and more advanced fluorescent probe is required with 
high sensitivity and specificity for colorectal cancers that could improve the outcomes of 
colorectal cancer surgery. 
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In Chapter 4, both target (anti-CEA) and control (anti-CD31) antibodies showed 
specificity for their respective cell surface antigens. Initially, the preferred orientated and 
direct conjugation to maleimide functionalised NPs to enhance the antigen-binding ability 
of antibodies through producing half-antibody fragments, via reducing whole antibodies, 
was explored but found to be a non-viable option. An alternative conjugation strategy 
was sought after finding that the volume of half-antibody fragment generated was too 
low. For future work, alternative antibody reduction protocols or optimisation of the 
current protocol should be explored. In addition, the presence of the glycoprotein chain 
on the target anti-CEA antibody was confirmed. However, the location of the chain on 
the antibody was not determined. This will need to be undertaken to establish that the 
glycoprotein chain is not located within the antigen binding site. The direct binding of 
antibody-to-NP would eliminate the need for the heterobifunctional crosslinker. 
 
The alternative conjugation pathway utilising heterobifunctional crosslinkers to conjugate 
maleimide functionalised NPs to oxidised antibodies proved to be feasible and allowed 
antibodies to retain antigen-specific binding. Similarly, the alternative targeting agents, 
anti-CEA (target) and y-SUMO (control) affimers, were also found be efficient in 
specifically binding to their respective antigens. 
 
Chapter 5 details the characterisation of the CN-PPV/PLGA-PEG non-functionalised and 
maleimide functionalised NPs. With peak absorption and emission at 470nm and 650nm 
respectively (wide Stokes shift), these NPs are potential candidates for developing 
probes for fluorescent-guided surgery. Both non-functionalised and maleimide 
functionalised NPs also demonstrated physically stability over prolonged periods of time 
with no change in their optical properties. Maleimide functionalisation of NPs using light 
PEG chains also demonstrated efficient cellular uptake and stability in physical sizes and 
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absorbance/emission properties over time. Maleimide functionalised NPs were also 
found to induce very little cytotoxicity. 
 
In Chapter 6, target and control antibodies were conjugated to maleimide functionalised 
CN-PPV/PLGA-PEG NPs using the heterobifunctional crosslinker, PDPH. Both antibody-
NP conjugates bound to their respective target cell lines and antigens. However, non-
specific binding of both target and control antibody-NP conjugates was also found. 
Optimisation of the antibody-NP conjugation protocol to address the non-specific binding 
was undertaken but a clear explanation for the underlying cause of non-specific binding 
was not found. An alternative conjugation strategy was investigated utilising streptavidin-
functionalised NPs and biotinylated antibodies, but these antibody-streptavidin NP 
conjugates also demonstrated the same pattern of non-specific binding. 
 
Finally, affimer-conjugated CN-PPV NPs were explored and found to bind to target cell 
lines with reduced non-specific binding to control cell lines. Affimer-conjugated CN-PPV 
NPs could potentially be more effective agents for the active targeting of colorectal 
cancer cells and aid fluorescence guided surgery. 
 
7.2 Limitations of study 
During the characterisation of CN-PPV/PLGA-PEG NPs described in Chapter 5, the 
effects of centrifugation and repeated centrifugation following wash steps on the 
hydrodynamic diameter and emitted fluorescence of the MNP were investigated. It would 
be of interest to have conducted characterisation of these processed MNPs over time to 
examine changes in hydrodynamic diameters and fluorescence profiles over time. 
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In Chapter 6, the pattern of fluorescence observed when investigating the conjugation 
between the oxidised antibodies and the heterobifunctional crosslinker, PDPH, 
demonstrated non-specific binding to control cell lines. Other studies have suggested 
that the non-specific binding observed could have potentially been due to unoccupied 
maleimide functional groups on the DyLightTM 488 Maleimide dye that was used during 
experiments. Reduction of the PDPH crosslinker prior to conjugation to the DyLightTM 
488 Maleimide dye will need to be investigated as well as investigating the effect of 
increasing the concentration of cysteine to further block any unoccupied maleimide 
functional groups. The 6th optimisation step assessed the impact of multiple wash cycles 
on the non-specific binding of antibody-NP conjugates. Less than two wash cycles (i.e. 
one wash or no washes) were not evaluated and therefore the full impact of the wash 
cycles cannot be assessed. 
 
Another potential limitation of this research project was the PEGylation of the CN-PPV 
NPs. As discussed in Chapter 6, PEGylation can hinder the binding of targeted-NPs to 
their respective antigens. PEGylation can also create an electrical surface charge 
polarising the NP, leading to non-specific binding of the antibody-NP conjugate to cell 
surface proteins. This is supported by the similar pattern of non-specific binding seen 
when between maleimide and streptavidin functionalised antibody-NP conjugates. 
However, it is not known why this is contradicted by the lack of non-specific binding seen 
when the target affimer-NP conjugate was incubated with control cell lines.  
 
7.3 Future work 
In this study, NP characterisation studies were carried out over time however, storage of 
the NPs was in an aqueous solution. It would be interesting to see whether there is any 
difference in the stability of the non-functionalised and maleimide functionalised NP over 
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time when stored in more physiologically representative solutions such as cell culturing 
medium and may give an explanation as to the variation seen in emitted fluorescence in 
Chapter 6. Further work also needs to be conducted in identifying the cause of the non-
specific binding of bare maleimide-functionalised NPs seen in Chapter 6, contradicting 
the findings in Chapter 5. Determining whether there is any batch-to-batch variability in 
the PEG component of non-functionalised and maleimide functionalised NP, or if time-
induced changes to PEG could be responsible for the non-specific binding and 
differences in emitted fluorescence seen in Chapter 6 is important. 
 
With regards to optimising the antibody-NP conjugation process reduction of the PDPH 
heterobifunctional crosslinker, prior to conjugation to maleimide functionalised NPs 
would be an important step to investigate. In this study, blocking unoccupied hydrazide 
groups with galactose was conducted however, the blocking of unoccupied maleimide 
functional groups, using cysteine, should have also been investigated. The use of a 
different heterobifunctional crosslinker could also be investigated however, the direct 
conjugation of antibody-to-NP is ideal and would eliminate the need for a crosslinker. 
There is also an inherent disadvantage in using crosslinkers as this would not allow for a 
direct comparison between antibody-NP and affimer-NP conjugates. This was shown by 
Barua et al.(286), who demonstrated that the physical and structural properties of NPs 
can influence the ability of targeted NPs to bind to their antigens. It would also be of 
interest to investigate whether changes made to the shapes and structures of targeted 
CNPVV/PLGA-PEG NPs could influence their ability to specifically identify and bind to 
antigens. Smith et al.(291) demonstrated that increasing the concentration of functional 
groups on the surface of NPs enhanced the amount of protein binding to the NP. It would 
be of interest to test a range of NPs with varying concentrations of maleimide present on 
their surfaces to see if this had an impact on the antibody-NP conjugates ability to 
specifically bind to target antigens.  
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To summarise this research project, fluorescent guided surgery is a viable strategy in 
stratifying the extent of resection in colorectal cancer patients on the basis of their lymph 
node status if an accurate, sensitive fluorescent probe can be developed. Transitioning 
away from the conventional 5-ALA, the NP investigated in this study fulfils the 
requirements of a clinical fluorescent probe however, it requires modification with a 
suitable CEA-targeting agent to enable it to actively target colorectal cancers. Different 
conjugation strategies have been employed to create a specific antibody-NP conjugate. 
However, further work is required to optimise this system. Affimer-NP conjugate appears 
to be a more promising candidate as a fluorescent probe and additional work should be 
undertaken to continue developing this through pre-clinical studies (both in vitro and in 
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